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Summary 
Pancreatic cancer maintains one of the worst prognoses of all malignancies. Fewer 
than 1% of patients survive 10-years post-diagnosis. It is an aggressive disease with 
as many as 80% of patients diagnosed in the most advanced stages of disease. This 
severely limits treatment options, contributing to the dismal prognosis.  
Diagnosis remains a challenge. Often, imaging alone cannot differentiate between 
benign or malignant disease. Blood-based biomarker CA19-9 cannot be relied upon 
since it is a modified Lewis antigen so 5-10% of the population do not express it. 
Tissue biopsies remain the gold-standard for final confirmed diagnoses, yet 
collection of pancreatic biopsies is invasive, time and resource intensive and have a 
range of risks associated.  
Blood-based biomarkers offer a less invasive, cheaper, and more accessible 
alternative to more traditional diagnostic techniques. Here, we explored the use of 
novel DNA mutation assay, the human erythrocyte PIG-A assay, as a blood-based 
biomarker to determine whether it had any potential in diagnosing pancreatic cancer. 
An elevated frequency of PIG-A mutant erythrocytes was observed within pancreatic 
cancer patients in comparison to controls of healthy donors and a benign pancreatic 
disease cohort. Furthermore, the more well-established human peripheral blood 
mononuclear cell cytokinesis block micronucleus assay provided a secondary 
measure of DNA damage. An elevation was also viewed in this assay in malignant 
donors. Both assays were additionally explored within an in vitro setting, modelling 
the induction of DNA damage by known risk factors for pancreatic cancer. 
Given the complexity of pancreatic cancer diagnosis, a panel of biomarkers was 
explored, combining clinical markers of inflammation with our two DNA-based 
biomarkers and clinically approved CA19-9. Combination of the novel PIG-A 
mutation assay and CA19-9 blood-test appeared the most suitable panel of 
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Chapter 1: Introduction 
1.1 Diagrams depicting the growth of cancer cells in blue to form A) a localised 
tumour which remains in the tissue which it originated from B) a locally advanced 
tumour which is growing into normal tissue outside of primary site of tumour 
(Cancer Research UK, 2020a). 29 
1.2 A) Cancer incidence rate (per 100,000) in countries grouped by development as 
measured by HDI. B) Cancer mortality rates (per 100,000) in nations grouped by 
development measured by HDI (Fidler et al., 2018). 31 
1.3 Anatomical diagram of a human pancreas (Modified from Dolenšek et al., 2015). 
33 
1.4 PC incidence increases at greater ages seen in England and Wales in the year 
2000 (Wood et al., 2006). Males represented by a solid line; females represented by 
a dashed line. 34 
1.5 Progression from healthy pancreatic epithelium to increasing stage of PanINs 
(modified from Batey, 2019). 39 
1.6 GPI anchor structure and associated genes involved in the biosynthesis of the 
GPI anchor. PIG-A, highlighted, is the only X-linked gene involved (Krüger et al., 
2016). 51 
1.7 A) PIG-A wildtype cell with GPI anchor present on cell surface, GPI anchors 
identified with fluorescently labelled antibodies for GPI anchored proteins. B) PIG-
A mutant cell deficient in GPI anchors. PIG-A mutant is non-fluorescent in flow 
cytometric analysis (Haboubi et al., 2019). 52 
1.8 CBMN assay 1) Cell exposed to chemical, DNA damage is induced 2) Cells 
divide in the presence of cytochalasin-B, blocking cells in the binucleate phase as 
cytokinesis is inhibited 3) example binucleate cells in control, without micronuclei, 





Chapter 2: Methodology 
2.1 PANC-1 cell line at both low and high-density under light microscope (ATCC, 
2016a). 65 
Chapter 3: In Vitro Model of Pancreatic Cancer 
3.1 B[a]P-bound cytosolic AhR translocates to the nucleus mediated by chaperone 
HSP90 and binds the xenobiotic response element to induce gene transcription of 
various genes, including CYP1A1, responsible for B[a]P metabolism (Mackowiak 
and Wang, 2016). 72 
3.2 CYP-dependent metabolism of B[a]P to its mutagenic derivative, BDPE, which 
forms DNA adducts (Krais et al., 2015). 73 
3.3 Metabolic pathways of ethanol metabolism through A) oxidative and B) non-
oxidative pathways (Zakhari, n.d.). 79 
3.4 Formation of acetaldehyde induced DNA adducts from a deoxyguanosine (dG) 
(Mizumoto et al., 2017). 81 
3.5 Production of MN from cell undergoing mitosis in the presence of cytochalasin 
B in the CBMN assay, producing a binucleate cell with a MN. MN can be formed in 
two mechanisms (Iarmarcovai et al., 2008). 82 
3.6 How a haemocytometer would look under a light microscope. The four outer 
large squares labelled 1, 2, 3 and 4 are counted with cells touching top and far left 
edges (solid line) are counted whereas cells touching the right hand side and lower 
edge (dashed line) would not be counted (Fuentes, n.d.). 85 
3.7 Screenshots from Metafer 4 software showing A) a gallery of binucleate PANC-
1 cells which the software has identified B) a closer image showing the binucleate 
PANC-1 cell with no identifiable objects in black surrounding nuclei C) image of 
binucleate PANC-1 cell with a potential micronuclei, highlighted by an arrow. If this 
was seen during scoring, the eyepiece and 63 x objective and oil would be used to 
either confirm or deny the presence of a micronuclei. All images shown at 10 x 
magnification. 87 
3.8 Examples of bicnucleated PANC-1 cells scored by manual scoring with Giemsa 
stain under 100 x magnification on a light microscope. A) A binucleate cell B) A 
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binucleate cell with a micronucleus denoted by an arrow C) a binucleate with small 
amount debris in the cytoplasm, which is stained a pink colour. 88 
3.9 Zombie violet viability dye discrimination seen in A) a live cell control and B) a 
dead cell control which had been heated at 90°C for 3 minutes to induce cell death. 
Live cells are identified in gate C. 91 
3.10 Example graphs from flow cytometry analysis of stained sample during in vitro 
Pig-A assay A) Live-dead discrimination using the zombie violet viability dye. 
Population in gate C are live. 60.02% of cells are live. B) Selection of CD-45 
positive cell population. 93.29% of live cells from gate C are CD-45 positive and are 
grouped in gate D. C) Cytogram of all cells in gate D (live, CD-45 positive 
population) with APC fluorescence on X axis and PE fluorescence on the Y axis. 
Solid line gate drawn based on positive control mutant population. Cells below this 
line in quadrant B4 are mutant. In this example, 0.04% of live, CD-45 positive cells 
are CD-90.2 deficient and are defined as mutant. 92 
3.11 Cytotoxicity determined through RPD and the trypan blue exclusion assay in 
the PANC-1 cell line exposed to increasing concentrations of B[a]P over 24h. A dose 
dependent decrease in cell viability is seen. Bars represent the mean (n=3) and error 
bars show standard deviation. (* show p<0.05, ** show p<0.01). 93 
3.12 Cytotoxicity determined by RPD and the trypan blue exclusion assay in PANC-
1 cell line exposed to increasing concentrations of DCA over 24h. No decrease is 
seen. Bars represent the mean value (n=3) and error bars show the standard 
deviation. 94 
3.13 Cytotoxicity determined through RPD and the trypan blue exclusion assay in 
PANC-1 cell line exposed to increasing concentrations of acetaldehyde for 24h. A 
dose dependent decrease in viability is seen in RPD with increasing acetaldehyde 
concentrations. Bars represent the mean (n=3) with error bars representing the 
standard deviation. (* shows p<0.05, ** shows p<0.01) 95 
3.14 Comparison of manual and semi-automated metafer scoring for the CBMN 
assay in the PANC-1 cell line. 3 slides were scored per dose, per method (n=1). Bars 
represent the mean and the error bars show the standard deviation. 96 
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3.15 Percentage of binucleated PANC-1 cells with micronuclei following 24 hour 
exposure to B[a]P (n=3). There is a dose dependent induction of micronuclei with 
significance above 20 µM. Bars represent the mean and error bars represent the 
standard deviation. (* shows p<0.05, ** shows p<0.01). 97 
3.16 Percentage of binucleated PANC-1 cells with micronuclei following 24 hour 
exposure to DCA. No clear pattern is shown, even if significant increases at 50 and 
300 µM. Bars represent the mean and the error bars represent the standard deviation. 
(* shows p<0.05) 98 
3.17 Percentage of binucleated PANC-1 cells with micronuclei following 24 hour 
exposure to acetaldehyde. A dose dependent increase in MN induction is seen at 0.5 
and 2.5 µM of acetaldehyde. Bars represent the mean (n=3) and the error bars 
represent the standard deviation. (* shows p<0.05, ** shows p<0.01) 99 
3.18 Frequency of CD-90.2 deficient live L5178Y cells measured across a 21-day 
period following 4 hour exposure to 20 or 150 µM of DCA, vehicle control (VC) 
ethanol or untreated (Un). (n=3) 101 
3.19 Percentage of CD-90.2 deficient live L5178Y cells on day 9 following a 4 hour 
exposure to DCA. An increase in mutated cells is seen between untreated (Un) and 
the treated cells although this is non-significant. The increase seen between the 
vehicle control (VC) of ethanol and the treated cells is significant. Bars represent the 
mean value of CD90.2 deficient cells (n=3) and error bars show the standard 
deviation. (* shows p<0.05, **<0.01). 102 
3.20 Percentage of CD-90.2 deficient cells as a percentage of live L5178Y cells 
across a 21-day period following 4 hour exposure to acetaldehyde. Mutant frequency 
peaks around day 9, with treated cells having more mutations induced in comparison 
to the vehicle control (VC) which was exposed to media alone (n=3). 103 
3.21 Induction of CD-90.2 deficient live L5178Y cells on day 9 as a result of 4 hour 
exposure to acetaldehyde at 0.25 or 1 µM or the vehicle control (VC) of media. A 
significant induction of Pig-A mutant cells is seen in treated cells in comparison to 
the control. Bars show the mean value and error bars show the standard deviation. (* 





Chapter 4: Human Erythrocyte PIG-A Assay in Pancreatic Cancer 
4.1 Initial staging scans of an 80-year-old female diagnosed with PDAC. A) MRI 
scan identified hypoenhancing mass in the body of the pancreas, identified by arrow 
B) PET/CT showing avid FDG uptake in primary mass, corresponding with MRI 
mass, identified by arrows C) An avid FDG peripancreatic lymph node identified by 
PET/CT (Modified from Yeh et al., 2018). 117 
4.2 Diagram depicting interior workings of a flow cytometer. A light source excites 
fluorophores in a single stream of focused particles, any fluorescence and light 
scattering is detected by the detector and sent to a computer for analysis (Büscher, 
2019). 123 
4.3 Excitation and emission spectra of the two fluorophores used in this study. A) PE 
is excited at 495nm and emits at 578nm B) APC is excited at 650nm and emits at 
660nm(Absorption and Emission Spectra | BD Biosciences-US, 2020). 124 
4.4 Example cytograms from a healthy donor A) Unstained ICS which gates (blue 
line) are drawn by B) stained sample, showing wildtype red blood cells in H2 
quadrant, mutant cell population in quadrant H4. In this example, 7 mutant red blood 
cells per 1.4 million wild-type red blood cells, or 5 x 10-6 PIG-A mutant 
erythrocytes. 127 
4.5 Dot plot comparing PIG-A mutant erythrocytes frequencies in donors who are 
healthy (n=6), with benign (n=10) or malignant pancreatic disease (n=30). Donors 
with cancer of the pancreas have a higher frequency of mutant erythrocytes. (p<0.05 
signified with *) 128 
4.6 PIG-A mutation frequency in PC patient donors with increasing tumour size (T-
stage) (n = 3 T1, n = 9 T2, n = 2 T3, n = 3 T3b, n = 1 T4). Crosses show the mean 
values. 129 
4.7 PIG-A mutation frequency in donors with PC with increasing lymph node 
involvement (n = 5 N0, n = 7 N1, n = 6 N2). Crosses represent the mean. 130 
4.8 PIG-A mutant frequency in donors with PC with patients with localised disease 
(0) or metastatic disease (1) (n = 18 M0, n = 7 M1). Crosses represent the mean. 131 
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4.9 Box and whisker plot of PIG-A mutant erythrocyte frequency as stage of PC 
increases (n = 2 IA, n = 4 IB, n = 6 IIB, n = 6 III, n = 7 IV). 132 
4.10 : Resection completeness of the PC patients who underwent pancreatic 
resection as part of their treatment. Completeness rated as 0, complete (n = 5), or 1, 
where microscopic tumour was present along resection margins (n = 6). Bars 






















Chapter 5: Human Peripheral Blood Mononuclear Cell Micronucleus Assay 
and Additional Biomarkers for Pancreatic Cancer 
5.1 Blood separation following centrifugation with Histopaque®-1077 into (top to 
bottom): plasma, PBMCs (buffy layer), histopaque, red blood cells. 152 
5.2 Frequency of micronuclei within binucleated PBMCs from patients with benign 
and healthy (n=12) and malignant (n=18) pancreatic disease. Bars represent the 
mean and error bars show standard deviation. (** signifies p<0.01) 154 
5.3 Frequency of micronucleated binucleate PBMCs of PC patients as tumour size, 
represented by T-staging increases (n=4 T1, n=6 T2, n=2 T3, n=1 T3b). Bars 
represent the mean and the error bars represent the standard deviation. 155 
5.4 Frequency of binucleated PBMCs with micronuclei in PC patients  as nodal 
involvement of disease, signified by N-stage, increases (n=5 N0, n=5 N1, n=2 N2). 
Bars represent the mean and error bars show the standard deviation. 155 
5.5 Frequency of binucleated PBMCs with micronuclei from PC patients with either 
non-metastatic disease (M0) or distant metastatic disease (M1) (n=15 M0, n=3 M1). 
Bars represent the mean and error bars the standard deviation. 156 
5.6 Frequency of binucleated PBMCs with micronuclei from peripheral blood of PC 
patients as overall stage of disease increases (n=2 IA, n=4 IB, n=4 IIB, n=3 III, n=3 
IV). Bar shows the mean and error bars represent the standard deviation. 157 
5.7 Correlation between the human erythrocyte PIG-A assay and human peripheral 
PBMC CBMN assay in patients with pancreatic disease (n=20). 158 
5.8 Mean serum CA19-9 concentrations in patients with benign and malignant 
pancreatic disease (n=5 benign, n=22 malignant). Bars represent the mean and error 
bars show the standard deviation. 159 
5.9 Mean concentrations of serum CA19-9 in PC patients with increasing staged 
disease (n=1 IA, n=4 IB, n=3 IIB, n=5 III, n=6 IV). 159 
5.10 Mean NLR values in patients with benign and malignant pancreatic disease 
(n=6 benign, n=22 malignant). 160 
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5.11 Mean NLR in PC patients with increasing tumour staging (n=1 IA, n=4 IB, n=3 
IIB, n=5 III, n=6 IV). 161 
5.12 Mean CRP values in patients with benign and malignant pancreatic disease 
(n=6 benign, n=22 malignant). 161 
5.13 Mean CRP concentrations in PC patients with increasing disease stage (n=1 IA, 
n=4 IB, n=3 IIB, n=4 III, n=6 IV). 162 
5.14 Score from combining PIG-A and CA19-9 blood test results in patients with 
benign and malignant pancreatic disease (n=6 benign, n=20 malignant). 163 
5.15 Score from combination of PIG-A and CA19-9 across PC patients with 
increasing stage of disease (n=1 IA, n=3 IB, n=3 IIB, n=5 III, n=6 IV).164 
5.16 Score from NLR and PIG-A results in donors with benign and malignant 
disease (n=6 benign, n=22). 165 
5.17 Score calculated with PIG-A and NLR values as PC stage increases (n=1 IA, 
n=3 IB, n=3 IIB, n=5 III, n=6 IV). 165 
5.18 Score generated with CRP and PIG-A values in patients with benign and 
malignant pancreatic disease (n=6 benign, n=22 malignant).(* shows p<0.05). 166 
5.19 Score generated with CRP and PIG-A values as disease stage increases in 
donors with PC (n=1 IA, n=4 IB, n=3 IIB, n=4 III, n=6 IV). 167 
5.20 Score generated with PIG-A and PBMC CBMN assay in patients with benign 
and malignant pancreatic disease (n=3 benign, n=17 malignant).168 
5.21 Score calculated from PIG-A and PBMC CBMN results as disease stage 
increases in PC patients (n=2 IA, n=4 IB, n=4 IIB, n=3 III, n=3 IV). 168 
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Chapter 1: General Introduction 
1.1 Cancer 
Cancer is one of the most common diseases globally, arising from the abnormal 
growth of cells which results in tumour formation, with exceptions found in bone 
marrow cancers (Roy and Saikia, 2016). Tumours initiate from a single cell which 
over time has acquired DNA mutations in driver genes which leads to initiation of 
disease (Wodarz et al., 2018). Often, driver genes are either a proto-oncogene or a 
tumour suppressor gene. Mutation within the proto-oncogene can turn the gene into 
an oncogene, which then promotes the formation of cancer. Both proto-oncogenes 
and oncogenes encode proteins which induce cell division, inhibit cell 
differentiation, and inhibit cell death. Oncogenes produce these in a much higher 
quantity or produce a gene product with increased activity, contributing to 
carcinogenesis (Chial, 2008).  Under normal conditions, tumour suppressor genes 
prevent formation of cancers through controlling cell division, initiating DNA repair 
mechanisms and inducing apoptosis (Hooper, 1998; American Cancer Society, 
2014). Tumour suppressor genes require two mutational hits to inactivate both 
copies of the gene to stop tumour suppressing activities of the gene and initiate 
tumourigenesis (Wodarz et al., 2018). Examples of tumour suppressor genes which 
are implicated in carcinogenesis when mutated are: RB-1 linked with retinoblastoma 
and osteosarcoma, p53 linked with a wide variety of tumours including breast and 
brain cancer, BRCA1 and 2 linked with breast and ovarian cancer and APC linked 
with familial adenomatous polyposis which leads to colon carcinoma (Hooper, 
1998). The result of these driver mutations is uncontrolled cell division, as seen in 
Fig. 1.1A, which forms a localised tumour. As tumours grow, requirements for 
nutrient supply increases and as a result, tumours attract their own blood supply to 
ensure survival (Arnold, 1985; Hanahan and Weinberg, 2011). Tumour cells can also 
harness this blood supply to enter circulation and extravasate into a novel deposit 
where use of proliferation, apoptosis, dormancy, and angiogenesis develop from a 
single cell deposit into a full-blown metastatic tumour (Steeg, 2006). Metastatic 




1.1.1 Cancer throughout history 
Cancer is often claimed to be as old as humanity, yet evidence of cancer has been 
identified in prehistoric animal remains like an osteosarcoma in a hominin bone from 
1.7 million years ago, before the evolution of the human race (Hajdu, 2011a; Peters 
and Gonzalez, 2018). The first documented written description of cancer came in 
approximately 3000 BC, around the same time that Stone Henge was erected. The 
Edwin Smith Papyrus described a bulging tumour of the breast with no curative 
treatment (Hajdu, 2011a). It is likely that some knowledge of tumours came before 
written documentation, with knowledge passed on verbally. Cancer knowledge has 
improved significantly over the last 5,000 years, with notable breakthroughs. 
Towards the 1500s, realisation came that early treatment, especially before tumours 
became ulcerated, resulted in better patient outcomes (Hajdu, 2011a). During the 
Renaissance period, many developments came as a result of physicians and surgeons 
uncovering more on the human anatomy and physiology through dissections (Hajdu, 
2011b). Eventual replacement of gross pathology of the 18th century by microscopic 
pathology in the 19th century allowed for classification of tumours before treatment, 
and allowed for better clinical and surgical decisions to be made for the patient’s 
benefit (Hajdu, 2012). The first half of the 1900s allowed for further tumour 
classification dependent on histopathological grading and an increase in oncology 
based research (Hajdu and Darvishian, 2013).  Up to the 1970s, discovery of anti-
Figure 1.1: Diagrams depicting the growth of cancer cells in blue to form A) a 
localised tumour which remains in the tissue which it originated from B) a locally 
advanced tumour which is growing into normal tissue outside of primary site of 
tumour (Taken from Cancer Research UK, 2020a). 
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cancer chemotherapeutic drugs and radiation-based therapies revolutionised 
treatment and great advances were made with imaging modalities for visualisation of 
tumours, but no real improvements were made in the survival despite advances in 
diagnosis and treatment of disease (Hajdu and Vadmal, 2013). Most advances in 
cancer knowledge has come around within the last 50 years, including elucidation of 
the DNA damage and DNA mutations which result in tumour formation, and  
multidisciplinary team cancer treatments which allowed for more effective treatment 
and breakthroughs with patient survival (Hajdu et al., 2015). 
1.1.2 Incidence, mortality, and survival 
Cancer is a growing concern, globally. Cancer is generally a disease of age and as 
other diseases are becoming more treatable, the burden of cancer is increasing. Data 
collected from cancer cases across the UK between the years of 1979 and 2014 in 
combination with ONS national population predictions were used to forecast future 
trends of cancer incidence and mortality between 2015 and 2035 (Smittenaar et al., 
2016). It was concluded that overall age standardised rate of cancer incidence would 
increase 0.07% per year (Smittenaar et al., 2016). 
A global study monitored cancer incidence and compared this with the Human 
Development Index (HDI). HDI was calculated using 3 aspects: life expectancy at 
birth, mean and expected years in education, and standard of living based on gross 
national income per capita, by the United Nations Development Programme (United 
Nations Development Programme, 2015). The study grouped nations by HDI into 
four categories of low, medium, high, and very high HDI and studied both cancer 
incidence and mortality rates, seen in Fig. 1.2. Cancer incidence was greater in more 
developed countries, but mortality is comparable between all HDI groups (Fidler et 
al., 2018). There are various reasons which account for this imbalance between 
cancer incidence and national development. A westernised lifestyle made up of a 
high fat diet combined with alcohol intake, tobacco smoking and a more sedentary 
lifestyle, may contribute to this. Cancers linked with Western lifestyles include 
breast, prostate and colorectal cancer, which are all more prevalent in western 
society in comparison to developing nations (Kanavos, 2006). In contrast, lower HDI 
regions tend to have greater prevalence of infection-related malignancies including 
liver, stomach and oesophageal cancer (Fidler et al., 2018). In lower HDI countries, 
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healthcare may not be as widespread and easily accessible. Diseases which may be 
easily treatable and manageable within more developed regions may not be so 
manageable within lower HDI areas. This may also contribute to the lower cancer 
incidence in lower HDI nations if life expectancy is reduced and cancer is a disease 
of aging. Nations with low and medium HDI have been predicted to have the biggest 
projected increase of 81-100% in cancer cases between 2008 and 2030 (Fidler et al., 
2018). 
 
Figure 1.2: A) Cancer incidence rate (per 100,000) in countries grouped by 
development as measured by HDI. B) Cancer mortality rates (per 100,000) in 
nations grouped by development measured by HDI (Fidler et al., 2018). 
In a lifetime, an individual in the UK has a 50% chance of developing cancer 
(Cancer Research UK, 2018). There are several factors which will increase the risk 
of developing cancer, some factors specific for pancreatic malignancies are 
discussed further in 1.2.2.  
Cancer is no longer the death sentence it once was thanks to improvements in 
diagnosis and treatment. Now, 50 % of patients survive 10 years post cancer 
diagnosis which has more than doubled in the last four decades, from 24% (Cancer 
Research UK, 2014a). Survival is dependent on several factors including age, stage 
of disease at diagnosis and type of cancer since different malignancies have vastly 
different survival rates. Survival is greatest in patients aged 15-40, and lowest 
between ages of 80 and 99 (Cancer Research UK, 2016a). Patients aged over 65 
account for 60% and 70% of cancer incidence and mortality, respectively (Given and 
Given, 2008). At the greater age, radical oncological treatments may not be tolerated 
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as easily, resulting from increased comorbidities and reduced functional status 
(Given and Given, 2008). However, there may also be some unfair barriers which 
block patients above a certain age from getting the treatment a younger patient may 
do. These include no staging of disease, no surgical options when disease may be 
early enough to cure through resection and the use of subclinical doses of 
chemotherapy and radiotherapy with no curative intent (Given and Given, 2008). 
Stage of disease will have a great influence on survival statistics since stage of 
disease will limit treatment options available. Type of malignancy plays a huge role 
in patient survival. Different tumour types have different characteristics which will 
influence how the tumour behaves, resulting in survival differences. For example, 
pancreatic cancer is a highly aggressive malignancy, often diagnosed once disease 
has spread and only surgery can cure the disease. More information on pancreatic 
cancer survival is found in 1.2.6. Ten-year survival data for pancreatic cancer shows 
that fewer than 1% of patients survive ten years post-diagnosis, in comparison to 
prostate cancer which has a ten-year survival rate of 98% (Cancer Research UK, 
2014a). 
1.2 Pancreatic Cancer 
The pancreas is a mixed gland which resides in the retroperitoneal space linked to 
the gastrointestinal tract, Fig 1.3. From an anatomical standpoint, the pancreas 
consists of the head, adjacent to the duodenum and the tail which is next to the 
spleen (Murtaugh and Keefe, 2015). The exocrine gland accounts for 80% of the 
pancreatic mass, comprised of acinar cells which secrete digestive enzymes into the 
branched pancreatic ductal network (Hezel et al., 2006; Murtaugh and Keefe, 2015). 
In combination with bile acids stored in the gallbladder, this comprises pancreatic 
juice which is released into the duodenum, via the ampulla of Vater, to aid digestion, 
particularly of fatty foods (Murtaugh and Keefe, 2015). Endocrine islets consist of α 
and β cells which produce, store and secrete hormones glucagon and insulin, 
respectively, to maintain blood glucose homeostasis. Both endocrine and exocrine 




Figure 1.3: Anatomical diagram of a human pancreas (Modified from Dolenšek et 
al., 2015). 
Cancer can arise in any region of the pancreas. Pancreatic cancer (PC) is classified 
dependent on the region of the gland the tumour originates from. Approximately 1-
2% of PC cases arise from endocrine regions of the gland and are referred to as 
pancreatic neuroendocrine tumours (PNETs).  They can be further classified 
depending on their functionality. Functional PNETs have an incidence of 0.2 cases 
per million and induce hormonal changes often identified through diagnostic studies 
(Halfdanarson et al., 2008; Tadokoro et al., 2016). Functional PNETs are usually 
named after the hormone produced in excess by the tumour, the most common form 
being an insulinoma (Shin et al., 2010). Insulinomas are diagnosed using Whipple’s 
triad: hypoglycaemia, low glucose and symptoms reduced after glucose 
administration (Miron et al., 2016). The more common non-function PNET are 
considerably harder to identify and diagnose without altering hormonal levels 
(Halfdanarson et al., 2008). Patients with functional PNETs have shown a 28 month 
increase in median survival in comparison to non-function PNET patients, indicating 
that earlier diagnosis and treatment are key to extending patient survival 
(Halfdanarson et al., 2008). 
Exocrine tumours account for the majority of PC cases. 85% of all PC cases are 
pancreatic ductal adenocarcinoma (PDAC) (Polireddy and Chen, 2016; Barone et al., 
2016), named after the resemblance to ductal cells (Hezel et al., 2006). Most PDAC 
tumours arise in the head of the pancreas, allowing for infiltration into surrounding 
organs, namely the liver, spleen and lungs (Hezel et al., 2006). PDAC has the lowest 
34 
 
overall survival of all solid tumours, with 1-3% survival in five years (Karandish and 
Mallik, 2016).  
1.2.1 Epidemiology of Pancreatic Cancer 
Pancreatic cancer (PC) accounts for approximately 3% of cancer cases in the UK 
(Cancer Research UK, 2014b). This is the equivalent to the 11th most common form 
of cancer in the UK (Pancreatic Cancer UK, 2020). In 2011 in the US alone, 44,030 
cases of PC were diagnosed, coupled with 37,660 fatalities (Siegel et al., 2011). In 
the UK, 10,000 cases were diagnosed coupled with 9,000 fatalities in 2016 
(Pancreatic Cancer UK, 2020). Imbalances in PC incidence are seen dependent on 
gender. Global incidence rates in males and females were 4.9 and 3.6 per 100,000, 
respectively, in the year 2012 (Ilic and Ilic, 2016). As age increases, the chances of 
developing PC also increase, Fig. 1.4. Approximately 90% of PC cases occur in 
patients above the age of 55, with median age of diagnosis of 71 (Wood et al., 2006; 
Gordon-Dseagu et al., 2018). 
Incidence of PC is also variable dependent on ethnicities and nationalities. A study 
analysed PC data collected between 1974 and 2013 within registries accounting for 
30% of the US population. Ethnicity data was collected and collated with PC 
incidence data. Black residents were shown to have a higher incidence of PC in 
comparison to other ethnicities with incident rate ratio of 1.24 and 1.37 in males and 
Figure 1.4: PC incidence increases at greater ages seen in England and Wales in 
the year 2000 (Wood et al., 2006). Males represented by a solid line; females 
represented by a dashed line. 
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females, respectively, in comparison to the Caucasian population (Gordon-Dseagu et 
al., 2018). In the study, the lowest incidence of PC was found in the Asian and 
Pacific islander population (0.78), closely followed by the native American/ native 
Alaskan population (0.79) and the Hispanic population (0.88) (Gordon-Dseagu et al., 
2018). Globally, PC incidence is not uniform. Particularly high incidence of PC is 
found within Armenia, Czech Republic, Slovakia, Japan and Hungary with lowest 
incidence in Middle Africa and Pakistan (Ilic and Ilic, 2016). The imbalance in PC 
incidence can be accounted for by lifestyle differences, exposure to different risk 
factors and different health care systems.  
1.2.2 Risk Factors 
Numerous risk factors have been associated with the development of PC. These have 
been further categorised. 
1.2.2.1 Lifestyle Factors 
As many as 37% of all PC cases are preventable through better lifestyle and dietary 
choices (Cancer Research UK, 2014b). Tobacco smoking has long been linked with 
lung cancer risk but additionally increases risk of PC development. As many as 29% 
of PC cases have been linked with smoking and additionally increases the risk of 
death in PC patients by 1.71-fold (Cancer Research UK, 2014b; Wang et al., 2014). 
Obesity has been linked to increased risk of PC, likely due to inflammation and 
metabolic alterations. Overall, 12% of PC cases have been linked with obesity 
(Cancer Research UK, 2014b; Lennon et al., 2016). Additionally, excessive alcohol 
consumption has been shown to increase PC risk by 20% (Cancer Research UK, 
2014b). Many lifestyle factors are modifiable risks, with reduced risk of cancer if 
factors are changed, for example with losing weight, risk of PC is reduced (Xu et al., 
2018). More knowledge and awareness of lifestyle factors which increase the risk of 
cancer development may result in more lifestyle changes for the better. Lifestyle 
factors have been discussed further in depth in chapter 3.1.  
1.2.2.2 Hereditary Disease 
Several hereditary conditions increase the risk of developing PC. Two examples 
include familial adenomatous polyposis (FAP) and hereditary breast and ovarian 
cancer syndrome (HBOC). 
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FAP is autosomal dominant as a result of mutation in the adenomatous polyposis 
colis (APC) gene, 70% of cases are a result of inheritance and 30% are a result of a 
novel mutation (Lipton and Tomlinson, 2006). FAP induces an excess of colorectal 
polyps (>100) (Lipton and Tomlinson, 2006; Capasso et al., 2018). Each individual 
polyp has a risk of turning malignant, greatly increasing the chances of colorectal 
malignancies.  Patients with FAP are also at a greater risk of developing 
extraintestinal cancers, including cancer of the thyroid, adrenal gland, bile duct and 
pancreas (Giardiello et al., 1993). In a study of 1,391 FAP patients, there was an 
increased absolute risk of developing PC with 21.4 cases per 100,000 (Giardiello et 
al., 1993) in comparison to risk of general population, with male and female absolute 
risks of 5.5 and 4 per 100,000, respectively (Rawla et al., 2019).  
HBOC is characterised by a germline pathologic variant in BRCA1 or BRCA2 
(Petrucelli et al., 1993). It has been well established that HBOC increases the chance 
of developing both breast cancer in males and females, and ovarian cancer in female 
(Moran et al., 2012). To a lesser extent, HBOC can increase the risk of developing 
other cancers including cancer of the prostate, pancreas, and malignant melanoma 
(Petrucelli et al., 1993). Chances of developing PC with BRCA1 and BRCA2 variants 
are 1-3% and 2-7%, respectively, in comparison to the general risk of 0.5% 
(Petrucelli et al., 1993). BRCA1 and BRCA2 both act as tumour suppressors, 
involved in the DNA damage response pathways. BRCA1 is involved in checkpoint 
activation and DNA repair while BRCA2 mediates homologous recombination but 
the relationship between the two proteins is still not fully understood (Roy et al., 
2012).  
1.2.2.3 Pre-existing Conditions 
A range of pre-existing chronic conditions will increase the likelihood of developing 
PC over a lifetime. Two examples are found in chronic pancreatitis and diabetes 
mellitus. 
Chronic inflammation has been long associated with the development of cancer; in 
the pancreas this is no exception. Chronic pancreatitis (CP) is characterised by 
repeated periods of pancreatic inflammation which cause intense abdominal pain, 
nausea and vomiting which eventually become constant symptoms (Raphael and 
Willingham, 2016). Over time, the continual inflammation leads to loss of pancreatic 
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function leading to diabetes mellitus (DM) and maldigestion from endocrine and 
exocrine insufficiency, respectively (Kleeff et al., 2017). CP induces a unique, 
complex form of diabetes described as type 3c DM. Like type 1 DM, this is insulin 
dependent, but there is greater risk of hypoglycaemia because of α cell involvement, 
reducing glucagon production (Lew et al., 2017). Chronic inflammation drives NF-
κB activation, which is elevated in a number of cancers, including PC (Gudkov and 
Komarova, 2016). Pancreatitis in all of its forms: acute, chronic, autoimmune; have 
all been shown to increase the risk in developing PC (Ikeura et al., 2016).  Chronic 
inflammation from CP has been shown to increase the formation of pre-malignant 
pancreatic lesions including pancreatic intraepithelial neoplasm, intraductal papillary 
mucinous neoplasm and mucinous cystic neoplasms (Krška et al., 2015). CP is the 
strongest risk factor for PC, increasing the risk of developing PC by 13.3-fold, likely 
due to inflammatory changes and subsequent ROS release which initiates a cascade 
of DNA damage which leads to mutation (Lew et al., 2017). 
DM is both a risk factor for developing PC and a potential symptom of early PC so is 
likened to the chicken and the egg (Lishan Wang et al., 2016). PC can be caused by 
DM in many ways. DM induces chronic inflammation in pancreatic islets, mediated 
by p38 MAPK. Wang et al. (2016) showed p38 MAPK plays a regulatory role in 
proliferation, apoptosis, and metastasis. All effects were only exacerbated further by 
hyperglycaemia. A study of 600 patients showed a significant (p<0.0001) increased 
prevalence of DM in PC patients (67%) in comparison to other malignancies (breast, 
lung, colorectal, prostate) and over control patients (Aggarwal et al., 2013). A study 
of 8 autoimmune pancreatitis patients who went on to develop PC showed 65% (5) 
of patients had DM before PC diagnosis (Ikeura et al., 2016). Any conclusions 
which could be drawn about DM, are complicated further given novel DM or 
uncontrollable blood sugar levels in longstanding DM are symptoms of PC, and they 
may arise before a pancreatic tumour is clinically recognisable. 
Despite the complicated pattern, patients with concurrent CP and DM have a further 
increased risk, with a 33-fold increased risk of PC development (Lew et al., 2017). 
1.2.2.4 Pre-malignant Lesions 
A range of pre-malignant pancreatic lesions exist which can develop into fully 
neoplastic disease. Three known precursors to PC are pancreatic intraepithelial 
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neoplasms (panIN), and then the cystic mucinous cystic neoplasms (MCN) and 
intraductal papillary mucinous neoplasms (IPMN) (Zamboni et al., 2013). Of the 
three, panINs are the most abundant premalignant pancreatic lesion (Zamboni et al., 
2013). PanINs are typically smaller than 5mm in size and are much harder to 
diagnose in comparison to the larger, cystic premalignant lesions which are 
identifiable on radiological examinations (Yu et al., 2018). As a result, panIN are 
often only identified through pathological examination of surgical specimens. 
PanINs are graded depending on their morphology, Fig, 1.5. Low risk panIN1 is 
categorised as either flat (panIN1A) and papillary (panIN1B), panIN2 are more 
abundant within PDAC associated pancreatic tissue and panIN3 are believed to be 
carcinoma in situ (De Wilde et al., 2012).   Accumulation of specific mutations 
progress healthy pancreatic epithelium to advancing stages of panIN, with early 
stage neoplasia associated with KRAS and CDKN2A with panIN3, carcinoma in 
situ, associated with TP53 and SMAD4 (Batey, 2019). A study of surgical specimens 
from 95 PDAC patients who underwent a pancreatectomy discovered panIN lesions 
within 59% of patients, with panIN3 being the most abundant (Yu et al., 2018). 
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1.2.3 Symptoms of Pancreatic Cancer 
Early stage PC is asymptomatic and so the tumours can advance undetected in the 
retroperitoneal space and by the time symptoms present, the disease is often too 
advanced for surgical intervention in around 80% of cases (Lahoud et al., 2016). 
Common late presenting symptoms of advanced PC include upper abdominal pain, 
which radiates along the spine, accounting for it being one of the most painful 
malignancies from a clinical standpoint within its final stages (Lahoud et al., 2016). 
Jaundice is another common symptom observed in 50% of PC cases, as a result of 
the obstruction of the bile duct by tumours in the head of the pancreas which are seen 
in 75% of all cases (Tummala et al., 2011; Cancer Research UK, 2016b).  Other 
symptoms experienced early in PC cases include weight loss, poor appetite, and new 
onset or poorly controlled DM. As the disease progresses, the symptoms become 
progressively worse (Lahoud et al., 2016). The problem with the symptoms of PC is 
that they are unspecific, not unique to pancreatic cancer and can be ignored for some 
time.  
1.2.4 Diagnosis 
Diagnosis of PC is discussed in depth in later chapter 4.1.1. Diagnosis of PC is 
achieved through a combination of imaging, blood tests and histological 
confirmation since imaging and blood tests alone cannot fully differentiate between 
benign and malignant disease. Currently, the majority of patients are diagnosed with 
Figure 1.5: Progression from healthy pancreatic epithelium to increasing stage of 
PanINs (modified from (Batey, 2019). 
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advanced disease (stage III and IV), severely limiting possibility of curative 
treatments (National Cancer Registration and Analysis Service, 2019). 
Improvements in PC diagnosis are urgently needed to help change the bleak 
prognosis of PC patients, which have failed to improve despite therapeutic advances. 
Particularly, improvements in diagnosis of early stage PC where disease is still 
resectable, would vastly improve disease outlook. 
1.2.5 Treatment 
Current treatment regimens for PC are based on the tumour size, the blood vessel 
involvement, whether metastatic disease has been confirmed and the fitness of the 
patient. Under the NHS, there are three main treatment options for those with 
confirmed PC cases including surgery, chemotherapy, radiotherapy, or a 
combination thereof. To date, the only treatment with curative potential is surgery, 
however due to the late onset of symptoms and challenges in diagnosis, fewer than 
20% of PC patients are eligible for pancreatic tumour resection (Lin et al., 2015). It’s 
estimated that 80-90% of PC patients have locally advanced or metastatic disease, 
which further complicates treatment (Krempien et al., 2006). 
Pancreatic surgery is no small undertaking. Due to complex positioning of the 
pancreas within the retroperitoneum and its involvement with surrounding organs 
and blood vessels, pancreatic surgery continues to have risks and is hailed as the 
most complicated general surgery (Wang et al., 2016; Lemke et al., 2016). Even 
with all the risks associated with pancreatic surgery, only 20% of patients who 
undergo successful surgical resection survive 5 years (Bellon et al., 2016). 
Pancreatic surgery is categorised as open or laparoscopic. Open pancreatic surgery 
tends to have more associated risks and requires a lengthy hospital stay including a 
couple of days within intensive care. Laparoscopic or key hole surgery is used for 
the removal of smaller tumours, and is more commonly used for distal 
pancreatectomies since it has been shown to reduce blood loss, post-operative pain, 
and improve recovery to minimise hospital stay required in comparison to an open 
distal pancreatectomy (Kocaay et al., 2016). Laparoscopy is still a developing 
technique and although has shown promises in some areas, major drawbacks still 
exist, and further development may bring it forward to overtake open surgery as a 
technique (Al-Taan et al., 2010). In a study of 47,685 patients who underwent either 
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a liver or pancreatic resection over 10 years, minimally invasive surgical approaches 
were more common in patients aged 66 to 85 years (Okunrintemi et al., 2016). 
The aim of pancreatic surgery is complete resection of the tumour, which is the only 
curative option. Complete resection is referred to as R0, where no remaining cancer 
cells are found along the resection margins upon histopathology review. Even in 
surgeries where this is achieved, patient survival over 5 years is between 3 and 16% 
(Krempien et al., 2006). Post-surgery, 92% of cases of PDAC have been shown to 
relapse without any ongoing therapy and this often presents around 9-15 months 
after the initial presentation (Krempien et al., 2006; Bittoni et al., 2014). Relapse is 
common because of the aggressive nature of PC, the disease may have progressed 
into regions without the surgeon’s knowledge, and so remaining neoplastic tissue 
can develop into a tumour. There are various surgeries available which can be 
carried out on the pancreas depending on the disease present, the location and the 
vascular involvement of the rumour. Types of surgery include: the Whipple 
procedure, distal pancreatectomy, total pancreatectomy.  
As mentioned previously, the aggressive nature of the disease, late onset of 
symptoms and difficulty in diagnosis results in up to 90% of patients having locally 
advanced or metastatic disease at presentation (Krempien et al., 2006). Thus, only 
20% of PC patients are candidates for surgical resection (Lin et al., 2015). The 
remaining patients maybe suited for other therapeutic interventions such as 
chemotherapy and radiotherapy or may be more suited for palliative surgery. This 
surgery has no intention of curing the disease. Traditional palliative double bypass 
surgery is carried out in cases of metastatic disease to prevent gastric outlet 
obstruction and further jaundice to reduce future symptoms and to ease future pain 
(Adham and Perinel, 2019). Obstructive jaundice can also be relieved through the 
use of stents which support the biliary duct, allowing effective draining to relieve the 
symptoms of jaundice (Isayama et al., 2016). Biliary stents generally come in two 
forms: plastic and self-expandable metal stents, each with their own benefits and 
risks (Moole et al., 2016). In a meta-analysis, Moole et al. (2016) compared covered 
and uncovered self-expandable metal stents and found that in the thirteen studies 
analysed that there were no significant differences overall when comparing survival 
and overall adverse event rates.  
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Chemotherapy is one of the main treatment options available for PC patients since 
fewer than 20% of patients are eligible for surgery upon diagnosis (Lin et al., 2015). 
Unlike surgery, chemotherapy is not a curative treatment option. Although there 
have been advances in treatment options and knowledge of PC, the outcome of 
therapy has failed to improve within the last 30 years (Polireddy and Chen, 2016). A 
range of chemotherapeutic agents have been in use against PC, yet none have had a 
significant impact upon survival rates. In recent years 5-fluorouracil (5-FU) was the 
standard chemotherapeutic treatment from discovery in the 1950s until only recently 
(Teague et al., 2015). Its successor, gemcitabine, is a nucleoside analogue which was 
shown in a randomised trial of PC patients to improve disease-related pain and 
survival rates in comparison to patients treated with 5-FU (Burris et al., 1997). This 
increased median survival from 4.41 months to 5.65 months and so gemcitabine 
became the key chemotherapeutic agent. More recently, combination therapy 
containing fluorouracil, oxaliplatin and irinotecan (FOLFIRINOX) outperformed 
gemcitabine monotherapy in a phase 2-3 trial in a number of areas including 
response to therapy and patient survival which was increased from 6.8 months to 
11.1 months (Conroy et al., 2011). Although promising, the Conroy et al. (2011) 
trials excluded patients aged over 76 so little data is available for elderly patients 
who make up the highest proportion of PC patients. A study was performed simply 
monitoring the geriatric response to FOLFIRINOX, and patients recruited were all in 
adequate health prior to treatment. The FOLFIRINOX therapy resulted in an overall 
survival of 12.51 months, which is easily comparable to the previous trials, coupled 
with toxicities including neutropenia and diarrhoea, which are common side effects 
of current chemotherapeutic regimes (Guion-Dusserre et al., 2016). However, the 
Guion-Dusserre et al. (2016) study had a small sample size, only recruiting 52 
patients, with only 18 having PC, with the remaining patients having colorectal 
cancer. As a result, further studies may be required to approve the use of 
FOLFIRINOX in an elderly patient cohort.  
Chemotherapeutic agents can also be used in conjunction with surgical intervention 
to improve the chances of surgery being successful. Neo-adjuvant chemotherapy is 
used before surgery in the hopes of turning borderline resectable disease to 
resectable disease, providing a more suitable candidate for surgical resection (Mirkin 
et al., 2016). Use of neo-adjuvant chemotherapy has increased by almost 4-fold 
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between 2003 and 2011 (Mirkin et al., 2016). A recent study considered the efficacy 
of a modified FOLFIRINOX without 5-FU (FIRINOX) as a neo-adjuvant therapy. 
Although a small study, consisting of only 10 patients, two treatment regimens were 
compared (4 cycles or 8 cycles of FIRINOX). Upon comparison of histopathologic 
results, R0 resection rate per case was 75 and 67% with 4 cycles and 8 cycles, 
respectively (Okada et al., 2016). Although a small sample size, Okada et al. (2016) 
demonstrated in a pilot study the efficacy of FIRINOX as a neo-adjuvant therapy, 
improving surgical resection rates in just 4 cycles of treatment, with toxicities 
reflecting commonly experienced chemotherapy side effects including leukopenia, 
anaemia, neutropenia, nausea and loss of appetite.  
Adjuvant chemotherapy has also been shown to be advantageous to PC patients. 
Unlike neo-adjuvant therapy, this is administered post-surgery. A comparison of 
neo-adjuvant and adjuvant chemotherapy with surgery resulted in overall survivals 
of 20.7 months and 13.7 months respectively (Shubert et al., 2016). The Shubert et 
al. (2016) study had a large sample size, following 593 patients and their treatment 
outcomes, and concluded that neo-adjuvant therapy resulted in an increased overall 
survival in comparison to adjuvant therapy. There are many reasons for neo-adjuvant 
therapy increasing the survival rate of PC patients in comparison to adjuvant therapy. 
One of the main reasons is that pancreatic surgery is no light undertaking and 
approximately 25% of patients who undergo surgical resection cannot undergo their 
expected course of adjuvant therapy due to surgical complications, comorbidities and 
disease recurrence (Bittoni et al., 2014). Thus, fewer patients tolerate the full 
treatment regime and so cannot benefit from the treatment in contrast to neo-
adjuvant chemotherapy patients. 
Palliative treatment is an important aspect of PC management. This occurs when the 
disease is too advanced for surgical resection and patients are simply too weak to be 
able to tolerate chemotherapy or radiotherapy treatment regimes. Not only is the 
malignancy the most painful from a clinical standpoint, it is a complex pain 
consisting of visceral, somatic and neuropathic pains (Lahoud et al., 2016). The 
traditional treatment of pain resulting from PC was opiate painkillers such as 
morphine. However, there are alternatives to opioid drugs. A coeliac plexus block is 
a temporary form of pain relief whereby an injection of anaesthetics or steroids into 
the celiac plexus provides long term relief of pain for a couple of months however, 
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celiac plexus neurolysis is a more permanent solution achieved through injection of 
ethanol or phenol into the coeliac plexus of nerves around the pancreas (McAninch 
et al., 2016). In a meta-analysis comparing 27 independent studies, the coeliac 
plexus block was shown to temporarily reduce pain and reliance upon opioid drugs 
regardless of which technique was used to perform the block (Mercadante et al., 
2015). When coeliac plexus neurolysis is performed, its effects have been shown to 
last at least 6 months or up until patient death showing only minor adverse effects 
including diarrhoea and mild hypotension, both of which were milder than opioid 
side effects (Yang et al., 2012).  
Given the poor prognosis and current treatment options which although have 
advanced have not improved disease survival rates, the search for new PC treatments 
is ongoing. Opioid growth factors have recently shown a therapeutic potential 
through their interactions with the G1/S interface of the cell cycle and so have been 
developed into biotherapies that could be used alongside traditional chemotherapies 
(Zagon and McLaughlin, 2014). In their study, Zagon and McLaughlin (2014) 
showed that combination of opioid growth factors with chemotherapeutic drugs 
gemcitabine and 5-FU resulted in greater inhibition of DNA synthesis than the 
chemotherapeutic drugs alone. Pancreatic stellate cells are also being investigated for 
their potential in therapy due to the complex roles they play in the maintenance of 
tumour growth and proliferation (Phillips, 2012).  
1.2.6 Survival 
Survival in patients with PC is bleak, with PC having the worst prognosis of all 
gastrointestinal malignancies (Bittoni et al., 2014). Despite its low incidence, it is the 
fourth leading cause of cancer related mortality globally and fifth within the UK 
(Cancer Research UK, 2014b; Aroldi et al., 2016). It is predicted to become the 
second leading cause of cancer related mortality by 2030 (Teague et al., 2015). This 
bleak prognosis results from most cases being too advanced for surgical resection at 
time of diagnosis (de Mestier et al., 2016).  
Median overall survival for PC patients is between 20 and 24 months (Bittoni et al., 
2014). One, five and ten-year survival rates for PC in the UK are 25.4, 7.3 and 5%, 
respectively (Cancer Research UK, 2020b). Female patients are shown to have a 
slight increase in survival over male PC patients, 1- and 5-year post diagnosis, but 
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this is not seen in the 10-year survival rates. Patient age has an influence on survival. 
Younger patients showed a higher 5-year survival rate in comparison to older 
patients. In male and female patients, 5-year survival decreases from 17% to 2% and 
26% to 2% from age 15-49 to age 80-99 (Cancer Research UK, 2020b). Stage of 
disease also impacts upon patient survival, given more advanced disease limits 
treatment options available. A multinational study analysed data from 125,183 PC 
patients, advanced stage disease (III and IV) resulted in shorter survival in 
comparison to earlier disease (I and II) and surgical resection increased survival both 
short and long-term (Huang et al., 2018). 
1.3 Cancer and DNA 
Cancer is a disease which starts in the DNA. DNA can be altered through mutation 
and DNA damage, both of which can play important roles in carcinogenesis.  
1.3.1 DNA Damage 
DNA is continually exposed to both endogenous and exogenous factors which can 
induce damage, which can in turn cause mutations as described above and hence 
alter health and cause disease (Chatterjee and Walker, 2017). DNA damage is 
defined as an alteration in the structure of DNA which could potentially cause 
cellular damage (Kaufmann and Paules, 1996). Depending on cell type in which the 
DNA damage is induced, it can have various effects. DNA damage can result in 
functional decline, aging and carcinogenesis (Hoeijmakers, 2009).  
1.3.1.1 Quantification of DNA Damage 
DNA damage quantification is a commonly used genotoxicity assessment tool. 
Numerous techniques can quantify the DNA damage induced in various cells and 
tissues following exposure to test chemicals. One of the main techniques used for 
this is the comet assay. First established in 1984, this assessed the migration of DNA 
in single cell gel electrophoresis under neutral conditions (Ostling and Johanson, 
1984). Developments came in 1988, comparing DNA migration in human 
lymphocytes exposed to x-ray radiation and hydrogen peroxide under alkaline 
conditions rather than neutral conditions (Singh et al., 1988). In the assay, cellular 
and nuclear membranes are removed through use of detergents and histones are 
removed from DNA using a high concentration of NaCl. DNA remains coiled within 
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a nucleoid region. Damaged DNA with single or double stranded breaks will not 
remain supercoiled without histone support. When an electrical charge is applied, the 
damaged, uncoiled DNA migrates towards the anode (Collins, 2015). DNA 
migration following exposure to genotoxic compounds is measured, quantified, and 
compared. During gel electrophoresis, the DNA fragments induced by DNA damage 
migrate from the nucleoid body to the anode to form a comet tail. The tail moment 
describes the DNA migration looking at both the tail length and the percentage of 
DNA found within the tail (Møller, 2018). The comet assay has been used in a range 
of cell types, assessing DNA damage in response to varying stimuli. Limitations of 
the assay are apparent, with wide inter-laboratory variations (Sirota et al., 2014). 
Sources of said variations include the temperature of the alkaline solution used and 
the temperature the electrophoresis steps are carried out in (Sirota et al., 2014).  
1.3.2 DNA Mutation 
Mutation results in the altering of the sequence of nucleotides in the DNA sequence, 
whether in the coding or non-coding regions of DNA (Mahdieh and Rabbani, 2013). 
DNA mutation is a heritable change in the DNA, including point mutations (base 
changes) and chromosome level alterations (copy number changes, translocations 
etc). There are three main types of point mutation, which can occur in the DNA: base 
substitutions, deletions, and insertions.  
Substitution mutations are when nucleotides are replaced with alternative 
nucleotides, altering the DNA sequence. The effect that a base substitution mutation 
has depends on the location of the mutation within the DNA and whether it 
influences the protein encoded in the gene. Mutation in non-coding DNA regions 
may have an influence on the transcription of the downstream gene rather than 
altering the gene product itself. For example, the substitution mutation may increase 
the strength of the promoter region, resulting in greater gene expression (Mahdieh 
and Rabbani, 2013). Mutations in coding regions of DNA can be categorised as 
nonsense, missense and silent. During translation, silent mutations result in a codon 
which recruits the same amino acid as the wildtype sequence, missense mutations 
result in a codon which recruits a different amino acid, altering the resulting 
polypeptide’s amino acid sequence and finally nonsense mutations encode a stop 
codon, halting translation and forming a truncated polypeptide product (Scitable, 
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2014). Some missense mutations are phenotypically silent, with amino acid changes 
not altering protein function. One of the most common mutational signatures found 
in majority of cancer types is a base substitution found at a CG:CG dinucleotide 
(Bacolla et al., 2014). Commonly, a C→T mutation is induced by deamination of 5-
methylcytosine to form a TG:CG. The resulting mismatched T:G causes a G→A 
transition during the following round of DNA replication to form TG:CA sequence 
(Bacolla et al., 2014). Specific base substitution mutations have been linked with 
different cancer developments. For example, lung cancer has been linked with 
different base substitutions dependent on chemical cause of disease. Arsenic 
exposure linked lung cancer has a mutational signature of T:A→G:C in contrast to 
the tobacco linked lung cancer with its signature of C:G→A:T (Bacolla et al., 2014). 
Both deletion and insertion mutations result from a slipped template strand of DNA 
during DNA replication, either nucleotides can be omitted resulting in a deletion or 
an extra nucleotides can be added by DNA polymerase (Scitable, 2014). The 
resulting daughter strands of DNA with altered DNA sequence can result in a 
frameshift mutation. Insertion of bases of multiples of 3 (3, 6, 9 bases) will not alter 
frame given codons read in blocks of 3 bases.  mRNA transcribed from the altered 
DNA acts as the template for the ribosomes for translation, but the reading frame is 
shifted resulting in a different amino acid sequence in the polypeptide chain 
(Scitable, 2014). Examples of insertion and deletion mutations are present within 
human cancers. Insertion within the EGFR exon 20 is a rare mutation. Within non-
small cell lung cancer has been linked with lack of sensitivity to first line treatment, 
which has been suggested to be as a result of conformational changes within mutant 
EGFR (Byeon et al., 2019). A 12 base insertion mutation has been identified in lung 
cancer within driver gene HER2, which has been identified using Sanger sequencing, 
next generation sequencing and a modified PCR method (Takase et al., 2017). 
Sequencing of exons 4-10 of p53 in samples from ovarian cancer tumours identified 
microdeletions within 4% of samples (Kohler et al., 1993). 
1.3.2.1 DNA Mutation Identification and Quantification 
Various techniques have been established and utilised to identify mutations within 





The polymerase chain reaction (PCR), first carried out experimentally in 1986, is a 
highly useful tool used to amplify and replicate segments of DNA (Mullis et al., 
1986; Lorenz, 2012). It can amplify a small starting fragment of DNA 106-107 fold 
before additional techniques like endonuclease digestion and gel electrophoresis can 
be employed (Boehm, 1989). Overall, PCR has three main steps of denaturation of 
the DNA double strands, annealing of primers to the template DNA and elongation 
of the PCR product with DNA polymerase and nucleotides, repeated in a cycle up to 
40 times (Lorenz, 2012). PCR as a technique can occasionally result in poor results 
which are a mixture of sizes seen on agarose gels, mutations can be introduced 
during the experiment and sometimes no product can form at all (Lorenz, 2012). 
Careful preparation can make the technique a powerful tool. Modifications of the 
technique include real-time PCR, allow the technique to be used quantitatively. PCR 
based techniques have been used to assess the mutation status of KRAS genes, 
proto-oncogenes involved in carcinogenesis of the lung, colon, rectum and pancreas 
(Van Mansfeld and Bos, 1992). Notably, in pancreatic cancer and lung cancer, point 
mutations in RAS were exclusively found within codon 12, corresponding to the 
active site of the GTPase (Van Mansfeld and Bos, 1992; Imamura et al., 2012). 
Restriction fragment length polymorphism analysis on PCR products is one of the 
most useful PCR-based mutation detection techniques since it is quick, simple, 
reliable and does not rely on radiolabelled chemicals (Van Mansfeld and Bos, 1992). 
Allele-specific PCR has also been shown to be a valuable tool for identifying 
mutation and single nucleotide polymorphisms. Using highly specific primers for 
known alleles, any primer, which mismatches at the 3’ end will stall DNA synthesis 
(Ugozzoli and Wallace, 1991). This has shown usefulness within a clinical setting, 
being used for a range of genetic and infectious disease diagnosis (Ugozzoli and 
Wallace, 1991).  
1.3.2.3 DNA Sequencing 
Despite this, PCR alone could not describe the whole DNA sequence. DNA 
sequencing elucidates the specific nucleotide sequence, which can then be compared 
against wild type DNA sequences to identify mutations. DNA sequencing was first 
introduced by Fred Sanger in 1977 in a ground-breaking technique, utilising dideoxy 
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terminator nucleotides (Sanger et al., 1977; McGinn and Gut, 2013). This remained 
the best sequencing technique for  decades. Sanger sequencing was used for the first 
sequencing of our own genome in the Human Genome Project, which began in 1990, 
at a huge time investment of multiple groups across the globe working 
collaboratively and a massive financial investment of approximately $3 billion 
(Lander et al., 2001; McGinn and Gut, 2013). As novel sequencing techniques have 
built upon Sanger’s foundations, sequencing is now a much quicker and cheaper 
process. Next generation sequencing techniques allow for parallel sequencing of 
small DNA fragments, compiled using bioinformatics and human reference genomes 
(Behjati and Tarpey, 2013). Next generation sequencing has huge potential to assist 
in a clinical setting, identifying more mutational signatures than Sanger sequencing, 
including larger insertions and deletions. However, drawbacks of next generation 
sequencing include GC rich regions, which tend to form secondary structures within 
the DNA, commonly found in Fragile X syndrome and Huntington’s Disease and the 
financial sacrifice which would be required to assemble this within a clinical setting, 
with staff, equipment and required infrastructure. A high sample volume would be 
required to justify its clinical use due to the high costs (Behjati and Tarpey, 2013). 
1.3.2.4 HPRT Mutation assay 
The hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assay, first 
established in 1981, determines the mutation status of reporter gene HPRT through 
studying resistance to toxic nucleotide analogue 6-thioguanine (Furth et al., 1981; 
Johnson, 2012). It was first used in human lymphoblastic cell lines and more 
recently, it has been used in human AHH-1, MCL-5 and most commonly the 
Chinese hamster ovary, cell line (Furth et al., 1981; Johnson, 2012). Studies have 
also applied the assay to primary lymphocytes isolated from humans and rodents 
(Lambert et al., 1995; Casciano et al., 1999). HPRT is the endogenous X-linked gene 
commonly mutated in the rare neurological disorder Lesch-Nyhan syndrome 
(Nguyen and Nyhan, 2016). The assay is split into two stages: mutant cleansing and 
mutant selection. Cleansing is achieved using a hypoxanthine-aminopterin-
thymidine (HAT) addition into culture medium which in turn blocks endogenous and 
salvage pathways for nucleotide synthesis, which is fatal for HPRT- cells (and TK-/- 
HPRT+). Only HPRT+ cells survive the cleansing stage. Surviving cells are exposed 
to the test genotoxin before the second stage of mutant selection. HPRT mutants are 
50 
 
selected through exposure to 6-thioguanine, a toxic analogue of deoxyguanosine 
triphosphate. HPRT- cells survive the mutant selection phase given they are unable 
to incorporate toxic 6-thioguanine into their DNA through the salvage pathway 
(Johnson, 2012). The assay measures induction of mutation in the HPRT locus 
following exposure to test genotoxins, with ethyl-methanesulphonate commonly 
used as a positive control (Johnson, 2012). The assay has been used in a variety of in 
vivo studies, both within healthy populations and exposed workers, including those 
who survived nuclear events including Chernobyl and atomic bombs (Richard J. 
Albertini, 2001). Benefits of the assay include the simplicity of an X-linked gene, 
requiring one mutational hit for an altered phenotype. It is heavily relied upon 
technique within the genotoxicology community.  However, drawbacks include both 
the time and labour-intensive nature of the assay (Bryce et al., 2008).  
1.3.2.5 PIG-A Mutation Assay 
1.3.2.5.1 PIG-A Assay Background 
The phosphatidylinositol glycan biosynthesis class A gene (PIG-A in humans and 
Pig-A in rodents), found on p22.1 of the X chromosome, is also used as a reporter 
gene, similar to HPRT (Kawagoe et al., 1994). PIG-A encodes the catalytic domain 
of N-acetylglucosamine transferase, used in the very first step of 
glycophosphatidylinositol (GPI) anchor biosynthesis (Gollapudi et al., 2015). GPI 
anchor biosynthesis is a complex mechanism, involving 21 genes but PIG-A remains 
the only X-linked gene, so a single mutation in this gene can inactivate the enzyme 
and prevent GPI anchor biosynthesis (Fig. 1.6) (Krüger et al., 2015; Gollapudi et al., 
2015; Horibata et al., 2016).  
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Much of the development of the assay was based on the knowledge of the rare, 
acquired, genetic disease paroxysmal nocturnal haemoglobinuria (PNH). An 
estimated incidence of the disease is around 0.1 - 0.2 person per year per 100,000 
people but a definite figure is unknown (Devalet et al., 2015). The most common 
form of PNH is due to a de novo somatic mutation in PIG-A. If this mutation arises 
in a pluripotent haematopoietic stem cell, all resulting blood cells (erythrocytes, 
leukocytes and thrombocytes) will also have this mutation in PIG-A (Devalet et al., 
2015). The result of this is significant numbers of blood cells lacking GPI anchored 
complement inhibitors CD-55 and CD-59 (Sahin et al., 2015).  CD-55, more 
commonly known as the decay accelerating factor, inhibits the activation of the 
complement system through interaction with C3 and C5 convertases (Liu et al., 
2005). CD-59 also inhibits the complement system through blocking the formation 
of the membrane attack complex through binding of C8 and C9 (Cai et al., 2014). 
Lacking these complement inhibitors, blood cells are vulnerable to complement 
Figure 1.6: GPI anchor structure and associated genes involved in the biosynthesis 




attack. Notably erythrocytes are prone to intravascular haemolysis, which can lead to 
fatal thromboses (Chrobák, 2000). This potentially life-threatening disease can be 
treated through bone marrow transplantation, preventing complete bone marrow 
failure; and monoclonal antibody eculizumab, which prevents formation of the 
membrane attack complex through binding C5 (Brodsky, 2009).  
Diagnosis of PNH involves flow cytometry for identifying a large population of GPI 
deficient cells, lacking both CD-55 and CD-59. This approach was adopted in the 
PIG-A mutation assay to screen for the much rarer induced PIG-A mutations through 
the phenotypic assessment of GPI deficient mutant blood cells using fluorescent 
antibodies for GPI anchored cell surface proteins (Fig 1.7). GPI anchor deficient 
cells are non-fluorescent and defined as PIG-A mutant. 
  
Figure 1.7: A) PIG-A wildtype cell with GPI anchor present on cell surface, GPI 
anchors identified with fluorescently labelled antibodies for GPI anchored proteins. 
B) PIG-A mutant cell deficient in GPI anchors. PIG-A mutant is non-fluorescent in 
flow cytometric analysis (Haboubi et al., 2019). 
The assay, as well as being based on knowledge of PNH and diagnostic techniques 
involved, aimed to mirror and build upon pre-existing genotoxicity assays. The 
HPRT and GPA genotoxicity assays have been previously established. The HPRT 
assay has been previously discussed in Chapter 1.3.2.4. The GPA assay is an in vivo 
approach to study two erythrocyte populations using allele-specific monoclonal 
antibodies via flow cytometry (Grant, 2005). Loss of a single allele followed by 
53 
 
replication of the other allele has been linked to loss of heterozygosity in a tumour 
suppressor gene. As a result, this assay has been used to study genotoxicity and used 
more diagnostically in patients with known predispositions for developing cancer 
(Myers and Grant, 2014). The assay is complicated through the autosomal nature of 
the GPA gene, requiring test subjects to co-express the M and N allele, limiting the 
assay to approximately 50% of the population (Bryce et al., 2008). The PIG-A assay 
combines the accessibility of a flow cytometry-based assay, with the simplicity of an 
endogenously expressed X-linked gene.  
The assay has been optimised in a range of cell types both in vitro and in vivo.  
1.3.2.5.2 The Human Erythrocyte PIG-A Assay 
The erythrocyte PIG-A assay was first established in 2008 and since then has been 
extensively used in rodent genotoxicity studies, assessing induction of mutation 
following exposure to test chemicals (Bryce et al., 2008). Following its success, the 
assay has been applied to a range of human blood cell populations (Rondelli et al., 
2013). In the human erythrocyte PIG-A assay, wild type and mutant erythrocytes are 
distinguished using fluorescent antibodies. Various commercial kits are available for 
assessing the mutation status of PIG-A depending on the organism and cell type to 
be analysed. Our laboratory uses a trio of antibodies against the GPI anchored 
complement inhibitor proteins CD-55 and CD-59, and against the erythroid marker 
CD235a (Karsten et al., 2010). This allows sufficient separation of the erythrocytes 
into wild type and PIG-A mutant populations. 
Although the use of the assay in humans is in its infancy stage, it has been applied in 
several population studies and is showing promise. For example, a Chinese group 
performed a population study on a cohort of 217 healthy volunteers with ages 
ranging between 18 and 92 years (Cao et al., 2016). The average frequency of PIG-A 
mutant erythrocytes in these patients was 5.25 ± 3.6 x 10-6. Age was shown not to be 
an influencing factor on the PIG-A mutant frequency by Poisson univariate analysis. 
Cao et al. (2016) also investigated whether smoking had an impact on the PIG-A 
mutation frequency. Smoking alone was insignificant, but cigarette pack years, 
defined as 20 cigarettes per day per year, was slightly associated with an increase 
PIG-A mutant frequency. Interestingly, in this study, there was found to be 
significant differences with mutant frequency in male and female donors with 
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mutation frequencies of 5.97 ± 4.0 and 4.19 ± 2.5 x 10-6 PIG-A mutant erythrocytes, 
respectively (Cao et al., 2016). A smaller healthy population study on 52 donors 
found no significant difference between sex and mutant frequency, but did suggest a 
correlation between the age of the donor and the PIG-A mutant frequency in contrast 
to the Cao et al. (2016) study (Dertinger et al., 2015). An earlier, Italian study 
monitored the PIG-A mutant frequency in an alternative blood cell population. 
Rondelli et al (2013) studied the peripheral granulocyte cells in a healthy population 
study of 110 donors, showing a mean mutant frequency of 4.9 x 10-6 PIG-A mutant 
granulocytes. This showed the assay can be applied to various blood cell populations 
with ease. 
Not only has the assay been used in human population studies, but it has also been 
used in a small number of oncology studies. For example, a study of 27 cancer 
patients undergoing therapeutic intervention of chemotherapy, radiotherapy or a 
combination of the two (Horibata et al., 2016). Of these, three patients (of the 27) 
had PC treated with gemcitabine and had blood drawn and analysed six days post-
gemcitabine treatment. The conclusion of this study was that cancer patients have 
unremarkable levels of PIG-A mutant erythrocytes in comparison to healthy donors. 
However, problems with the study design lead to questioning this conclusion. A 
wide and inconsistent range of cancers were analysed within this study, all with 
differing treatment regimens, so data collected was not comparable. No baseline 
measures of the PIG-A mutant frequency were collected from newly diagnosed, 
treatment-naïve patients before their treatments were initiated. Therefore, it could not 
have been determined whether the mutations change over time following treatment 
initiation. The slow turnover of erythrocytes was not considered when choosing the 
timings of blood collection post-therapy. They may not have been timed best to view 
the phenotypic change in PIG-A mutant erythrocytes. Within our own research 
group, the human erythrocyte PIG-A assay has been explored in patients with 
oesophageal adenocarcinoma and pre-malignant Barret’s metaplasia. In this study, 
337 participants consisting of 137 healthy controls and 200 patients (77 gastro-
oesophageal reflux, 62 non-dysplastic Barrett’s metaplasia, 11 dysplastic Barrett’s 
metaplasia, 42 oesophageal adenocarcinoma) were examined using the PIG-A assay 
(Haboubi et al., 2019). Within this, healthy donors had a median frequency of 2.8 x 
10-6 PIG-A mutant erythrocytes, high grade dysplastic patients had a median of 7.89 
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x 10-6 PIG-A mutant erythrocytes, and oesophageal adenocarcinoma patients had 
further elevated mutation frequency around 9.75 x 10-6 PIG-A mutant erythrocytes. 
1.3.2.5.3 In Vitro Pig-A Assay 
Given the success and ease of the erythrocyte PIG-A assay, an in vitro PIG-A assay 
has also been established. A range of cell lines commonly used within genotoxicity 
studies have been explored in the in vitro PIG-A assay, including human 
lymphoblastoid cell lines TK6 (Krüger et al., 2015; Krüger et al., 2016; Rees et al., 
2017; Piberger et al., 2018) and metabolically capable MCL5 (Rees et al., 2017) and 
the mouse lymphoblastoid L5178Y cell line (David et al., 2018). The L5178Y cell 
line will be utilised within this study due to low background Pig-A mutant frequency 
(0.08 ± 0.06%) (David et al., 2018). 
1.3.2.6 Micronucleus Assay 
The micronucleus (MN) assay is one of the most widely used genotoxicity assays, 
further discussed in chapter 3.1.6. This well-established technique has been in use 
for almost 40 years (Sommer et al., 2020). The MN assay monitors genomic stability 
through studying the induction of micronuclei, small, membrane bound vesicles 
containing DNA outside of the primary nucleus following exposure to genotoxins 
(Kisurina-Evgenieva et al., 2016; Sommer et al., 2020). Induction of micronuclei is 
achieved by a range of physical factors including radiation, as well as chemical 
factors which affect DNA structure (Kisurina-Evgenieva et al., 2016).  
MN are produced during the process of mitosis. During anaphase, chromatids 
migrate towards the poles of the cell as kinetochore microtubules shorten. At this 
stage, the MN begin to form. They can be formed through two separate processes. 
Disturbances with the mitotic spindle result in a whole chromosome not migrating to 
the cellular pole. Alternatively, unrepaired strand breaks and unrepaired DNA 
lesions result in an acentric chromosomal fragment not migrating far enough to be 
incorporated into the primary nucleus (Iarmarcovai et al., 2008).  Micronuclei then 
form, containing either the chromosomal fragment or an entire chromosome. MN 
containing acentric fragments are classified clastogenic events and MN containing 
full chromosomes are defined as aneugenic events since they result in aneuploidy 
(Iarmarcovai et al., 2008). Different chemicals will induce either aneugenic or 
clastogenic MN depending on their mode of action. Example clastogenic chemicals 
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include mitomycin C, bleomycin and doxorubicin, and aneugenic chemicals include 
diethylstilbestrol, griseofulvin and vincristine sulphate (Rosefort et al., 2004). 
Kinetochore/centromere staining of the MN post-fixation (chromosome paints or 
antibodies to the kinetochore) can be harnessed to determine whether chemicals act 
as a clastogen or an aneugen since clastogenic MN will lack 
kinetochores/centromeres.  
The most common form of the MN assay is the cytokinesis block MN (CBMN) 
assay, Fig 1.8. Cytochalasin-B is used to block cytokinesis, discussed in 3.1.6. 
 
Figure 1.8: CBMN assay 1) Cell exposed to chemical, DNA damage is induced 2) 
Cells divide in the presence of cytochalasin-B, blocking cells in the binucleate phase 
as cytokinesis is inhibited 3) example binucleate cells in control, without 
micronuclei, and in treated cells with micronuclei, signified by red arrows (Sommer 
et al., 2020). 
Scoring numbers of MN allows for comparison of the induction of MN by different 
agents or environments. Scoring criteria are shown in Table 1.1. These criteria were 





Table 1.1: Scoring criteria for MN assay according to (Fenech, 2007). 
Scoring Criteria for Micronuclei 
Morphologically identical to primary nuclei, but smaller 
Diameter of MN between 1/16th and 1/3rd of primary nucleus 
Can be readily distinguishable from staining artifacts 
Not linked or connected to primary nucleus 
May touch primary nuclei, but not overlap. Nuclear boundaries should be 
distinguishable 
Staining intensity should be similar to primary nuclei, although can be brighter on 
occasion 
 
There are many benefits of using the MN assay. The assay has been well established 
and used for decades. It is a flexible technique, established in a wide variety of cell 
lines, adherent or suspension, as well as primary cell cultures. This allows the 
assessment of DNA damage induction in a wide variety of cell and tissue types.  
The in vitro CBMN assay has been applied to numerous cell populations isolated 
from human living donors. For example, blood cells have been assessed by the MN 
assay to monitor overall DNA damage of individuals. Within a lymphocyte 
population, the CBMN assay has been used a biomonitoring tool (Sommer et al., 
2020). The lymphocyte CBMN assay has been previously used for genotoxin 
exposure assessment, studying micronutrient deficiencies and excesses, assessment 
of genome stability, but has also been used for a measure of overall risk of 
development of cancer or other age-related degenerative diseases including 
Alzheimer’s disease, Parkinson’s disease and cardiovascular disease (Migliore et al., 
2011; Andreassi et al., 2011; Bolognesi and Fenech, 2013). The human peripheral 
lymphocyte CBMN assay is further explored in chapter 5.1.1. The human buccal 
micronucleus cytome assay assesses the induction of DNA damage in human buccal 
cells, obtained through non-invasive cheek swabs (Bolognesi and Fenech, 2013). 
The buccal MN assay has been used to monitor induction of DNA damage induced 
by lifestyle and dietary factors, and also showed a correlation with cancer risk, aging 
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and specific neurodegenerative diseases (Sommer et al., 2020). The MN assay can 
also be carried out in the reticulocytes lacking nuclei and less commonly in cells 
collected from nasal passages and derived from urine samples (Sommer et al., 2020).  
The in vitro CBMN assay is one of the best established, widely used assays for the 
study of induced DNA damage. It’s been utilised within the field of toxicology, as 
well as nutritional and pharmaceutical industries (Ladeira et al., 2015). It has been 
established in a number of cell lines including rodent cell lines CHO, V79 and 
L5178Y as well as human cell lines including TK6 and MCL5 (OECD, 2016). 
Cytochalasin-B use results in more trustworthy results in the CBMN assay (Heddle 
et al., 2011). Use of cytochalasin-B arrests cytokinesis and the resulting scoring of 
binucleated cells ensures all cells scored have undergone division following 
exposure to the test chemical (Heddle et al., 2011). However, drawbacks of the 
technique include that cytochalasin-B cannot be used with all cell lines. This is seen 
with commonly used cell line L5178Y. Cytochalasin-B has shown poor results when 
used with L5178Y cell line with reports of sensitivity. Notably, cytochalasin-B has 
been potentially linked to poorly preserved L5178Y cells for micronucleus scoring 
(Oliver et al., 2006; OECD, 2016).  
1.4 Aims 
PC diagnosis is late, resulting in late clinical intervention and poor disease 
prognosis. Early detection systems are urgently needed for PC. The human 
erythrocyte PIG-A assay has been previously explored in a patient cohort with 
oesophageal adenocarcinoma (Haboubi et al., 2019) and various healthy population 
studies and shown to suggest elevated numbers of mutated cells in cancer patients. In 
this study, we aimed to determine whether the non-invasive, blood-based, human 
erythrocyte PIG-A assay has any potential in diagnosing PC. This was achieved 
through recruiting patients with benign and malignant disease to the study who 
donated whole blood and a lifestyle questionnaire. The PIG-A mutation assay was 
carried out on whole blood and the remainder of the blood was separated and buffy 
layer was harvested for the peripheral blood mononuclear blood cell (PMBC) 
CBMN assay to establish a second measure of DNA damage in an alternative blood 
cell population. Mutation induced in erythrocytes monitored by the PIG-A assay was 
compared with DNA damage explored in the PMBC CBMN assay, with additional 
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clinical parameters also assessed.  I established here whether PIG-A mutation 
frequency was associated with pancreatic disease and if so, was it linked with disease 
staging. Additionally, we looked at combining biomarkers to see whether this is 
more predictive for PC. Alongside in vivo work, an in vitro model was utilised to 
study known pancreatic carcinogens which are known to increase the risk of 
developing PC. We aimed to monitor the DNA damage and mutation induced 
through high fat diets, tobacco smoking and alcohol abuse through use of the MN 
assay and an in vitro Pig-A assay. The in vitro model explored whether poor lifestyle 
choices may account for some of the mutations viewed in the human erythrocyte 























Chapter 2: Materials and Methods 
2.1 General Materials and Methods 
Specific methods are described in more detail in individual results chapters. Here, we 
describe general materials and methodologies used. 
2.1.1 Equipment  
Table 2.1: Equipment used within study and suppliers of the equipment 
Equipment Supplier 
Centrifuge tubes: 15mL and 50mL Fisherbrand 
Centrifuge 5810R Eppendorf 
 
CO2 air-jacketed incubators Nuaire™ 
Cytospin™ 4 Thermo Scientific™ 
Flow cytometers: 
BD FACS Aria I™ Flow Cytometer 
Navios™ Flow Cytometer 
 
Becton Dickson Biosciences 
Beckman Coulter Life Sciences 
Freezer (-20°C) Proline 
Freezer (-80°C) Proline 
Fridge (4°C) Proline 
Fume hood Clean Air Limited 
Heat block Techne Dri-Block 
Microcentrifuge tubes Eppendorf 
Microscopes: 







Pipette tips StarLAB 
Pipettes Gilson, Eppendorf 
Pipettors StarLAB, Fisherbrand 
Shandon ™ White Filter Cards Thermo Scientific™ 
Shandon™ Cytofunnel Thermo Scientific™ 
Tissue Culture Flask: 25, 75, 125 cm2 Cellstar 
Tissue Culture Hood Scanlaf Mars 
SUB Aqua 18 Waterbath 
 
Grant 
Z1 Coulter Counter Beckman Coulter Life Sciences 
 
2.1.2 Reagents 
Table 2.2: Reagents used within the study and suppliers of the reagents 
Reagent Supplier 
Acetaldehyde Solution Sigma-Aldrich 
Acetic Acid Fisher Scientific 
Benzo-[a]-pyrene Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Cytochalasin B Merck 
Deoxycholic Acid Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO) Fisher Scientific 
DMEM Gibco® 
DPX Mounting Medium Fisher Scientific 
Ethanol Fisher Scientific 
63 
 
Foetal Bovine Serum (FBS) Gibco® 
Glutamine  Gibco® 
Heat-inactivated Horse Serum Gibco® 
Histopaque®-1077 Sigma-Aldrich 
Methanol Fisher Scientific 
Penicillin-Streptomycin Gibco® 
PHA Sigma-Aldrich 
Phosphate Saline Buffer (PBS) Gibco® 
Pluronic F-68 Gibco® 
Potassium chloride Sigma-Aldrich 
RPMI 1640 Gibco® 
RPMI Dutch Modification Gibco® 
Sodium chloride Sigma-Aldrich 




2.1.3 Stains and Antibodies 




APC anti-CD-235a BD Pharmingen 
APC anti-CD-45 Biolegend 
Giemsa Stain Solution Gurr® VWR International limited 
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PE anti-CD-55 BD Pharmingen 
PE anti-CD-59 BD Pharmingen 
PE anti-CD-90.2 Biolegend 
Trypan Blue Solution (0.4%) Sigma-Aldrich 
VECTASHIELD® Antifade Mounting 
Medium with DAPI 
Vector Laboratories 
Zombie Violet™ fixable viability kit Biolegend 
 2.1.4 Computer Software 
Table 2.4: Computer software used in the study with associated version numbers and 
suppliers. 
Software Version Supplier 
Microsoft Word  Microsoft 
Microsoft Excel  Microsoft 
SPSS 26 IBM 
BD FACS Diva 8.0 Becton Dickson 
Biosciences 
Navios Software  Beckman Coulter Life 
Sciences 
Metafer 4 3.9.8 Metasystems 
 
2.2 In Vitro Studies 
2.2.1 Cell lines 






PANC-1 is an adherent pancreatic adenocarcinoma cell line isolated from a 56-year 
old Caucasian male. Cells, seen in Fig. 2.1, were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% foetal bovine serum, 1% 
glutamine and 1% penicillin-streptomycin at 37°C, 5% CO2 humidified atmosphere. 
Cells were detached through trypsinisation, diluted and sub-cultured every 48 hours.  
2.2.1.2 L5178Y 
L5178YTK+/- is a suspension lymphoblastoid cell line derived from a chemically 
induced lymphoma from Mus musculus (mouse) (ATCC, 2016b). Cells were 
maintained in RPMI Dutch modification media supplemented with 10% heat-
inactivated horse serum, 1% glutamine, 1% penicillin-streptomycin, 5.5 mL sodium 
pyruvate and 5.5 mL pluronic F-68 at 37°C, 5 % CO2 humidified atmosphere in the 
density of 3 x 104 and 5 x 105 cells/mL. L5178Y cells required sub-culturing every 
24 hours. 
 




2.2.2 Cell Culture 
All cell culture was carried out in sterile conditions. This included wearing 
laboratory coats only worn within cell culture and gloves. All work was carried out 
within tissue culture hood sterilised with 70 % ethanol before and after use, with all 
plastic consumables sterilised through autoclaving and every item taken into the 
tissue culture hood was wiped down with 70 % ethanol before use. Further cell 
culture details are found within chapter 3. 
2.2.3 Cell Counting 
Cell counting was achieved using the automated Z1 Coulter Counter. Cell 
suspension was diluted with 100 µL cell suspension in 10 mL of diluent and returned 
and particles were counted between the sizes of 5 and 13 µm, providing a count of 
cells per mL. With adherent cell lines, cells were detached through trypsinisation 
initially so were in a solution.  
Cell counting was achieved using the haemocytometer for the trypan blue exclusion 
assay, further detailed in 3.2.2.  
2.3 In Vivo Studies 
2.3.1 Study Design and Patient Recruitment 
Study documents were prepared, and ethical approval was sought using the 
integrated research application system (IRAS) (IRAS project ID: 218936). Ethical 
approval was granted by Plymouth and Cornwall Research Ethics Committee (REC 
reference: 17/SW/0012) followed by R&D approval from the Swansea Bay 
University Health Board. 
Patients with benign and malignant pancreatic disease were recruited from October 
2017 to September 2019 in the outpatient surgical clinics at Morriston Hospital, 
Swansea. Valid informed consent was taken, and patients completed a modified 
validated questionnaire and donated 9 mL of whole blood.  
2.3.2 Questionnaire 
Participants in the study completed a modified Extended Prostate Cancer Index 
Composite (EPIC) questionnaire to provide further information about dietary and 
lifestyle choices of the patient, Appendix 7.1.3.  
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Dietary information was used to provide a dietary quality score (DQS), calculated 
using guidelines in Table 2.5 (Toft et al., 2007). The DQS was first developed 
according to recommended guidelines for daily or weekly intake of food groups and 
allowed for classification of dietary habits into healthy (7-9 score), average (4-6) and 
poor (3) categories (Toft et al., 2007).   
Table 2.5: Guide for calculating DQS from EPIC questionnaire (Toft et al., 2007). 




 ≥5-7 servings per 
week 
3 
  In between 2 
  ≤2 servings per 
week 
1 
Fruit  ≥3 pieces per day 3 
  ≥3 pieces per week 
and ≤2 pieces per 
day 
2 
  ≤2 pieces per week 1 
Fish  ≥200g per week 3 
  In between 2 
  No intake 1 
Fat – Bread  None 3 
  Vegetable 
margarine 
2 
  Butter, blended 
spread, or lard 
1 
Fat – Cooking  None, olive oil 3 
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  Vegetable 
margarine, oil 
2 
  Margarine, butter, 
blended spread, or 
lard 
1 
Fat – Summarised  6 points total 3 
  3-5 point total 2 
  2 points total 1 
Furthermore, our questionnaire collected general health information and information 
regarding exercise levels for an overall snapshot of the patient’s health, diet, and 
lifestyle. 
2.3.3 Blood Collection 
Whole blood was collected by venepuncture into a 9 mL sodium-heparin coated 
blood tube. All blood collection was carried out within the outpatient’s department 
of Morriston Hospital, Swansea with blood taken by suitably trained staff. Blood 
was packaged and transported to the university in the locked boot of a car before 
analysis on receipt at the university.   
2.4 Statistics 
Statistical analysis on data collected was carried out using SPSS (v.26, IBM) 
computer software. Normality of data was determined using the Shapiro-Wilk test. 
Data determined to be normally distributed was analysed using the ANOVA and t-
tests where appropriate. Non-normal data was analysed using the Mann Whitney U 






















Chapter 3: In Vitro Model of Pancreatic Cancer 
3.1 Introduction 
3.1.1 Risk Factors for Pancreatic Cancer 
Numerous risk factors have been associated with an increased risk of developing PC. 
As many as 37% of all cases of PC are thought to be preventable through better 
lifestyle and dietary choices (Cancer Research UK, 2014b). Ongoing health 
conditions also put patients at risk for developing PC. Diabetes mellitus increases the 
risk of developing PC but also poorly controlled or new onset diabetes is often a 
symptom of early PC (Cancer Research UK, 2016c; Lishan Wang et al., 2016). In 
this situation, chronic inflammation in pancreatic islets, mediated by p38 MAPK, 
increases proliferation, apoptosis and metastasis (Lishan Wang et al., 2016). 
Additionally, common treatment with insulin analogues have shown to increase the 
risk of developing PC in comparison to biguanide metformin (Amin et al., 2016). 
Chronic inflammation of the pancreas has also been linked with PC development in 
patients with chronic pancreatitis. This drives NF-kB activation, and increases the 
development of pre-malignant pancreatic lesions including IPMN, MCN and panINs 
(Krška et al., 2015; Gudkov and Komarova, 2016). Given the poor outcome for the 
disease and high proportion of avoidable cases, better education about the risks of 
poor lifestyle may be beneficial to reduce the 37% of avoidable causes. 
3.1.2 Tobacco Smoking 
Smoking continues to be a global health concern. Within the UK itself, the most 
recent Office for National Statistics (ONS) surveys state in 2018 that 14.7% of all 
adults (aged 18 and above) are current smokers (Adult smoking habits in the UK - 
Office for National Statistics, n.d.). When this is broken down into countries within 
the UK, England has the lowest incidence of smoking (14.4%) with Wales higher 
with 15.9% of all adults smoking. Swansea, where this study is based, had a greater 
than national average of 17.003% of adults smoking tobacco (Adult smoking habits 
in the UK - Office for National Statistics, n.d.). Increased smoking has been linked to 
more social deprivation, 17% of Swansea’s lower super output areas, defined as 
small geographical regions with mean population of 1,500 (minimum population of 
1,000), have been ranked in the top 10% of deprived areas in Wales in a recent study 
by the Welsh Government (Swansea Council, 2020). On a positive note, since 2011 
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there has been a 5-percentage point decrease in smokers across the UK. Much of the 
reduction of smoking has been attributed to awareness of health risks and 
alternatives including e-cigarettes which have 3.2 million users UK-wide (Adult 
smoking habits in the UK - Office for National Statistics, 2019).  
Smoking is renowned for negative health implications whether benign or malignant. 
Smoking has been associated with the development of cancers of several organs. As 
many as 29% of PC cases have been linked with tobacco smoking (Cancer Research 
UK, 2014b). Smoking is often a life-long habit and as a result of each decade of 
smoking, there is a 16% increased risk of PC development as well as a 1.71-fold 
increase in risk of death in PC patients who are current smokers in comparison to 
non-smokers (Wang et al., 2014; Barone et al., 2016). Smoking has also been shown 
to reduce median survival time in PDAC patients from 11 to 6 months (Zhang et al., 
2016).  
Cigarette smoke has a complex composition. Approximately 4,000 compounds are 
present in cigarette smoke, which could have a potential role in pancreatic 
carcinogenesis (Barone et al., 2016). One of the key carcinogens present in cigarette 
smoke is benzo-[a]-pyrene (B[a]P) which is formed through incomplete organic 
combustion (Souza et al., 2016). B[a]P exerts its genotoxic and oncogenic effects 
through its DNA reactive metabolites. Interestingly, B[a]P requires metabolic 
activation by Cytochrome P450 enzymes (e.g. CYP1A1) and can upregulate such 
enzymes through binding to the aryl hydrocarbon receptor (AhR), Fig. 3.1. AhR 
resides as an inactivated cytosolic complex bound to a HSP90 dimer, co-chaperone 
XAP2 and p23. B[a]P binding reduces the affinity of the receptor for p23 and XAP2, 
allowing HSP90 to translocate ligand bound AhR to the nucleus. Nuclear ligand-
bound AhR dimerises with arylhydrocarbon nuclear transporter, releasing the HSP90 
chaperone, binding to xenobiotic response elements inducing chromatin bending and 
initiating gene transcription (Wang et al., 2016; Mackowiak and Wang, 2016). 
Initiation of gene transcription results in upregulation of numerous genes, namely 
xenobiotic metabolism genes in order to eliminate the environmental contaminants 
which enter the cell, tissue or organ including CYP1A1. A key gene targeted by the 
AhR activation is the AhR repressor which suppresses the transcription of AhR 
genes through binding the AhR and ARNT to prevent overstimulation (Larigot et al., 
2018). Other genes upregulated, as a result of AhR and ARNT binding to the XRE 
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include genes, which regulate the cell cycle and apoptosis (Procházková et al., 2011; 
Stanford et al., 2016). There have been suggestions that different ligand binding can 
induce different gene expression (Larigot et al., 2018). AhR activation can also 
induce cellular changes without altering gene expression, protein interactions have 
also been shown to alter cell cycle progression (Barhoover et al., 2010).  
CYP1A1 is the enzyme from the family of cytochrome P450s, which is responsible 
for the metabolism of B[a]P. B[a]P exerts its genotoxic and carcinogenic properties 
following metabolism to an active metabolite, BDPE. B[a]P metabolism to the 
genotoxic BDPE is dependent on aryl hydrocarbon receptor (AhR) and CYP1A1 
expression, both of which have been found to be expressed in human pancreata, 
(Tissue expression of CYP1A1 - Summary - The Human Protein Atlas, n.d.; 
Yamamoto et al., 2004). B[a]P is metabolically activated by CYP1A1 through 
sequential oxidation and hydration followed by oxidation to form the mutagenic 
product, bay-region diol-epoxide (BDPE), seen in Fig 3.2 ,leads to DNA lesions 
through formation of DNA adducts, commonly at the N2 guanine position 
(Alexandrov et al., 2010; Shah et al., 2016). DNA adducts can lead to transversion 
mutations in the DNA, which increases the risk of carcinogenesis (Krais et al., 
2015).  
Figure 3.1: B[a]P-bound cytosolic AhR translocates to the nucleus mediated by 
chaperone HSP90 and binds the xenobiotic response element to induce gene 
transcription of various genes, including CYP1A1, responsible for B[a]P metabolism 




Figure 3.2: CYP-dependent metabolism of B[a]P to its mutagenic derivative, BDPE, 
which forms DNA adducts (Krais et al., 2015). 
B[a]P bioavailability in the human pancreas was explored through HPLC analysis of 
surgical specimens from three main types of pancreatic tissue: pancreatic tumour, 
pancreatic tissue adjacent to tumour and healthy pancreatic tissue not adjacent to the 
tumour (Liu and Lun, 2012). Four main types of PAH were identified by Liu and 
Lun et al. (2012) within human pancreas tissue including B[a]P, chrysene, pyrene 
and 2-methylanthracene. Interestingly, concentrations of B[a]P were significantly 
higher in pancreatic tumour tissue and tissue adjacent to the tumour in comparison to 
healthy pancreatic tissue (Liu and Lun, 2012). B[a]P consumption from cigarette 
smoking and dietary exposure may lead to pancreatic carcinogenesis. 
3.1.3 Obesity 
Obesity is defined as a body mass index (BMI) above 30 kg/m2. In England, 28.7% 
of adults are defined as obese with an additional 35.6% defined as overweight (BMI 
> 25kg/m2) (Obesity Statistics - Commons Library briefing - UK Parliament, n.d.). 
Obesity is an increasing problem due to an increased caloric intake and a more 
sedentary lifestyle. This caloric imbalance results in excess of adipose tissue to store 
surplus energy. A wide variety of chronic health concerns arise from obesity 
including diabetes mellitus, cardiovascular disease and osteoarthritis (Cascetta et al., 
2018). There is also an increased risk of developing a wide range of cancers (Stone 
et al., 2018). The World Cancer Research Fund has identified ten obesity-linked 
cancers including post-menopausal breast, endometrial and ovarian cancers in 
women, prostate cancer in men and GI cancers including oesophageal and colorectal 
cancers and hepatobiliary cancers including liver and gallbladder cancer and PC 
(Lennon et al., 2016). As many as 12% of PC cases are attributed to an excess in 
body weight (Cancer Research UK, 2014b; Lennon et al., 2016). On a positive note, 
obesity is a modifiable risk since weight loss has been shown to reduce the risk of 
cancers and may be beneficial to those at high risk of PC (Xu et al., 2018). 
74 
 
Obesity is thought to cause cancer in a number of different ways. Inflammation and 
metabolic alterations are two major drivers in obesity-linked cancer development. 
Chronic inflammation has been linked with cancer from as early as 1863, where 
Verchow hypothesised inflammation combined with irritants increased cell 
proliferation and lead to cancer development (Coussens and Werb, 2002). The 
interactions between inflammation and carcinogenesis is now a more complex image 
than it was in 1863. Inflammation is a physiological process that has a role in wound 
healing and repair, usually tightly controlled by anti-inflammatory cytokines. An 
example of chronic inflammation leading to carcinogenesis is via the recruitment and 
activation of leukocytes. Leukocyte production of reactive oxygen species (ROS) 
induces DNA damage in proliferating cells and is designed to fight infection by 
killing pathogens. However, continual ROS production will also induce DNA 
damage in bystander host cells inducing mutation, often in p53 (Coussens and Werb, 
2002). Inflammatory conditions including pancreatitis and diabetes mellitus have 
been previously linked with PC development.  
Diets high in fat are more likely to cause obesity. Dietary fats are digested with the 
aid of bile. Bile is the green-coloured fluid produced by hepatocytes in the liver, 
stored in the gallbladder and released into the duodenum via the common bile duct. 
Bile has numerous roles including being the main excretory routes of fats and larger 
biological molecules, which are unable to be excreted via the urine including bile 
salts themselves and bilirubin (Boyer, 2013).  Bile acids are one of the main 
constituents of bile besides water, which accounts for approximately 95% of bile 
(Boyer, 2013). Bile acids aid in the digestion of fats through emulsification of 
dietary fats into micelles (Chen and Cassaro, 2019). Bile acids form micelles due to 
their unique amphipathic structure, with a hydrophobic and a hydrophilic face 
(Hofmann and Hagey, 2014). Primary micelles are formed through hydrophobic 
interactions within the duodenum, forming a sphere where a hydrophobic core 
containing fat is established while polar, hydrophilic groups point externally 
(Pavlović et al., 2018). Pancreatic lipase adsorbs to the hydrophilic surface of the 
micelle, allowing for enzymatic lipolysis. Bile acids as a part of the micelle increase 
the solubility of the digested fats, allowing for the absorption (Pavlović et al., 2018).  
Deoxycholic acid (DCA) is a secondary bile acid formed from the primary bile acid 
cholic acid (CA). Ninety percent of primary bile acids are reabsorbed and recycled, 
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the remaining minority are present in the large intestine and deconjugated before 
bacterial mediated 7α-dehydroxylation to form DCA (Narushima et al., 2006). A 
population study showed a significant increase in serum DCA levels in overweight 
and obese males (BMI > 25 kg/m2) in comparison to lean males (BMI > 23 kg/m2) 
through use of UPLC-MS/MS (Xie et al., 2015). In data from our research group, 
greater serum levels of DCA, among other bile acids, has been found in PC patients 
(Rees et al., 2017). DCA has also shown some significance in in vitro genotoxicity 
studies. In studies of an oesophageal adenocarcinoma cell line, exposure to 
physiological levels of DCA (up to 300 µM) induced DNA damage, mediated by 
ROS production that was significantly diminished with treatment of the antioxidant 
vitamin C (Jenkins et al., 2007). 
Approximately 75% of PC patients will present with jaundice at one point during 
their disease journey due to extrahepatic bile duct blockage from pancreatic tumour 
progression (Cancer Statistics for the UK | Cancer Research UK, n.d.). This leads to 
an excess of bile acids in circulation, which are toxic to numerous organs. This can 
lead to multiple organ failure without intervention. As a result, pancreatic tissue has 
been shown to be particularly prone to bile acid exposure (Lu et al., 2000) and this 
may play a role in pancreatic carcinogenesis.  
3.1.4 Alcohol 
Consumption of alcoholic beverages is an ingrained part of Western society. Alcohol 
consumption is prevalent among adults and greatest alcohol consumption is found 
across western, central, and eastern Europe with respective alcohol consumption per 
capita of 11.13, 11.64 and 11.55 litres per year (Peacock et al., 2018). Globally, 
lowest alcohol consumption rates are found in North Africa and the Middle East, 
likely due to cultural and religious reasons (Peacock et al., 2018). According to the 
2018 NHS health survey for England 82% of adults had drank alcohol in the past 
year, with 49% drinking alcohol on at least a weekly basis (Health Survey for 
England 2018: Adult heath related behaviours, 2019). Males typically tend to drink 
more than females with 15.5 and 9 units consumed weekly, respectively (Health 
Survey for England 2018: Adult heath related behaviours, 2019). Alcohol intake has 
been measured in units, which are the equivalent to 10 mL or 8 g of pure alcohol, 
since 1987 in order to monitor and track consumption of alcohol (Alcohol units - 
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NHS, 2018). Unit contents of common alcoholic beverages are seen in Table 3.1. 
The NHS currently advises to not consume more than 14 units of alcohol over a 
week and advises to split this consumption over multiple days with alcohol free days 
in between (Alcohol units - NHS, 2018).  
Table 3.1: unit contents of common alcoholic beverages (Alcohol units - NHS, 
2018). 
Drink Units 
Single shot of spirit (25ml, ABV 40%) 1 
Alcopop (275ml, ABV 5.5%) 1.5 
Small glass of wine (125ml, ABV 12%) 1.5 
Bottle of lager, beer or cider (330ml, 
ABV 5%) 
1.7 
Pint of low-strength lager, beer or cider 
(ABV 3.6%) 
2 
Can of lager, beer or cider (440ml, 
ABV 5.5%) 
2 
Standard glass of wine (175ml, ABV 
12%) 
2.1 
Pint of higher strength lager, beer or 
cider (ABV 5.2%) 
3 
Large glass of wine (250ml, ABV 12%) 3 
   
Excessive alcohol intake can cause numerous negative health impacts from short-
term or long-term alcohol abuse. Alcohol has been defined as the third largest risk 
factor, globally, for a range of diseases and disabilities (Rocco et al., 2014). Between 
2017/2018, there were over 1.2 million hospital admissions as a result of alcohol 
related disease or injury, which is a large burden on the NHS (Health Survey for 
England 2018: Adult heath related behaviours, 2019). In 2014, the UK government 
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stated that alcohol-related harm cost society £21 billion, incorporating costs such as 
NHS funding, crime and loss in productivity. Due to limitations and criticism of the 
methodologies for calculating the figure, including omission of certain costs and 
using only one study to estimate A&E costs, no further review of costs is available 
(Institute of Alcohol Studies, 2016). Given inflation and rising costs, this number is 
likely to be higher. Short term risks associated with alcohol abuse include: accidental 
injuries such as breaks and sprains, which require hospital treatment, increased risk 
of being involved in a violent event either as a victim or carrying out violence, 
unprotected sex, which could lead to unplanned pregnancies or sexually transmitted 
diseases and alcohol poisoning which requires the stomach to be pumped (Alcohol 
misuse - NHS, 2018). Drink driving is also a risk associated with alcohol abuse. 
Alcohol impairs decision making, making drink driving a real danger to society. 
Drink-related driving accidents caused 5,700 injuries in the UK in 2017 (Department 
for Transport, 2020).  
Long-term alcohol dependencies can cause life-long issues, which are more complex 
to manage. The liver is one of the main organs responsible for the metabolism and 
elimination of alcohol from the body. As a result, excessive alcohol consumption can 
lead to both benign liver disease and liver cancer (Alcohol misuse – NHS, 2018). 
Chronic exposure to alcohol leads to fatty liver disease, which can sometimes 
develop further into cirrhosis, the final stage of liver disease (Rocco et al., 2014). 
Ethanol is metabolised by the liver in both oxidative and non-oxidative pathways, 
products of which, including acetaldehyde, can be cytotoxic and genotoxic 
hepatotoxins inducing damage to the liver (Rocco et al., 2014). Outside of the GI 
tract, alcohol can influence the development of heart disease and lead to an increased 
risk of stroke (Alcohol misuse - NHS, 2018). 
The pancreas is another victim of alcohol dependency. Pancreatitis is a major, 
potentially life-threatening inflammation of the pancreas that often requires hospital 
treatment. Although pancreatitis has various causes, including gallstones, drug use 
and injury, alcohol is one of the main risk factors (Alcohol misuse - NHS, 2018).  In 
the US, a third of acute pancreatitis cases are thought to be induced by alcohol 
(Chowdhury and Gupta, 2006). Despite this, the mechanisms involved are unclear. 
Pancreatitis has been thought to be stimulated by alcohol in a number of potential 
mechanisms including: ductal obstruction by mucoprotein plugs which inhibit cystic 
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fibrosis transmembrane conductance regulator (CTFR) function leading to fibrosis 
and scarring, alcohol increasing digestive and lysosomal enzyme contents of acinar 
cells increasing premature enzyme activation, and pancreatic stellate cell activation 
to myofibroblast-like phenotype inducing inflammation (Lankisch et al., 2015; 
Madácsy et al., 2018). Alcohol abuse alone may not be sufficient to develop 
pancreatitis, as fewer than 10% of heavy alcohol drinkers develop alcoholic 
pancreatitis, other lifestyle factors may play important roles (Vonlaufen et al., 2007). 
In a rat model, additional inhalation of cigarette smoke acted as a contributory factor, 
increasing pancreatic injury in comparison to alcohol alone (Hartwig et al., 2000). 
High fat diets may also play a contributory role in the progression of pancreatitis 
induced by alcohol (Chowdhury and Gupta, 2006). Alcohol abuse has also been 
shown to increase the chance of developing cancers around the body. Specifically, 
ethanol abuse has been shown to increase the risk of developing PC by 20% (Cancer 
Research UK, 2014b).  
Ethanol is metabolised in the liver through oxidative and non-oxidative pathways as 
seen in Fig 3.3 (Rocco et al., 2014). In oxidative metabolism (Fig 3.3a), ethanol is 
oxidised to acetaldehyde in the liver by cytosolic alcohol dehydrogenase (ADH) in a 
reversible reaction, reducing NAD+ to NADH. Extrahepatic tissue metabolises 
ethanol to acetaldehyde using ADH, for example pancreatic tissue expresses ADH, 
which accounts for some of the alcohol induced injuries to the pancreas (Chiang et 
al., 2009); non- ADH expressing tissue use catalase in peroxisomes and cytochrome 
P450 enzyme CYP2E1 in microsomes (Zakhari, n.d.). Acetaldehyde is further 
metabolised in the mitochondria to acetate using acetaldehyde dehydrogenase 
(ADH2) which enters the circulation. Acetate is taken in by tissues and oxidised to 
CO2 in the citric acid cycle.  Oxidative metabolism of ethanol eliminates 90 % of 
ingested alcohol (Heier et al., 2016). While non-oxidative metabolism (Fig 3.3b) is 
only a minor route of metabolism, the products, which are biomolecules conjugated 
to ethanol including fatty acid ethyl esters (FAEE), are eliminated at a much slower 
rate than ethanol (Heier et al., 2016). Non-oxidative metabolism of ethanol has been 
seen to be more prevalent in people with alcohol dependencies, often due to hepatic 




Figure 3.3: Metabolic pathways of ethanol metabolism through A) oxidative and B) 
non-oxidative pathways (Adapted from Zakhari, n.d.).  
Acetaldehyde is a toxic intermediate produced through the oxidation of ethanol. 
Under normal physiological conditions, it is produced in small quantities and is 
usually metabolised rapidly using a delicate balance of ADH to ALDH. However, in 
chronic alcoholism there is decreased elimination by oxidation with either reduced 
ALDH function or by mitochondrial dysfunction which leads to an accumulation of 
acetaldehyde (Cederbaum, 2012). Pharmaceutical interventions for alcoholism 
include disulfiram, an ALDH2 inhibitor. By blocking acetaldehyde oxidation, an 
excess of acetaldehyde accumulates in the blood, serum, liver and pancreas 
following treatment with ethanol and disulfiram (Petersen, 1992; He et al., 2001). 
This acts as a deterrent for alcohol consumption as a result of negative side effects 
include nausea, sweating and an increased heart rate (Cederbaum, 2012).  
Acetaldehyde has been classified by the IARC as “possibly carcinogenic to humans” 
in group 2B (IARC, 1987). Studies demonstrated carcinogenicity in animals but 





has been shown to be genotoxic. It induces single and double-stranded DNA breaks 
in primary human lymphocytes from low concentrations of acetaldehyde, although 
double stranded breaks were only induced at high concentrations (100mM) (Singh 
and Khan, 1995). DNA damage induction was also studied using the in vitro 
cytokinesis block micronucleus (CBMN) assay in the MCL-5 cell line showed an 
induction of clastogenic micronuclei in response to acetaldehyde, contrasting the 
aneugenic micronuclei induced following ethanol exposure (Kayani and Parry, 
2010).  One of the main routes by which acetaldehyde exerts its genotoxic effects is 
through formation of DNA adducts. Adducts are formed through reaction of 
acetaldehyde with the exocyclic amino group on deoxyguanosine (dG) (Mizumoto et 
al., 2017a). Adducts formed include the more abundant N2-ethylidene-2’-
deoxyguanosine (N2-ethylidene-2’-dG), and the less abundant N2-ethyl-2’-
deoxyguanosine (N2-Et-dG), and α-S and α-R-methyl-γ-hydroxy-1, N2-propano-2’-
deoxyguanosine (CrPdG). N2-ethylidene-2’-dG has shown to have a half-life around 
35h and is highly unstable (Hori et al., 2012). Increasing concentrations of 
acetaldehyde adducts increase the risk of a transversion mutations, which in turn 
increases the risk of developing cancers (Heymann et al., 2018). Acetaldehyde has 
also been found to form protein adducts with proteins including cytochrome C 
oxidase, impairing the electron transport chain; haemoglobin, putting red blood cells 
at risk of haemolysis and CYP2E1, which may have an effect of limiting the 





Figure 3.4: formation of acetaldehyde induced DNA adducts deoxyguanosine (dG) 
(Mizumoto et al., 2017). 
3.1.5 Measuring DNA damage induced by lifestyle factors 
DNA damage induced by exogenous factors, including the lifestyle factors discussed 
prior, can be quantified, and compared. A range of techniques exist for the 
quantification of how much the DNA has been damaged, which can look at 
numerous cell types from various organisms.  
The CBMN assay, discussed in 1.3.2, is one of the most well established and 
commonly used genotoxicity assays. In this, the induction of small, membrane 
bound, DNA containing vesicles, called MN, outside of the primary nucleus is 
studied in response to DNA damage (Kisurina-Evgenieva et al., 2016). MN are 
produced in response to genomic damage and the contents can vary from acentric 
chromosomal fragments, induced by clastogenic DNA lesions, up to full 
chromosomes, due to mitotic disturbances leading to aneuploidy (Iarmarcovai et al., 
2008). The type of MN can be identified using kinetochore staining. The CBMN 
assay is one of the most common in vitro techniques for quantifying chromosomal 
damage (Fenech, 2007; Rossnerova et al., 2016). Cytochalasin-B blocks cells in the 
multinucleate stage of mitosis through inhibiting cytokinesis (Ridler and Smith, 
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1968). Cytokinesis is blocked by preventing actin polymerisation so no actin ring is 
formed to mediate cytoplasmic division (Heddle et al., 2011). Cells being in the 
binucleate stage also ensures cells have undergone division following exposure to 
the test chemical. The frequency of binucleated cells with MN provide an overall 
view on the stability of the chromosomes, and whether this is altered following 
chemical exposure. 
As well as assessing chromosomal stability in the CBMN assay, induction of point 
mutations will be studied in the in vitro Pig-A assay, described in chapter 1.3.2.5.3..  
3.1.6 Aims 
Since lifestyle factors have a such a significant influence on the development of PC, 
studying them and their mechanisms is important to understand more about 
pancreatic carcinogenesis. Here, we aim to study the impact of smoking, a high fat 
diet and alcohol abuse modelled using B[a]P, DCA and acetaldehyde in the PDAC 
cell line PANC-1 in an in vitro model of PC. Cytotoxicity will be studied at 
increasing doses using both relative population doubling (RPD) values and the 
trypan blue exclusion assay. Chromosomal stability will be monitored using the in 
vitro CBMN assay in the PANC-1 cell line and a modified mononucleate MN assay 
will be carried out in the cytochalasin-B sensitive L5178Y cell line. Additionally, the 
in vitro Pig-A assay in the L5178Y cell line will be used to assess the induction of 
Figure 3.5: production of MN from cell undergoing mitosis in the presence of 
cytochalasin B in the CBMN assay, producing a binucleate cell with a MN. MN can 
be formed in two mechanisms(Iarmarcovai et al., 2008). 
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point mutation following exposure to the trio of chemicals linked with lifestyle 
factors. Here, we will employ the same techniques we will be using in our ex vivo 
experiments on patient samples. This will aid in the analysis of patient data, since 
many of the patients recruited may also be influenced by these lifestyle factors 
explored in this chapter.  
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 PANC-1  
Pancreatic adenocarcinoma (PANC-1) cells were maintained in DMEM media 
(Gibco) supplemented with 10% foetal bovine serum, 1% glutamine and 1% 
penicillin streptomycin at 37°C, 5% CO2 humidified atmosphere. Cells were 
subcultured through media removal, washing cell monolayer twice in PBS (Gibco) 
followed by trypsinisation. Detached cells were neutralised through the addition of 
media and trypsin-media mix removed through centrifugation at 30 g for 5 minutes. 
Supernatant was discarded and pellet was resuspended in fresh complete media and 
diluted further before incubation. PANC-1 required subculturing every 48 hours.  
3.2.1.2 L5178Y  
Mouse lymphoma (L5178YTK+/-) cells were maintained in RPMI Dutch modification 
(Gibco) supplemented with 10 % heat-inactivated horse serum, 1% glutamine, 1% 
penicillin streptomycin, 5.5 mL sodium pyruvate (Gibco) and 5.5 mL pluronic F-68 
(Gibco). Cells were maintained at 37°C, 5 % CO2 humidified atmosphere in the 
density of 3 x 104 and 5 x 105 cells/mL. L5178Y required subculturing every 24 
hours.  
3.2.2 Cytotoxicity Measure in PANC-1 
PANC-1 cells between passages 18 and 24 were seeded at 1x105 cells/mL in T25 
flasks in complete PANC-1 media as described previously. Cells were returned to an 
incubator and left to adhere for 24 hours.  An hour before exposure to chemicals, 
cells were put into suspension through trypsinisation to be counted by Beckman 
Coulter Counter. 100 µL of cell suspension was added to 10 mL Coulter Counter 
diluent (Beckman) and cells were counted between sizes of 5 and 17µm. Cells were 
left to adhere to the flask once again for an hour in the incubator before exposure to 
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test chemicals: B[a]P, DCA and Acetaldehyde. B[a]P was made up in a solution of 
DMSO to make final concentrations ranging from 0-50 µM, a solvent control of 
DMSO was used. DCA was diluted in ethanol with concentrations ranging from 0-
300 µM with ethanol alone as a solvent control. Acetaldehyde solution (Sigma) was 
diluted further with media in concentrations of 0-2.5 µM. Following 24 hour 
exposure to the test chemicals, media was removed, and the cell monolayer was 
washed twice in PBS before 10 mL fresh media was added. Cells were incubated for 
further 48 hours to recover before cytotoxicity analysis.  
Cells were removed from flasks through trypsinisation and resuspended in 10 mL 
media. Cells were counted again with the Beckman Coulter Counter and cell counts 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 (𝑅𝑃𝐷) = (𝑃𝐷 ÷ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑃𝐷) × 100 
The viability of treated cells was also determined through the trypan blue exclusion 
assay. 10 µL of the harvested cell suspension was diluted in 1:1 ratio with 0.4% 
trypan blue solution (Sigma) and mixed through gentle pipetting. 10 µL of this mix 
was loaded onto a haemocytometer for analysis under a light microscope. The four 
outer squares of the haemocytometer were counted, Fig. 3.6. Live cells are 
impermeable to the stain and remain white whereas dead cells are permeable to the 




Figure 3.6: How a haemocytometer would look under a light microscope. The four 
outer large squares labelled 1, 2, 3 and 4 are counted with cells touching top and far 
left edges (solid line) are counted whereas cells touching the right hand side and 
lower edge (dashed line) would not be counted (Fuentes, n.d.). 
The percentage of viable cells was then determined using the following formula: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) = (1 − (𝑁𝑜. 𝑜𝑓 𝑏𝑙𝑢𝑒 𝑐𝑒𝑙𝑙𝑠 ÷ 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠)) × 100 
3.2.3 Cytokinesis Block Micronucleus Assay in PANC-1 cell line 
PANC-1 cells were seeded at the density of 2 x 105 cells/mL in a T25 flask in 
supplemented media. Cells were returned to an incubator to adhere for 24 hours. An 
hour before dosing with test chemicals, satellite flasks were removed, cells were 
detached and counted as described above. Cells were then left to adhere for an hour. 
Cells were dosed as described above with B[a]P, DCA and acetaldehyde. Following 
24 hour exposure, media was removed, and cells were washed twice with PBS. 10 
mL fresh media was added to all flasks along with 30 µL cytochalasin B (0.6 µg/mL) 
to all test flasks excluding satellite flasks. Cells were left for 1 cell cycle (48 hours) 
to recover before cells were harvested and satellite flasks were counted for RPD 
calculations. 
Harvested cells were fixed according to two protocols by Seager et al. (2014): one 




3.2.3.1 Semi-automated Metafer Scoring  
Harvested cells were washed in PBS and suspended in 0.56% hypertonic KCl 
solution. Cells were centrifuged at 14 g for 10 minutes, supernatant was discarded. 
The pellet was resuspended in fixative 1 (5 parts methanol: 6 parts 0.9% NaCl 
solution: 1-part acetic acid) and incubated for 10 minutes before centrifugation. 
Supernatant was removed and pellet was resuspended in fixative 2 (5 parts methanol: 
1-part acetic acid) and incubated for 10 minutes before centrifugation. Cells were 
washed twice more in fixative 2 before storage overnight at 4°C.  Microscope slides 
were stored in fixative 2 were transferred into ddH2O before being wiped with slide 
tissue. Cells were centrifuged and resuspended in 1 mL fixative 2. 100 µL cell 
suspension was spread over the slide, checked under a light microscope to check if 
cell density suitable and then left to airdry for 24 hours. On day of analysis, the slide 
was stained with 30 µL Vectashield Mounting Medium, a coverslip was added, and 
slides were left to incubate for 10 minutes protected from light. 
Stained slides with coverslips were scanned using the Zeiss Imager.Z2 system with 
Metafer 4 software version 3.9.8 using classifier “MicronucFL-10-BN0sjmodif”. 
Slides originally scanned at 10 x magnification but 63 x objective and oil used to 
confirm or deny the presence of MN following guidelines outlined by Fenech 
(2007), explored in Table 1.1. 2000 binucleated cells were scored per slide, with 3 
scored per dose and per biological repeat (n=3).  
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3.2.3.2 Manual Scoring  
Harvested cells were washed in PBS and resuspended in 1 mL PBS. 100 µL of cell 
suspension was adhered to microscope slides using a Cytospin at 1200 rpm (162.58 
g) for 5 minutes. Slides were left to airdry before fixing in 90% ice cold methanol for 
10 minutes. Once dry from fixing step, cells were stained with an 20% Giemsa 
solution for 8 minutes before washing and being left to airdry. Once dry, slides were 
dipped in xylene solution for 10 seconds and coverslips were applied using DPX 
mounting medium before slides were left to dry in a fume hood. 
Figure 3.7: Screenshots from Metafer 4 software showing A) a gallery of binucleate 
PANC-1 cells which the software has identified B) a closer image showing the 
binucleate PANC-1 cell with no identifiable objects in black surrounding nuclei C) 
image of binucleate PANC-1 cell with a potential micronuclei, highlighted by an 
arrow. If this was seen during scoring, the eyepiece and 63 x objective and oil would 
be used to either confirm or deny the presence of a micronuclei. All images shown at 





Prepared and stained slides for manual scoring were scored under a standard light 
microscope at 100 x objective using oil. Care was taken to assess all cells on the 
slide, following left to right hand side of the cells in the dot on the slide before 
dropping down and following right to left and so on until entire slide examined. 1000 
binucleated cells were examined per slide and of these, the number of cells with 
micronuclei as outlined by Fenech et al. (2007), Table 1.1, were quantified. 3 slides 
were examined per dose, only one biological repeat was quantified.  
Figure 3.8: Examples of bicnucleated PANC-1 cells scored by manual 
scoring with Giemsa stain under 100 x magnification on a light microscope. 
A) A binucleate cell B) A binucleate cell with a micronuclei denoted by an 
arrow C) a binucleate with a small amount of debris in the cytoplasm, 





3.2.4 Mononucleate Micronucleus Assay in L5178Y cell line 
L5178Y cells were seeded at the density of 2 x 105 cells/mL in T25 flasks in 
complete media. Cells were returned to the incubator for 24 hours. Cells were 
counted for cytotoxicity calculations as seen above, before exposure to chemicals. 
Cells were exposed to test chemicals (DCA and acetaldehyde) while in a low serum 
media. DCA solutions made up with ethanol in the range of 0-300 µM with ethanol 
as a solvent control. Acetaldehyde solution was diluted further with media in the 
range of 0-150 µM. Low serum media was made up the same as the complete media 
as seen above but with only 5% of heat inactivated horse serum. Following a 4 hour 
exposure period, cells were washed twice in a wash media made up of blank RPMI 
1640 with added 1% penicillin streptomycin before cell pellets were resuspended in 
complete media and returned to the incubator for 24 hour. After 24 hour incubation, 
cells were harvested following the steps in 3.2.3.1 up to the step of scoring, since no 
cytochalasin B was used this is the mononucleate micronuclei assay and so 
“MONOMicronucFL-10-BN0sjmodif” classifier was used instead. However, 
micronuclei were still identified using the details outlined by Fenech (2007), defined 
in Table 1.1. 
3.2.5 In Vitro Pig-A Assay in L5178Y cell line 
3.2.5.1 Cell dosing 
L5178Y cells were revived from liquid nitrogen storage and grown in complete 
media for 6 days ensuring that the cells were always in their logarithmic growth 
phase. On the first day of the Pig-A assay, 6 x 106 cells were seeded in 10 mL of 5% 
serum media with the cells counted once seeded. Cells were exposed to test 
chemicals for 4 hours: DCA diluted in ethanol at doses of 20 and 150 µM with 
vehicle control of ethanol and acetaldehyde solution diluted in media at doses of 0.25 
and 1 µM with media as a vehicle control. Following 4 hours exposure, cells were 
washed twice in wash media and then were resuspended in complete media and 
returned to the incubator. The experiment was carried out in triplicate. 
3.2.5.2 In Vitro Pig-A Assay Preparation 
In vitro Pig-A assay was carried out on days 1, 5, 9, 12, 15, 18 and 21 following test 
chemical exposure. On Pig-A analysis days, 2 x 106 cells were added to centrifuge 
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tubes. 1 per replicate of doses and 1 live cell control, 1 dead cell control, 1 mutant 
tube and 3 untreated L5178Y cells. Cells were washed once in wash media at 250 g 
for 5 minutes. A dead cell control was heated to 90°C for 3 minutes on a heating 
block to ensure cell death. Cell pellets were resuspended in 200 µL Zombie Violet 
Fixable Viability dye (Biolegend) (1:200 dilution in PBS) and incubated in the dark 
for 30 minutes at room temperature. Cells were washed once in antibody wash buffer 
(0.2% BSA in PBS) before resuspending pellet in 300 µL antibody solution (0.18 µg 
of antibody:1 µL of APC-CD-45 and PE-CD-90.2 (Biolegend) to 1110 µL antibody 
dilution buffer). Tubes were incubated protected from light at 4°C on a rocker for 30 
minutes followed by 10 minutes at room temperature. Cells were washed once in 
antibody wash buffer (0.2% BSA in PBS) and resuspended in 1 mL antibody wash 
buffer. Samples were then analysed immediately by flow cytometry.  
3.2.5.3 In Vitro Pig-A Assay Flow Cytometry Analysis 
Stained samples were immediately analysed via flow cytometry. Samples were 
analysed using the Beckman Coulter Navios and Navios software. 250,000 events 
were analysed per sample on a low flow rate to try and capture the rare Pig-A 
mutation. 
Initially, live and dead cells were discriminated between using the zombie violet 
viability dye. Live cells are impermeable to the dye, leaving dead cells positively 
stained. Fig 3.9 shows an example cytogram from both a live and dead cell control 
which was ran at the beginning of each experiment. The live cells in Fig 3.9A 
remain unstained by the zombie violet dye, unlike the heated dead cell control in Fig 
3.9B. Live cells were therefore put into gate C. In this example, the live cell control 
had 95.56% of cells in gate C (238,902 cells) in comparison to just 4.28% (5,288) in 




Figure 3.9: Zombie violet viability dye discrimination seen in A) a live cell control 
and B) a dead cell control which had been heated at 90°C for 3 minutes to induce 
cell death. Live cells are identified in gate C. 
All live cells from gate C were then gated further dependent on APC fluorescence. 
APC-CD-45 antibody ensured L5178Y cells were being analysed, not debris or other 
contaminants. Cells which stained positive for the APC-CD-45 antibody were 
categorised into gate D. Cells in gate D were then analysed by a final cytogram with 
APC fluorescence for the APC-CD-45 antibody on the X-axis and PE fluorescence 
on the Y-axis for the PE-CD-90.2 antibody, which identified GPI anchored CD-90.2. 
Gates were drawn in this cytogram based on a positive control of fluorescently 
activated cell sorted L5178Y Pig-A mutant cells. Mutant cells were identified as 
those with positive APC fluorescence but PE fluorescence beneath the threshold set 
using the mutant control. In the example shown in Fig 3.10, 0.04% of cells are 




Figure 3.10: Example graphs from flow cytometry analysis of stained sample during 
in vitro Pig-A assay A) Live-dead discrimination using the zombie violet viability 
dye. Population in gate C are live. 60.02% of cells are live. B) Selection of CD-45 
positive cell population. 93.29% of live cells from gate C are CD-45 positive and are 
grouped in gate D. C) Cytogram of all cells in gate D (live, CD-45 positive 
population) with APC fluorescence on X-axis and PE fluorescence on the Y-axis. 
Solid line gate drawn based on positive control mutant population. Cells below this 
line in quadrant B4 are mutant. In this example, 0.04% of live, CD-45 positive cells 







3.3.1 In Vitro Cytotoxicity Assessment and CBMN Assay in PANC-1 cell line 
The pancreatic adenocarcinoma cell line PANC-1 was used to model PC. Literature 
searches for the risk factors of PC identified chemicals of B[a]P, DCA and 
acetaldehyde, which modelled smoking, a high fat diet and alcohol abuse. 
Initial cytotoxicity experiments established the sensitivity of the PANC-1 cell line to 
24 hr exposures to the chemicals to determine suitable dose ranges for subsequent 
experiments. Cytotoxicity was determined through two methods, RPD and the trypan 
blue exclusion assay. The cytotoxicity of B[a]P is seen in Fig. 3.11. A dose 
dependent decrease in both RPD and cell viability determined by the trypan blue 
exclusion assay was seen. A significant decrease in viability was seen at 3µM using 
RPD (p= 0.045) but this was not reflected in the trypan blue assay. Viability 
determined by trypan blue exclusion decreases became significant from 10 µM (p= 
0.01) and the top dose of 50 µM (p= 0.003).  
Figure 3.11: Cytotoxicity determined through RPD and the trypan blue exclusion 
assay in the PANC-1 cell line exposed to increasing concentrations of B[a]P over 24 
hours. Bars represent the mean (n=3) and error bars show standard deviation. (* 
show p<0.05, ** show p<0.01). 
The cytotoxicity assessment of DCA, Fig. 3.12, did not show a dose-dependent 
decrease in the levels found at normal physiological levels (up to 300 µM).  A 


























reflected in the trypan blue assay (p= 0.093 trypan blue, p= 0.481 RPD). An 
expanded range of doses were also assessed, Appendix 7.2 which showed 
cytotoxicity beyond 50 % above 300 µM DCA. 
 
 
Figure 3.12: Cytotoxicity determined by RPD and the trypan blue exclusion assay in 
PANC-1 cell line exposed to increasing concentrations of DCA over 24 hours. Bars 
represent the mean value (n=3) and error bars show the standard deviation. 
Acetaldehyde exposure significantly reduced the RPD of PANC-1 cells from 0.75 
µM upwards but this was not reflected in the trypan blue exclusion viability assay, 
Fig 3.13 (p=0.006 at 0.75 µM, p=0.011 at 1µM, p=0.004 at 2.5 µM RPD, p= 0.535 
trypan blue). Comparing the three test chemicals and the dose ranges selected, B[a]P 
reduced the RPD and the viability the most, but acetaldehyde is potentially the most 
























Figure 3.13: Cytotoxicity determined through RPD and the trypan blue exclusion 
assay in PANC-1 cell line exposed to increasing concentrations of acetaldehyde for 
24 hours. Bars represent the mean (n=3) with error bars representing the standard 
deviation. (* shows p<0.05, ** shows p<0.01)  
Following the initial cytotoxicity experiments, suitable doses were selected to use for 
the in vitro CBMN assay. The methods of scoring of the in vitro CBMN assay are 
divided into two methods the traditional manual scoring or semi-automated scoring 
method using the Metafer system. Traditional manual slide preparation and scoring 
detailed in 3.2.3.2 examines 1000 binucleated cells per slide under 100 x 
magnification on a light microscope and the binucleated cells with MN are 
quantified by the user. In comparison, the semi-automated Metafer system, detailed 
in 3.2.3.1, examines 2000 binucleated cells per slide and the user confirms or denies 
the presence of MN using the eyepiece and 62 x magnification and oil. The variation 
between the techniques may result in differing results if quantified through the 
different techniques. Both methods were compared using a replicate of the in vitro 
CBMN assay with a control and the top dose of B[a]P, Fig 3.14. Similar results were 
observed with both techniques but due to the ease and greater statistical power of the 

























Figure 3.14: Comparison of manual and semi-automated Metafer scoring for the 
CBMN assay in the PANC-1 cell line. 3 slides were scored per dose, per method 
(n=1). Bars represent the mean and the error bars show the standard deviation. 
The quantity of binucleated PANC-1 cells with additional micronuclei were scored 
according to Fenech (2007) rules with the semi-automated Metafer system using a 
fluorescent microscope. Two thousand binucleated cells were scored in triplicate per 
biological repeat (n=3) repeated three times in total with cells of increasing passages 
to score 18,000 cells per dose. Cells were exposed to B[a]P, DCA and acetaldehyde 
in separate experiments. 
A dose dependent induction of micronuclei was seen in PANC-1 cells following 24 
hour exposure to B[a]P in the in vitro CBMN assay, Fig. 3.15. Induction of 
micronuclei was seen at the two highest doses of B[a]P analysed with micronuclei 
frequencies of 2.301 ± 2.301 % and 4.905 ± 4.905 % at 20 and 50 µM, respectively 
(p= 0.04, p=0.01). Below 20 µM of B[a]P, there is no statistical difference from 





































Figure 3.15: Percentage of binucleated PANC-1 cells with micronuclei following 24 
hour exposure to B[a]P (n=3). There’s a dose dependent induction of micronuclei 
with significance above 20µM. Bars represent the mean and error bars represent the 
standard deviation. Red dashed line indicates the RPD. (* shows p<0.05, ** shows 
p<0.01). 
DCA didn’t show a dose-dependent induction of MN, Fig. 3.16. Despite this, 
elevated MN levels at 50 and 300 µM of 3.79 ± 0.551% and 4.059 ± 1.332%, 
respectively, showed a significant increase over the vehicle control (p =0.05 and 







































































Figure 3.16: Percentage of binucleated PANC-1 cells with micronuclei following 24 
hour exposure to DCA. No clear pattern is shown, even if significant increases at 50 
and 300 µM. Bars represent the mean and the error bars represent the standard 
deviation. Red line shows the RPD. (* shows p<0.05) 
The induction of micronuclei in binucleated PANC-1 cells was studied in the in vitro 
CBMN assay following 24h exposure to acetaldehyde, Fig. 3.17. Micronuclei 
frequency started 5.273% in the vehicle control. From 0.55 µM to 1 µM there was an 
elevated frequency of micronucleated binucleate PANC-1 cells ranging from 7.438 ± 
4.727% to 8.267 ± 2.510%. This was close to significance following a t-test at 0.5 
µM (p = 0.08). The greatest induction of micronuclei was at 2.5 µM acetaldehyde 


















































Figure 3.17: Percentage of binucleated PANC-1 cells with micronuclei following 24 
hour exposure to acetaldehyde. A dose dependent increase in MN induction is seen 
at 0.5 and 2.5 µM of acetaldehyde. Bars represent the mean (n=3) and the error 
bars represent the standard deviation. Red line shows RPD. (* shows p<0.05, ** 
shows p<0.01) 
 
3.3.2 In Vitro mononucleate micronucleus assay with L5178Y cell line 
Since the in vitro Pig-A assay has been optimised for a couple of suspension cell 
lines, including L5178Y, mutational modelling by Pig-A had to be performed in this 
cell line. We therefore chose to compare MN response in comparison to the PANC-1 
cell line explored earlier in the chapter. The L5178Y cell line is not metabolically 
competent, so assays following exposure to B[a]P were not performed. Additionally, 
the mononucleate MN assay had to be performed using the L1578Y cell line due to 
the sensitivity of the cell line to cytochalasin-B. Comparison of the MN results 
allowed selection of appropriate doses for the in vitro Pig-A assay in the L1578Y 
cells. 
Results of the in vitro MN assay in the L5178Y cell line are found in Appendix 7.3. 
Initial cytotoxicity experiments determined the suitable maximum doses of DCA and 

















































RPD in the L5178Y cell line was reduced by 150 µM DCA and 1 µM acetaldehyde 
to 71.67% and 74.34%, respectively. Doses above these concentrations reduced RPD 
to below the 50 %, threshold outlined in the OECD guidelines for the in vitro 
micronucleus assay (OECD, 2016). Both chemicals showed induction of MN at top 
doses, but only acetaldehyde showed significant induction (p=0.003).  
3.3.3 In Vitro Pig-a assay in L5178Y Cell Line 
Following on from initial cytotoxicity experiments and the mononucleate MN assay, 
the in vitro Pig-A assay was carried out to determine the frequency of GPI-deficient 
L5178Y cells over a 21-day period following exposure to the chemical of interest or 
control substance. Previous in vitro studies have shown a peak in Pig-A mutant cells 
around day 10 post chemical exposure (David et al., 2018). Monitoring the 
frequency of Pig-A mutant L5178Y cells over a 21-day period was carried out to 
determine the peak expression of the mutant phenotype. 
3.3.3.1 DCA 
The Pig-A mutant frequency was monitored in L5178Y cells exposed to DCA over a 
21-day period, Fig. 3.18. Pig-A mutant frequencies in untreated L5178Y cells 
peaked around day 9 with 0.074 % of the cells showing a spontaneous mutant 
phenotype. The remaining treated cell types showed an unclear pattern across the 21-













Figure 3.18: Frequency of CD-90.2 deficient live L5178Y cells measured across a 
21-day period following 4 hour exposure to 20 or 150 µM of DCA, vehicle control 
(VC) ethanol or untreated (Un). (n=3) 
Although a complex pattern, the Pig-A mutant frequencies peaked on day 9 
following exposure to DCA and the vehicle control. Day 9 was chosen as a suitable 
time point to compare the mutations induced, Fig. 3.19. Both doses of DCA induced 
Pig-A mutant frequencies of 0.174 and 0.160% at 20 and 150 µM, respectively. 
Although there was an increase, this was not statistically significant in comparison to 
































Figure 3.19: Percentage of CD-90.2 deficient live L5178Y cells on day 9 following a 
4 hour exposure to DCA. Bars represent the mean value of CD90.2 deficient cells 
(n=3) and error bars show the standard deviation.  
3.3.3.2 Acetaldehyde 
The induction of Pig-A mutations following 4 hour exposure to acetaldehyde was 
monitored in the L5178Y cell line over 21-days, Fig. 3.20. In comparison to the 
pattern with DCA, Fig. 3.18, there is a clearer induction of mutation in the exposed 
populations around day 9 and these return to baseline mutation frequencies over the 
remainder of the experiment. Fig. 3.21 depicts the Pig-A mutant frequencies at the 
peak of phenotypic expression day 9. At both doses of acetaldehyde there is an 
induction of Pig-A mutant cells in comparison to the vehicle control. This is not 
dose-dependent, as Pig-A mutant frequencies are very similar with 0.233 ± 0.151% 
and 0.243 ± 0.068%, respectively for 0.25 and 1 µM of acetaldehyde. However, 
despite this, statistical significance was only seen at 1 µM following a t-test which 












































Figure 3.20: Percentage of CD-90.2 deficient cells as a percentage of live L5178Y 
cells across a 21-day period following 4 hour exposure to acetaldehyde. Mutant 
frequency peaks around day 9, with treated cells having more mutations induced in 
comparison to the vehicle control (VC) which was exposed to media alone (n=3).  
 
Figure 3.21: Induction of CD-90.2 deficient live L5178Y cells on day 9 as a result of 
4 hour exposure to acetaldehyde at 0.25 or 1 µM or the vehicle control (VC) of 












































































Here, we have explored the induction of DNA damage induced by three chemicals to 
model known risk factors for PC. This includes B[a]P, DCA and acetaldehyde to 
model cigarette smoking, a high fat diet and alcohol abuse, respectively. 
Experiments utilised included the in vitro CBMN assay in the PANC-1 cell line and 
mononucleate MN assay in the L5178Y cell line. This was followed up by the in 
vitro Pig-A assay in the L5178Y cell line. Both mutation methods will be employed 
with human samples in future chapters. 
Table 3.2: Table change in RPD(%), induction of MN (%) following either the 
CBMN in PANC-1 cell line or mononucleate MN assay in L5178Y, and induction of 
Pig-A mutants (%) in the L5178Y on day 9 (peak in mutant phenotype). Results 
shown in PANC-1 cell line (grey boxes) and L5178Y cell line (white boxes). PANC-1 
cells were exposed to chemicals for 24 hours and L5178Y cells were exposed for 4 
hours. (* p<0.05, ** p<0.01, NS non-significant). 
 
 
Chemical RPD (%) MN (%) Pig-A Mutant 
(%)  
B[a]P 50 µM 
reduction 52.24 
± 32.40 (*) 
20 µM induction 
5.09 ± 2.30 (*) 
50 µM induction 
10.89 ± 4.91 
(**) 
- 
- - - 
DCA 300 µM 
reduction 
85.14 ± 31.91 
(NS) 
50 µM induction 






4.06 ± 1.33 (*) 
150 µM 
reduction 




0.26 ± 0.10 (NS) 
20 µM 
induction 




0.16 ± 0.14 
(NS) 
Acetaldehyde 0.75 µM 
reduction 
74.35(**) 







15.67 ± 10.94 
(**) 
- 
1 µM reduction 
74.34 ± 16.97 
(*) 
1 µM induction 
0.37 ± 0.08 (**) 
1 µM 
induction 
0.24 ± 0.07 (*) 
 
 
Table 3.2 compares induction of DNA damage by the 3 chemicals associated with 
risk factors for PC. All three chemicals in turn reduced the RPD in both the PANC-1 
cell line and induced DNA damage in the CBMN assay. We also assessed the 
cytotoxicity in the L5178Y cell line followed by the mononucleate MN assay and in 
vitro Pig-A assay following exposure to only DCA and acetaldehyde. The L5178Y 
cell line was chosen since the in vitro Pig-A assay has been optimised in this cell 
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line, but drawbacks of the cell line include its sensitivity to cytochalasin B, which 
results in the mononucleate MN assay being employed; and the lack of metabolic 
competency, so B[a]P wasn’t explored due to the need of S9 mix to ensure 
metabolism to the active metabolite BDPE.  
Cytotoxicity was assessed using both RPD and the trypan blue exclusion assay. RPD 
alone only provides a measure of how a treated cell population doubles in 
comparison to a control cell population. Population doubling alone cannot give a full 
picture of cytotoxicity as we do not know further information including whether cells 
quantified are alive or viable, introducing possible error. The trypan blue exclusion 
assay differentiates live cells from dead since the azo dye is impermeable to intact 
plasma membranes. Under microscopic examination, this leaves live, viable cells 
white whereas non-viable cells with compromised membranes are blue. This 
technique is vulnerable to false positive non-viable cells with intact membranes and 
false negatives, where cells are able to repair their membranes to become viable once 
more (Strober, 2015). Haemocytometer counting also provides counting errors 
around 10% (Aslantürk, 2018). Haemocytometer counting can also be time 
consuming with numerous samples. A combination of RPD and the trypan blue 
assay provides a more accurate overview of cytotoxicity.   
From Table 3.2, acetaldehyde appears to be the most potent cytotoxic agent, 
reducing RPD significantly from the lowest concentrations of 0.75 µM. 
Acetaldehyde has been previously shown to induce pancreatitis-like injuries in vitro 
in isolated pancreas models, but this hasn’t been able to be reproduced in vivo (He et 
al., 2001). It is also seen that L5178Y cell line is more sensitive to DCA than the 
PANC-1 cell line, showing greater reduction in RPD at a lower dose. PANC-1 may 
be less sensitive since pancreatic ductal epithelial cells would be naturally exposed to 
more bile acids than a lymphoblastoid cell line. PANC-1 cell growth inhibition has 
previously been achieved through exposure to crude bile in the media (Lu et al., 
2000). A longer, 48 hour exposure achieved greater inhibition, so perhaps the 24 
hour exposure used in our PANC-1 cells was not long enough to see significant RPD 
decrease. In contrast, a 4 hour exposure in the L5178Y cell line reduced RPD 
further, this is attributed to greater sensitivity and a considerably shorter cell cycle 
than PANC-1 cells. 
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The in vitro MN assay is one of the most used techniques in in vitro genotoxicity 
studies. The CBMN has a benefit over the mononucleate variety since cytochalasin 
B ensures cells scored have undergone cell division following chemical exposure. 
The CBMN was harnessed in the PANC-1 cell line but L5178Y cells have been 
shown to be negatively impacted by cytochalasin B, but the rapid cell cycle of 
L5178Y cells ensures that division has occurred following chemical exposure thus 
the mononucleate MN assay was used (Lorge et al., 2016).  Background MN 
frequency observed in PANC-1 cultures exposed to vehicle controls ranged between 
3 and 5%. Since 3 separate solvents were used to dissolve test chemicals, they could 
not be combined. DMSO, ethanol and media were used to dissolve and dilute B[a]P, 
DCA and acetaldehyde, respectively. Natural variation in background MN frequency 
is expected.  
Fig. 3.14 compares manual and semi-automated MN scoring techniques. Semi-
automated scoring was used for this study due to ease of technique, user friendly 
software, clear imaging of scored cells and more cells scored per slide (2,000 in 
comparison to 1,000). The software also allowed for quicker observation of cells in 
comparison to the more time-intensive manual scoring. Despite the improvements, 
the semi-automated scoring still required human input to be able to confirm or deny 
presence of MN. Some studies have used flow-cytometry based techniques in order 
to score MN in both the L5178Y and TK6 cell lines (Bryce et al., 2007). Although 
scoring thousands of cells within minutes is quicker, semi-automated scoring 
allowed for visualisation of individual nuclei, making the Metafer approach better 
suited to the study.  
Similarly to RPD, acetaldehyde appears to be the most potent genotoxin to induce 
MN at lower concentrations than DCA and B[a]P. Acetaldehyde significantly (p < 
0.01) induces MN at 1 µM and 2.5 µM in the L5178Y and PANC-1 cell line, 
respectively. This supports the idea that the L5178Y cell line is more sensitive than 
PANC-1. Lymphoblastoid cell line, MCL5, has also shown an increase MN 
frequency following acetaldehyde exposure (Kayani and Parry, 2010). Acetaldehyde 
has been shown to induce DNA damage through forming DNA adducts at the N2 
position of guanine rings (Mizumoto et al., 2017). This is the same residue, which is 
targeted by the genotoxic B[a]P metabolite, BDPE during adduct formation 
(Alexandrov et al., 2010; Shah et al., 2016). MN induction is well studied with 
108 
 
B[a]P, given its status as a model clastogen. HepG2 studies have shown induction of 
MN from around 25 µM, given B[a]P is often used as a positive control at 25 or 50 
µM following 24 hour exposure, similar to results seen in our PANC-1 cells (Wu et 
al., 2005; Wei et al., 2009). Previous studies in lymphoblastoid lines have shown 
induction of MN in the TK6 cell line (Takeiri et al., 2019) and the L5178Y cell line 
(Kirsch-Volders et al., 2003), but both required S9 mix since both cell lines lack 
metabolic capabilities. Kirsch-Volders et al. (2003) showed significant induction of 
MN in the L5178Y cell line from 8 µM with the use of S9 mix. Here, PANC-1 have 
required more than double that dose to induce significant MN. DCA appears to be 
the least potent genotoxic agent explored within this study. No significant results 
were seen with the L5178Y cell line, but some significant increases were seen in the 
PANC-1 cell line, but this was not dose dependent. The unclear results seen as a 
result of DCA exposure may be linked to the ROS based mechanism in which DCA 
induces DNA damage (Jenkins et al., 2007). ROS play an important role in PC at 
high levels whereby they damage macromolecules in the cells, but low levels of ROS 
have also shown an important role as secondary messengers (Durand and Storz, 
2017). A delicate balance of ROS levels is used in PC development to maintain 
activation of oncogenic pathways while being low enough to evade cell senescence 
(Durand and Storz, 2017). 
We also explored the induction of DNA damage using the in vitro Pig-A assay, 
which studies mutation induction rather than chromosomal stability as seen in the 
MN assay. Recently, studies have focused on development of the assay in vitro, 
although without much success as the in vivo counterpart. Many cell lines have been 
investigated for their use in the assay including TK6 and metabolically capable 
MCL5 cell lines (Rees et al., 2017). The TK6 cell line is well established in 
genotoxicity studies, often utilised for the HPRT and CBMN assays. Various groups 
established the assay in this cell line (Krüger et al., 2015; Krüger et al., 2016; Rees 
et al., 2017; Piberger et al., 2018). Various problems limited this development. TK6 
cells have a high background frequency of GPI-deficient cells which require a pre-
cleansing before assay initiation (David et al., 2018). Next generation sequencing 
identified a heterozygous deletion in the Pig-L locus on chromosome 17, which also 
resulted in a GPI anchor deficient phenotype alongside a mutation in Pig-A (Krüger 
et al., 2015). This results in the TK6 cell line being unsuitable for the flow cytometry 
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based Pig-A assay since surface markers alone couldn’t distinguish between Pig-A 
or Pig-L mutation (Krüger et al., 2015). The L5178Y is superior in comparison, 
having two copies of Pig-L, a lower Pig-A mutant frequency which remains stable 
(0.08 ± 0.06%) and no pre-cleansing steps are required before the assay (David et al., 
2018). 
Here, we monitored the percentage of GPI deficient live L5178Y cells over a period 
of 21-days post DCA and acetaldehyde exposure. Expression of the Pig-A mutant 
phenotype peaked around day 9, similar to Pig-A mutant peaks reported on days 8 
and 7 post-exposure (David et al., 2018). This expression period allows for the 
recirculation of cell surface anchors, which are in a constant state of flux and for the 
production and trafficking of freshly synthesised GPI anchors to the extracellular 
surface membrane, or not in the case of GPI-anchor deficient cells.  
DCA showed an unclear pattern across the 21-day period, Fig. 3.18. Despite this, a 
peak in Pig-A mutant frequency was found on day 9. This unclear pattern could be 
attributed to the ROS-based mechanism by which DCA exerts its genotoxic effects. 
David et al. (2018) assessed the in vitro Pig-A assay in chemicals with known modes 
of action. Two of those studied, mitomycin C and 4-nitroquinoline-N-oxide, partially 
exert their effects through ROS production. Mitomycin C did not induce Pig-A 
mutant cells, but 4-nitroquinoline-N-oxide did at the day 8 mark. No data was 
available for the 21-day monitoring period and they may have potentially shown an 
unclear pattern as seen here with DCA.  
Acetaldehyde, in contrast, showed a clearer pattern over the 21-day expression 
monitoring period and induced more Pig-A mutants on day 9 than DCA even at 
lower concentrations. This again strengthens the idea that acetaldehyde is a more 
potent genotoxin than DCA, we cannot draw conclusions about B[a]P since we did 
not assess it in the L5178Y cell line. Cells treated with acetaldehyde showed similar 
pattern in mutation across the 21-day period as seen with EMS, an adduct forming 
genotoxin which targets N7 of the guanine ring as opposed to N2, which acetaldehyde 
favours (David et al. 2018). A peak in mutant frequency was seen around day 9 
followed by a steady return to baseline level of mutant cells, which may signify 
DNA repair mechanisms at work to repair damage induced by acetaldehyde or may 
show mutant cells dying (Seitz and Homann, 2007).  
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Although the in vitro Pig-A assay has shown potential in a few studies, and in this 
study with acetaldehyde, more papers exist which are more critical than supportive 
of the method.  The assay is in its infancy, with several issues, which need to be 
overcome before the assay is as useful as its rodent erythrocyte counterpart. 
Problems arise with long experiment time. Cells are revived and maintained for 28 
days (6 days exponential growth, 1-day exposure, 21 days monitoring Pig-A 
mutation status). This increases contamination risk, which occurred during this study 
a few times, which required fresh vials of cells revived, starting over again. Another 
overall issue is found in the fragility of the GPI anchor on the surface of test cell line, 
whether that is L5178Y, MCL-5 or TK6. Care was taken to resuspend pellets 
carefully with gentle flicking and no mixing with pipettes as found in other staining 
protocols. Excessive roughness during processing resulted in false high mutant 
frequencies due to mechanical shearing of GPI anchors from the extracellular 
surface. One group in fact showed an increase in GPI-deficient cells through 
increased flicking of samples (unpublished). Additionally, staining was an issue, 
perhaps due to insufficient mixing, while taking care not to shear GPI anchors. 
Occasionally following the four-hour processing and staining stages seen in 3.2.5, 
cells were insufficiently stained, and no results were able to be collected. More 
reliable and less time-intensive techniques may have been more suitable to determine 
the quantity of GPI anchor deficient cells, but the flow cytometry based Pig-A assay 
in blood cells has been such a reliable and quick technique to quantify GPI anchor 
deficient blood cells, it doesn’t seem to have translated as easily into an in vitro 
setting. This is a shame, since a reliable in vitro Pig-A assay may be suitable for use 
as a control to calibrate flow cytometers and as a method to standardise results 
collected on different machines. 
3.5 Conclusion 
To conclude, in this chapter we have investigated an in vitro model in response to 
three chemicals linked to three known risk factors for PC. We have compared 
decrease in viability by RPD and induction of MN in the PANC-1 and L5178Y cell 
lines, followed by the in vitro Pig-A assay in the L5178Y cell line. Comparing all 
three chemicals assessed, acetaldehyde has shown to be the most potent genotoxin, 
inducing significant DNA damage, quantified through the MN assay and the in vitro 
Pig-A assay, at lower doses than the other chemicals assessed. B[a]P would be the 
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second most potent, given PANC-1 results but this chemical was not explored in the 
L5178Y cell line due to lack of metabolic capacity. Other studies carried out using 
S9 mix would support this conclusion. DCA would be the least potent chemical 
assessed. Additionally, the L5178Y cell line appeared to be more sensitive than the 
PANC-1 cell line. We have shown induction of DNA damage, assessed in two 
methods, following exposure to chemicals linked with poor diet, alcohol abuse and 
smoking. This is important preparatory work for a future chapter, where the MN 
assay and PIG-A assay will be utilised ex vivo. The work carried out in this chapter 
may account for some of the mutation we will see in donors, who may be patients 
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Chapter 4: The Human Erythrocyte PIG-A Assay as a diagnostic test for 
Pancreatic Cancer 
4.1 Introduction 
4.1.1 PC Diagnosis 
PC is a fairly rare form of cancer, only accounting for 3 % of cancer cases in the UK 
which is equivalent to the 10th most common form of cancer (Cancer Research UK, 
2020c). In 2017, there were 10,377 new cases of PC diagnosed with an even gender 
distribution with males accounting for 51 % of cases (Cancer Research UK, 2020c). 
Most PC cases are unfortunately diagnosed at advanced stages. Between the years of 
2012 and 2017, 52.57 % of PC patients were diagnosed with stage IV disease, more 
than the total of patients with either lower staged disease (I-III) or disease of an 
undetermined stage (National Cancer Registration and Analysis Service, 2019). 
There are numerous routes to a PC diagnosis. Currently, 46 % of cases are diagnosed 
via emergency presentation, which accounts for A&E attendance, emergency 
admission from GP, or emergency inpatient or outpatient referral (Cancer Research 
UK, 2016d). More PC patients present through emergency presentation (46 %) than 
general cancers (20 %) (Murchie et al., 2017). A number of factors have also been 
associated with increased chance of emergency presentation of general cancers 
including no prior GP appointment (OR = 3.89; CI 95 % 2.14 - 7.09), upper GI 
cancer, including PC (OR = 18.97; CI 95 % 6.08 - 59.23) and also ethnicity (OR = 
2.78; CI 95 %) (Murchie et al., 2017). Emergency presentation of cancer has been 
associated with high short-term mortality, contributing to the poor prognosis of PC 
given the high proportion of emergency PC admissions (Mcphail et al., 2013). 
Reducing the emergency presentation of PC has been predicted to increase the 
number of patients who would survive over one year (Pancreatic Cancer UK, 2013). 
Not only does the emergency route contribute to poorer disease outcome, it further 
burdens the NHS financially. Each individual emergency admission with PC costs 
approximately £5,000, triple the cost of other emergency admissions. This 
accumulates to costing the NHS approximately £14,650,000 per annum (Pancreatic 
Cancer UK, 2013). The high proportion of emergency PC presentation highlights the 
lack of early diagnosis. Earlier diagnosis would allow for more patients to be 
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diagnosed with potentially curable disease and improve the poor survival statistics 
for PC patients. 
Only 17 % of PC patients in England were diagnosed through the NHS’s “two week 
wait” referral route (Cancer Research UK, 2016d). Through this, patients with 
suspected cancer symptoms are referred for an urgent appointment with a specialist 
clinician within a fortnight. These emergency referrals have increased from 903,000 
in 2009 - 10 to more than 1.5 million in 2014 - 15 (Bankhead, 2017). No formal 
“two week wait” pathway exists in Wales.  Urgent referrals are available for 
suspected cancer cases to be seen urgently by suitable clinicians. NICE have set out 
guidelines in their 2015 report “Suspected cancer: recognition and referral” 
specifying patients over the age of 40 displaying jaundice should have a specialist 
appointment within a fortnight from initial GP presentation, and patients over the age 
of 60 displaying two or more symptoms need an urgent computer tomography (CT) 
within a fortnight (NICE, 2015). The formal “two week wait” system in England has 
only been in place a short period of time and it is too soon to tell whether it has made 
any benefit to patient survival (Bankhead, 2017). 
In Wales alone, two rapid diagnostic clinics have been established to help speed up 
cancer diagnoses to allow for better patient outcomes. Early detection of cancer is 
key for better treatment options and, in turn, longer survival. Particularly with PC, 
there is a desperate need for advances in early diagnosis, given the current bleak 
outlook for PC patients. In time, with more rapid diagnostic clinics and better 
diagnostic techniques available for PC, more patients would be diagnosed with early 
stage disease and have more treatment regimes available to them. In turn, this would 
increase the patient survival and improve on bleak outlooks, which have failed to 
improve over the last four decades.  
4.1.1.1 PC Diagnosis Methods 
4.1.1.1.1 Blood based biomarkers for pancreatic disease 
To date, there is only one blood-based biomarker in use for PC. The serum 
carbohydrate antigen 19-9 (CA19-9) is normally found in healthy patients at 
physiological levels below 37 kU/L (Thaker et al., 2014). It is elevated in PC, but 
can also be elevated in a number of benign conditions (Howaizi et al., 2003). With 
the standard cut off at 37 kU/L, the test has a sensitivity of 81% and a specificity of 
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90% (Thaker et al., 2014). PC patients can have levels of CA19-9 as high as 1,000 
kUmL and, at this level, the test shows an increased specificity at 99.8%, but at a 
compromise with 4% sensitivity (Thaker et al., 2014). Despite this being the only 
biomarker in use for PC, the assay isn’t without its problems. Elevated CA19-9 
levels are non-specific and are often raised in benign conditions including diabetes 
mellitus, jaundice, pancreatitis and chronic liver disease (Howaizi et al., 2003). More 
issues are raised since CA19-9 is a modified Lewis antigen and secretion of the 
marker are reliant on allele expression (Tempero et al., 1987). As a result, 5 – 10% 
of the population have the Lewis negative phenotype and the test will not be 
clinically relevant (Ballehaninna and Chamberlain, 2011).  
Often, the CA19-9 blood test is used in a wide panel of test results in order to narrow 
down the source of the patient’s symptoms. Another test result, which is helpful, is 
the c-reactive protein (CRP) level. CRP is produced in hepatocytes in response to 
inflammatory IL-6 (Agalianos and Dervenis, 2017). CRP indicates systemic 
inflammation and has been shown to be elevated in a wide range of cancers (Inoue et 
al., 2015). Many cancers including PC have an inflammatory origin (pancreatitis) 
and so the detection of an inflammatory biomarker is relevant. Normal physiological 
levels of CRP are below 5 mg/L (NHS, 2020). Elevation of CRP has been identified 
in PC patients, notably in patients with metastatic disease (Basso et al., 1988). 
Additionally, PC impacts upon the function of the liver and so monitoring the liver 
function tests (LFTs) is beneficial for diagnosing pancreatic disease. Elevated LFTs, 
especially bilirubin, can signify bile duct obstruction, which would require an 
intervention to relieve (Kim and Ahuja, 2015). 
4.1.1.1.2 Imaging techniques 
Imaging of the pancreas and surrounding organs is imperative when there is a 
suspected pancreatic pathology. The first port of call after the first presentation of 
symptoms is an abdominal ultrasound (Ciaravino and D’Onofrio, 2019). The 
ultrasound gives an image of the pancreas, gallbladder, liver and surrounding 
structures, allowing the identification of any abnormalities. PDAC, the most 
common solid pancreatic tumour, is identifiable by a solid, hyper-echoic mass and 
duct dilatation on ultrasound imaging (Lee and Lee, 2014; Ciaravino and D’Onofrio, 
2019).  Challenges are associated with pancreatic ultrasound, with careful 
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preparation and positioning of the ultrasound wand for diagnostic imaging. Patient 
preparation includes 7 - 8 hour fasting, as food consumption may occasionally result 
in false impression of pancreatic tumours, and 500 - 700 mL of non-carbonated fluid 
should be consumed 10 – 15 minutes prior to ensure the stomach is full of liquid and 
not gas, which can obstruct the view of the pancreas and result in non-diagnostic 
imaging (Sirli and Sporea, 2010).  If abnormalities are shown from an ultrasound, or 
imaging is insufficient, but symptoms and blood test results suggest pancreatic 
disease, further imaging techniques will be employed to further elucidate the issue 
and determine any involvement with surrounding organs and structures.  
Further imaging techniques include CT, magnetic resonance imaging (MRI) and 
positron emission tomography (PET) scans. CT scans of the abdomen and thorax are 
used to assess both local disease and any potential metastatic deposits. It is the most 
valuable imaging modality for the assessment of the resectability of PC, given the 
clear imaging of the associated vascular structures, but is limited due to often 
missing smaller peritoneal metastatic deposits (Lee and Lee, 2014). MRI imaging is 
preferred to CT as it has greater contrast when assessing soft tissue (Lee and Lee, 
2014). The adapted technique magnetic resonance cholangiopancreatography 
(MRCP) can be used to visualise the ductal system in the pancreas and can identify 
strictures and abnormalities often caused by tumours. PET scanning is less common 
for PC, but it is sometimes used in combination with CT scanning to distinguish 
between benign lesions and secondary tumours. Tumour cells have an increased 
glycolytic rate, commonly known as the Warburg Effect. This is exploited in PET 
scanning. The label, 18F-fluorodeoxyglucose (FDG) is a radioactive glucose 
analogue, which is taken up into cells but cannot be metabolised through glycolysis 
(Yeh et al., 2018). FDG enters the cells via glucose transporters, is phosphorylated 
by hexokinase, but cannot be metabolised further, unlike glucose (Rahman et al., 
2019). Tumour cells, with their increased glucose uptake accumulate more of the 
radiolabelled FDG and so emit more radiation than healthy tissues, which is captured 
through PET scanning, Fig. 4.1B. Problems arise as a result of glucose intolerance in 
PDAC, increased serum glucose decreased FDG uptake in pancreatic tumours for 
false negative results, and normal physiological processed result in the uptake of 
FDG in some tissues which can cause false positives (Lee and Lee, 2014; Yeh et al., 
2018). As a result, PET scans are used in limited scenarios where the nature of a 
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potential metastatic deposit is queried and is not clarified further through alternative 
scans and a biopsy is unsuitable. CT and MRI scans are the first port of call for 
visualising the pancreas and surrounding organs, with PET scanning used in special 
circumstances, Fig. 4.1. 
Figure 4.1: Initial staging scans of an 80-year-old female diagnosed with PDAC. A) 
MRI scan identified hypoenhancing mass in the body of the pancreas, identified by 
arrow B) PET/CT showing avid FDG uptake in primary mass, corresponding with 
MRI mass, identified by arrows C) An avid FDG peripancreatic lymph node 




Often in cancer, the only definitive proof of malignancy, rather than benign tissue, or 
inflammatory disease, is a histological confirmation given how ambiguous blood test 
and imaging results can be. Biopsies and cell brushings are methods to collect 
sufficient tissue for a diagnosis. There are several techniques available to do this. 
Endoscopic techniques include endoscopic ultrasound (EUS) and endoscopic 
retrograde cholangio-pancreatography (ERCP) are used to further image the 
pancreas and simultaneously collect tissue biopsies or cytology for histopathological 
analysis. To date, endoluminal ultrasonography (EUS) is one of the most sensitive 
imaging techniques used for the visualisation of the pancreas and is often used in 
combination with biopsy-collecting techniques such as fine needle aspiration (FNA) 
(Harris and Buscaglia, 2010). EUS combines the endoscope’s ability to reach the 
organs along the gastrointestinal tract with an ultrasound probe which can visualise 
smaller structures more easily for elucidation (The National Pancreas Foundation, 
2014). Benefits include that its high resolution has been shown to identify small 
tumours between 2 and 3 mm (Helmstaedter and Riemann, 2008). Additionally, 
combination with FNA allows for the aspiration of a biopsy sample for immediate 
histological assessment and in combination with EUS, has shown to have an 
accuracy ranging from 71 – 90 % (Harris and Buscaglia, 2010). Although highly 
accurate, this technique isn’t without its limitations. EUS can only be used to 
identify local metastases, but when combined with larger scale imaging such as a CT 
or MRI it paints a fuller picture. Questions have also been raised due to the extensive 
training required for the effective use of this technique and for the resulting images 
to be meaningful (Handgraaf et al., 2014). Similarly, this technique is invasive and 
does not come without risks. Complications that have been attributed to EUS-FNA 
include bleeding, iatrogenic pancreatitis, and perforation with a 3% cumulative 
prevalence (Majumder et al., 2012). Predictions state the use of core needle biopsies 
in the future instead of FNA to collect a larger sample of tissue whereby other 
aspects including the stroma could be analysed (Vera et al., 2016). ERCP also allows 
the endoscopist to collect biopsies through similar techniques as EUS and carries the 
associated risks. 
Suspected metastatic deposits, which are unable to be confirmed to be malignant 
from scans alone, and where the primary has been identified but not confirmed by 
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histology, would require biopsies before treatment could initiate. If the metastatic 
deposit is seen on CT scans, it is possible for biopsy to be taken through ultrasound 
guided biopsy by a trained consultant radiologist. If no metastatic disease is found on 
imaging, but it is suspected due to very elevated CA19-9 blood test results, a staging 
laparoscopy may be carried out (keyhole surgery). The minimally invasive 
exploratory surgery examines the inside of the abdomen to decide whether the PC is 
resectable in the future. Use of a staging laparoscopy has identified occult 
metastases, which were not present on imaging studies, in 15 – 51% of PC patients at 
high risk for unresectable disease (De Rosa et al., 2016).  
All biopsies and brushings are analysed by a trained pathologist to confirm or deny 
the presence of cancer. Often, cancer is not confirmed until after resection or surgical 
biopsy. Pancreatic surgeries are now focused in regional hepato-pancreato-biliary 
centres, where a specialised team of consultant surgeons, radiologists, and 
pathologists along with dedicated nursing staff allow for better specialised care for 
the complex pancreatic needs. Pathologists with special interest in pancreatic 
pathology assess tumours both macroscopically and microscopically to report back 
official diagnoses.  
4.1.1.2 PC Diagnosis Challenges 
There are a variety of problems when it comes to diagnosing PC. Currently, 80% of 
patients are diagnosed once their disease is either locally advanced or metastatic, 
which is too late for surgical intervention (Lahoud et al., 2016). Almost 50% of 
patients are diagnosed with stage IV disease (Public Health England and Cancer 
Research UK, 2018). As a result, only around 10% of patients diagnosed with PC 
had surgery as part of their treatment journey, whether alone or in combination with 
therapy (Public Health England and Cancer Research UK, 2018). Currently, radical 
surgical resection is the only curative treatment option for PC, so delays to diagnosis 
resulting in more advanced disease at diagnosis is detrimental and will contribute to 
the poor disease prognosis. Problems have been highlighted by NICE in their 2015 
report “Suspected cancer: recognition and referral” (NICE, 2015). This report 
provides guidelines for clinicians to aim for earlier diagnosis of PC to ensure the 
disease is still treatable. While most patients are diagnosed late, there is no screening 
system in place for early detection of PC. With low incidence of PC and presentation 
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with vague, non-specific symptoms; it is not a cost-efficient method. Other 
malignancies, like oesophageal cancer, have ongoing endoscopic screening (Lakatos 
et al., 2016). Questions have been raised to whether it would be worthwhile 
following up patients predisposed to developing PC such as those with familial links 
of PDAC. 
One of the many factors, which contributes to the late diagnosis of PC is the lacking 
symptoms, or only having minor, vague symptoms which can be easily brushed 
away. Early stage disease is often asymptomatic and so the disease can progress 
undetected within the retroperitoneal space. Once symptoms present, the disease has 
often spread into surrounding organs and tissues. A late-presenting symptom is 
jaundice, observed in 50% of PC cases, caused by the head of pancreas tumour 
expanding, causing common bile duct obstruction (Tummala et al., 2011; Cancer 
Research UK, 2016b). Some earlier, vague symptoms which can arise include 
fatigue, unexpected weight loss and poor appetite. They can start off unnoticeable 
and progressively get worse as the disease advances (Lahoud et al., 2016). Often, 
these symptoms can just be brushed aside and ignored as just a part of the aging 
process. This results in patients presenting through emergency admission for pain or 
jaundice.  
Questions have also been raised about the invasive nature of diagnostic techniques 
used for visualisation of the pancreas. This is particularly seen with endoscopic 
based approaches including EUS and ERCP mentioned above. There are risks of 
putting patients already in considerable pain through procedures which could result 
in side effects. Highly trained and skilled medical staff are also required to perform 
these procedures, which may not be available at local hospitals, hence travel to 
regional centres may be required.  
More problems arise with diagnosing PC from differentiating benign and malignant 
disease. The blood-based approach, using the CA19-9 serum marker, which has been 
shown to be elevated in benign conditions lead to false positive results. Additionally, 
the risk of serum negative patients means the test could also give false negatives and 
not identify PC at all. This was seen in a case by Muratore et al. (2016) of a patient 
who underwent a total pancreatectomy and islet autotransplantation for a suspected 
case of chronic pancreatitis, who later went on to develop PDAC within the 
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transplanted regions of the liver 10 months post-transplantation. At the time of the 
operation, serum analysis showed CA 19-9 levels were insignificant at 7 kU/L, yet 
retrospective serum analysis on the same sample showed elevated levels of 
microRNAs associated with early stage PDAC (Muratore et al., 2016). Imaging 
modalities also have problems differentiating between benign and malignant disease. 
Definitive proof of malignancy is often from histopathological examination of 
biopsies and cytology samples from the suspected tumour. However, sometimes 
tissue sampling is non-diagnostic. A study of 276 EUS patients found that 130 also 
had FNA to biopsy the suspected tumour. Of these, 67 patients had a positive 
confirmation of cancer, whereas 63 were negative for malignancy. Follow-up of the 
negative FNA patients found 17 with a final diagnosis of PC despite lacking 
pathology confirmation (Spier et al., 2009). Lack of a tissue confirmation cannot rule 
out a diagnosis of PC. Often, final diagnoses are made following pancreatic 
resection. 
4.1.2 Blood-Based Biomarkers 
Blood-based biomarkers are small biological markers which circulate in the blood, 
which can be identified and analysed to provide information about the health of the 
patient. Biomarkers exist for several different physiological processes and diseases. 
There are several benefits of blood-based biomarkers. In comparison to a lot of other 
diagnostic and biomonitoring techniques, it is a much cheaper alternative with blood 
tests ranging in cost from 24p to £13.28 depending on service provider (Robinson, 
2013). Blood tests also have a benefit of being a comparatively non-invasive method, 
especially considering endoscopic and surgical techniques. They are also an 
expected part of the healthcare system; regular blood tests are carried out during 
diagnostic investigation. Therefore, adding an additional biomarker into the battery 
of markers and metabolites already quantified and analysed would not be any extra 
commitment for the patient, but would require a little extra work from the 
haematology department. Blood collection is a common technique and can be carried 
out in local GP surgeries and health centres, which is more accessible for patients 
than some of the more complex investigations. Some blood-based biomarkers, such 
as the CA19-9 marker discussed prior, may not be suited for a biomarker alone but in 
combination with imaging, histology and other blood test results could help 
contribute to a full picture of disease. Alone, CA19-9 may be helpful as a tool to 
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stratify patients to determine those who are more in need of the more invasive and 
complicated procedures. This can be seen in patients with resectable PC from 
imaging but with CA19-9 elevated above 150 kU/L. These patients are selected to 
undergo staging laparoscopy to ensure there is no metastatic disease which would 
prevent a full pancreatic resection in the coming weeks (De Rosa et al., 2016).  
4.1.3 PIG-A Assay 
The human erythrocyte PIG-A assay was discussed previously in chapters 1.3.2.5 
and 1.3.2.5.1. The assay monitors the mutation status of X-linked PIG-A through 
flow cytometric detection of GPI anchored proteins CD-55 and CD-59 on the 
erythrocyte surface.  
4.1.3.1 Flow Cytometry 
The mutation status of PIG-A is determined indirectly by flow cytometry. Flow 
cytometry as a technique has been in use since the 1970s and has matured over the 
time to become a sensitive and sophisticated technique (Büscher, 2019). It is a 
commonly used analytical technique, often associated with blood analyses and 
immunological studies, making it an ideal technique for analysis of surface proteins 
on erythrocytes.  Thousands of cells can be analysed per second, allowing for 
millions of cells to be analysed in a short period of time. This is invaluable when 
assessing a rare event, such as the PIG-A mutation.  
Flow cytometers are made up of several parts. From a basic perspective there is a 
light source to excite fluorophores, a flow cell, where particles are focused into a 
single file stream for analysis through hydrodynamic focusing, and a detector to 
record the fluorescence emitted by fluorophores (Fig. 4.2) (Büscher, 2019). In 





Figure 4.23: Diagram depicting interior workings of a flow cytometer. A light 
source excites fluorophores in a single stream of focused particles, any fluorescence 
and light scattering is detected by the detector and sent to a computer for analysis 
(Büscher, 2019). 
In this study, two fluorophores are used, conjugated to antibodies specific for 
CD235a, the erythroid marker, and CD55 and CD59, the GPI anchored proteins of 
interest. The two fluorophores of choice for this assay are allophycocyanin (APC) 
and R-phycoerythrin (PE), with the excitation and emission spectra found in Fig. 
4.3. Both PE and APC are bright fluorophores, which allows for sufficient 
fluorescence intensity even with less expressed markers (Maecker et al., 2004). 
Between the two, PE is the brighter fluorophore and was used in the PIG-A assay to 
identify the GPI anchored proteins CD-55 and CD-59 (Biolegend, 2020). When 
using multiple fluorophores in an experiment, it is important to ensure the excitation 
and emission spectra do not overlap to avoid complication and need for additional 
compensation to remove the fluorescence overlapping into alternative channels 
(Maecker et al., 2004). The excitation and emission spectra of PE and APC are 
shown in Fig. 4.3. PE is excited at 495 nm and emits at 578 nm, around the yellow-
orange range of visible light. In comparison, APC is excited at 650 nm and emits 
light at 660 nm, which is in the red wavelength of visible light. There is sufficient 
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distance between the two spectra to collect clear results.
 
Figure 4.3: Excitation and emission spectra of the two fluorophores used in this 
study. A) PE is excited at 495 nm and emits at 578 nm B) APC is excited at 650 nm 
and emits at 660 nm (Absorption and Emission Spectra | BD Biosciences-US, 2020). 
4.1.4 Aims 
In this study, we aim to use the human erythrocyte PIG-A mutation assay in a cohort 
of patients with PC and benign pancreatic disease, not previously explored in detail 
in the literature. PC diagnosis remains a real clinical challenge and the search for 
novel blood-based biomarkers continues. The flow cytometry-based erythrocyte 
PIG-A assay quantifies GPI anchor deficient red blood cells by detecting GPI 
anchored CD-55 and CD-59 on the surface of red blood cells. GPI anchor deficient 
cells have been previously shown to have a mutation in the PIG-A gene. Quantifying 
GPI deficient erythrocytes provides a measure of circulating DNA damage, which 
has been used extensively in rodent genotoxicity studies and in a few healthy human 
population studies. We aim to determine whether patients with PC have an elevated 
level of circulating mutant red blood cells in comparison to healthy and benign 






4.2.1 Ethics and Permissions 
The study was planned, and documents were prepared for submission for research 
ethics committee (REC) approval. A protocol, patient informed consent form, patient 
information sheet and modified validated questionnaire (Appendix 7.1.3) were 
submitted via the integrated research application system (IRAS) (IRAS project 
ID:218936) to the Plymouth and Cornwall REC (REC reference: 17/SW/0012). 
Favourable opinion was granted on the 25th January 2017.  
Valid informed consent was granted from patients with benign pancreatic conditions 
including pancreatitis and pre-malignant conditions, and patients with malignant 
pancreatic disease. Patients donated a completed lifestyle questionnaire and 10mL 
whole blood in a sodium-heparin coated blood tube by venepuncture. Samples were 
returned to the university for analysis. 
4.2.2 The Human Erythrocyte PIG-A Assay 
4.2.2.1 Blood Preparation 
10 mL of venous whole blood was collected in sodium-heparin coated Vacutainer 
(Becton Dickson) tubes from consenting blood donors. Each tube was gently 
inverted 5 times. 10 µL whole blood pipetted into bottom of 15 mL centrifuge tube: 
once for an unstained instrumental calibration sample (ICS), and in triplicate for 
stained samples. Care was taken to ensure no blood was caught up the sides of the 
centrifuge tube to ensure thorough staining. Stained triplicates were stained with 5 
µL APC anti-CD235a (diluted 1:10) (BD Pharmingen) (0.1 µL/106 cells), 20 µL PE 
anti-CD59 and 20 µL PE anti-CD55 (both BD Pharmingen) (0.4 µL/106 cells). 
Samples were mixed through gentle pipetting. Mixtures were incubated at room 
temperature, protected from light for 30 minutes.  
Following 30 minute incubation, samples centrifuged at 500 g at room temperature 
for 5 minutes with full breaks and acceleration. Supernatants removed, with care 
taken not to disturb cell pellets. Pellets were washed twice in 2 mL antibody wash 
buffer (0.2 % BSA (Sigma) in PBS (Gibco)) using same centrifuge settings. Cell 
pellets were suspended in 1 mL antibody wash buffer (0.2 % BSA (Sigma) in PBS 
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(Gibco)) and transferred to flow cytometry tubes before immediate flow cytometry 
analysis. 
4.2.2.2 Flow Cytometry 
Initially, PIG-A blood samples were run on two flow cytometers: the FACSAriaI and 
the Beckman Coulter Navios. Unfortunately, over the course of the study, the 
FACSAriaI broke beyond repair and so all remaining samples ran solely on the 
Navios system. 
4.2.2.2.1 FACS Aria 
The BD FACSAria I (BD Biosciences) collected 100,000 events for the unstained 
ICS and 1,000,000 events positive for APC and PE for stained samples. A low flow 
rate and higher number of events used for stained samples since the PIG-A mutant 
phenotype is rare event. Data was collected and analysed using BD FACSDiva 
software, version 8.0 (BD Biosciences). Gates were drawn dependent on ICS. Gated 
population in the stained sample had positive staining for both APC and PE were 
determined to be wild type erythrocyte population. APC positive and PE negative 
population were concluded to be PIG-A mutant erythrocyte population and were 
quantified per million of wildtype erythrocytes.  
4.2.2.2.2 Navios 
The Navios (Beckman Coulter) flow cytometer analysed samples in a similar way to 
FACSAria seen in 4.2.2.1. Analysis was carried out using the Navios software 
(Beckman Coulter). Gating techniques remained the same with gates on stained 
samples drawn in respect to the unstained ICS. APC and PE positive population 
determined to be wildtype erythrocytes and APC positive, PE negative population 
determined to be PIG-A mutant erythrocytes, Fig 4.4. Mutant erythrocytes quantified 
per million wildtype erythrocytes. The only difference is all samples were analysed 
for 12 minutes, including the ICS, rather than for 1,000,000 events. More than 




Figure 4.4: Example cytograms from a healthy donor A) Unstained ICS which 
gates(blue line) are drawn by B) stained sample, showing wildtype red blood cells in 
H2 quadrant, mutant cell population in quadrant H4. In this example, 7 mutant red 
blood cells per 1.4 million wild-type red blood cells, or 5 x 10-6PIG-A mutant 
erythrocytes. 
4.3 Results 
4.3.1 Healthy, Benign and Malignant PIG-A  
In total, six healthy donors, 10 donors with benign pancreatic disease and 30 donors 
with pancreatic cancer provided blood for the human erythrocyte PIG-A mutation 
assay (Fig 4.5). The median PIG-A mutant frequencies for healthy donors were 4.55 
(95% CI 1.48-6.51) mutant red blood cells per million, similar to reported values 
from healthy population studies in the literature. Donors with benign pancreatic 
disease showed a median PIG-A mutant frequency of 2.64 (95% CI 2.11 - 4.16) per 
million red blood cells. The benign conditions of these donors included pancreatitis, 
pancreatic cysts, IPMN and PanINs. Comparison of healthy and benign donors using 
a non-parametric Mann Whitney U test determined there was no statistical difference 
between the two groups (U = 27, p = 0.745). The median mutant frequency for PC 
patients is 5.81 (95% CI 6.25 - 10.86) PIG-A mutant red blood cells per million. A 
non-parametric Kruskal-Wallis test showed a statistical difference between the 
groups of blood donors (p = 0.021) with mean ranks of 16.67, 15.10 and 27.03 in the 









benign and malignant pancreatic disease (p = 0.013). Although an increase between 
the mean values in the healthy and malignant group, the comparatively closer 
median values and overlapping confidence intervals in the two groups results in a 
non-significant increase (p= 0.078). With a bigger population of donors (particularly 











4.3.2 TNM Tumour Staging 
TNM tumour staging is used to define the size of the tumour, lymph node 
involvement and whether the disease has metastasised, providing a more detailed 
view of the disease. The TNM staging currently in use is the AJCC/UICC 8th edition, 
which is defined in Appendix 7.4. 
T-stage defines the primary tumour size. T-staging is further defined in Appendix 
7.4. As T-stage increases the tumour size does. Fig. 4.6 explores the PIG-A mutant 
frequency in PC donors with increasing T-stage. No clear pattern is seen as tumour 
size increases. An increase is seen at T4 with an PIG-A mutant frequency of 11.9 x 
Figure 4.5: Dot plot comparing PIG-A mutant erythrocytes frequencies in donors 
who are healthy (n=6), with benign (n=10) or malignant pancreatic disease (n=30). 
Donors with cancer of the pancreas have a higher frequency of mutant erythrocytes. 




























10-6, but only one donor had T4 staged tumour so more donors would be needed to 
confirm this increase. A Kruskal-Wallis test showed there was no statistical 
significance and that T-stage of disease did not increase the amount of mutant red 
blood cells (p=0.472). 
 
Figure 4.6: PIG-A mutation frequency in PC patient donors with increasing tumour 
size (T-stage) (n = 3 T1, n = 9 T2, n = 2 T3, n = 3 T3b, n = 1 T4). Crosses show the 
mean values. 
Lymph node involvement in disease increases as the cancer becomes more advanced 
and begins to spread. Definitions of N-staging is found in Appendix 7.4. No 
correlation is seen with the lymph node involvement of the tumour and the mean 
PIG-A mutant frequency, Fig. 4.7. The median values start lower for N0 disease 
with 5.69 x 10-6, it is then higher and comparable for N1 and N2 disease with 
medians of 7.46 and 7.58 PIG-A mutant per million erythrocytes, respectively. A 
Kruskal-Wallis statistical test showed non-significance overall (p = 0.7), with no 






Figure 4.7: PIG-A mutation frequency in donors with PC with increasing lymph 
node involvement (n = 5 N0, n = 7 N1, n = 6 N2). Crosses represent the mean. 
Metastasis has been shown to increase the mean frequency of PIG-A mutant 
erythrocytes in comparison to patients with no metastatic disease, Fig. 4.8. Donors 
with localised disease had median of 6.60 (95% CI 6.01 - 10.81) mutant red blood 
cells per million analysed in comparison to 8.22 (95% CI 5.20 - 19.69) mutant red 
blood cells per million in donors with metastatic disease. A Mann Whitney U 
statistical test showed this increase in PIG-A mutant erythrocytes was non-
significant (p = 0.226). 
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Figure 4.84: PIG-A mutant frequency in donors with PC with patients with localised 
disease (0) or metastatic disease (1) (n = 18 M0, n = 7 M1). Crosses represent the 
mean. 
From individual TNM staging of donors, numerical tumour stages were determined, 
Appendix 7.4. Of the patients with staging data available, donors were categorised 
as follows: 2 patients as stage IA, 4 were stage IB, 6 were IIB, 6 in stage III and 7 in 
stage IV. No donors were found to be stage IIA. Donors in stages IB, IIB and III had 
very similar levels of mean mutant red blood cells with 8.073 ± 6.804, 7.954 ± 6.137 
and 8.228 ± 3.200 x 10-6 PIG-A mutant erythrocytes, respectively. Donors in stage 
IA had an elevated mean mutant frequency in comparison to higher stages, with 
11.004 ± 1.421 x 10-6. However, it should be noted that only two donors had the 
earliest stage disease, and a greater number of donors may alter this result. Median 
values of PIG-A mutant erythrocytes are high for stage IA, perhaps because only two 
donors had stage IA disease. Values for stages IB and IIB were more similar with 
5.32 (95% CI 2.75 - 18.90) and 5.57 (95% CI 1.51 - 14.39), with a slight elevation at 
the more advanced stages III and IV with 7.58 (95% CI 4.87 - 11.59) and 8.22 (95% 
CI 5.20 - 19.69), respectively. Despite this elevation at more advanced stages, this 
was determined to be non-significant through the Kruskal-Wallis statistical test (p = 




Figure 4.9: Box and whisker plot of PIG-A mutant erythrocyte frequency as stage of 
PC increases (n = 2 IA, n = 4 IB, n = 6 IIB, n = 6 III, n = 7 IV).  
For the PC patients who underwent pancreatic resection as part of their disease 
journey, resection completeness was assessed. Five patients had complete resection 
with clear resection margins, but six had incomplete surgical resections where 
tumour was present on the resection margins microscopically. No difference was 
seen between the mutant PIG-A frequency and the completeness of the resection, 
Fig. 4.10. 
 
Figure 4.105: Resection completeness of the PC patients who underwent pancreatic 





























where microscopic tumour was present along resection margins (n = 6). Bars 
represent the mean and the error bars represent the standard deviation. 
4.4 Discussion 
In this study, we have explored the human erythrocyte PIG-A mutation assay in a 
novel population, i.e. patients with benign and malignant pancreatic disease, to 
determine whether there is an elevated number of circulating mutated red blood cells 
in PC patients. The human erythrocyte PIG-A mutation assay is in its infancy 
relatively, having previously been used extensively in rodent genotoxicity studies. 
The assay is straightforward, requiring only a trio of antibodies so the staining 
protocol is simple and quick, only requiring a 30-minute incubation step. Samples 
can go from arrival at the university laboratories to samples being run on the flow 
cytometer within an hour and a half. It is a high throughput method, analysing over 
3,000,000 erythrocytes per donor over a 40-minute period. Batches of samples can 
also be run together to make it even more high throughput. It is also a cheaper 
alternative to other diagnostic techniques, with estimates from our laboratory that 
this test only costs £30 per patient, mainly due to fluorescent antibody costs. As well 
as being cheap it only requires 40 µL of blood in total per patient, considerably less 
than other tests require. In previous studies, clinical laboratories have been shown to 
receive 8.5 times more blood than is needed for analysis for full blood counts, with 
12 times more blood received for electrolyte panels (Dale and Ruby, 2003). This 
resulted in average blood volumes being discarded of 2.8 mL/tube and 2.0 mL/tube 
for full blood counts and electrolyte analysis, respectively. Our blood test, which 
only uses a tiny volume of 40 µL could easily be added into the battery of tests run 
on a single blood sample used in a patient with suspected PC, reducing wasted blood 
samples while potentially providing further information which could be beneficial to 
the patient.  
One drawback of the assay is that the determination of the mutation in PIG-A is 
solely down to the phenotypic lack of GPI anchored CD55 and CD59, rather than 
through studying the DNA directly. DNA cannot be studied in the mature 
erythrocyte since the nucleus and organelles are expelled during terminal erythrocyte 
maturation within the bone marrow (Moras et al., 2017). Previous studies have 
shown in alternative nucleated blood cell populations that mutation in the PIG-A 
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gene has resulted in a GPI deficient phenotype (Dobrovolsky, et al., 2008). The use 
of antibodies against two different GPI anchored proteins, CD55 and CD59, also 
ensures the lack of GPI-linked proteins is due a mutation involved in GPI anchor 
biosynthesis rather than in a random mutation in the gene for the markers 
themselves. For novel biomarkers, the necessary equipment should ideally be present 
in a clinical setting, especially if the equipment is not cheap to purchase or maintain. 
However, flow cytometry is now found within most large hospitals around the 
United Kingdom. For example, the Cardiff and Vale University Health Board have 
flow cytometry and use it for the processing of immunological samples, primarily for 
exploration of immunodeficiencies (CVUHB, 2016) and Swansea Bay University 
Health Board also uses flow cytometry. Haematology based flow cytometry is also 
used for the detection of PNH, the potentially fatal disease caused by a somatic PIG-
A mutation, resulting in GPI deficient blood cells, which become lysed at the hands 
of the complement system.  It is also diagnosed by flow cytometric detection of red 
blood cells lacking in CD-55 and CD-59, or by the use of fluorescently labelled 
aerolysin which binds GPI anchors to induce haemolysis (Besa, 2019). Since PNH 
diagnosis is currently available within the clinical setting using a near-identical set-
up to our erythrocyte PIG-A assay, there is potential that this test could be rolled out 
into a clinical setting if proven to be suitable, although this is admittedly a long way 
off.  
Through using the human erythrocyte PIG-A assay, the mutant frequency was 
established in healthy donors and donors with benign and malignant pancreatic 
disease. Healthy donors were found to have a median PIG-A mutant frequency of 
4.55 x 10-6 (95 % CI 1.48 - 6.51) and patients with benign pancreatic disease were 
shown to have a very similar mutant frequency of 2.64 x 10-6 (95 % CI 2.11 - 4.16), 
no statistical difference was found between the two groups, Fig. 4.5. These mutant 
frequencies as well as being comparable to each other, were similar to reported 
mutant frequencies from healthy population studies including means of 2.9 x 10-6 
and 5.25 x 10-6 and median value of 2.8 x 10-6 (Dertinger et al., 2015; Cao et al., 
2016; Haboubi et al., 2019). This suggests that patients with benign pancreatic 
disease have not accumulated significant DNA damage and mutation in their blood 
cells over the healthy population. In a rodent study, acute necrotizing pancreatitis 
was induced in a Wistar-albino rat population and DNA damage was assessed in 
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tissues using the comet assay. Peripheral lymphocytes were assessed and showed no 
significant differences in comparison to lymphocytes from healthy rats measured by 
tail intensity, moment or migration (Şahin et al., 2007). Although this is in a separate 
blood cell population and a rodent model, it supports results seen in our donors with 
benign pancreatic disease. In contrast, a human study performed the comet assay on 
lymphocytes from acute pancreatitis patients and showed a significant induction of 
DNA damage in comparison to controls, which was also positively correlated with 
the severity of disease calculated by the Balthazar scoring system (Dur et al., 2016). 
Conflicting evidence is available within the literature, this may come as a result of 
using alternative techniques for identifying DNA damage. The comet assay is a 
quantitative technique which studies single and double strand breaks within the DNA 
which has been in use for over 25 years. It is sensitive enough to detect even low 
level DNA damage in small samples (Tsai et al., 2017). However, the comet assay 
may also detect transient breaks in the DNA induced by DNA repair processes. This 
normal physiological response may not ultimately lead to fixed DNA mutations. It 
may be sensitive enough to identify DNA damage in benign inflammatory conditions 
like pancreatitis, as well as in fully malignant disease. The PIG-A mutation assay 
may be less sensitive, since it studies mutation rather than damage, and only show an 
induction of mutation in malignant disease. More work on the PIG-A erythrocyte 
assay would have to be performed to establish this, especially given this is only a 
pilot study. 
Patients with malignant disease have shown to have a significantly elevated PIG-A 
mutant frequency, median of 5.81 (95 % CI 6.25 - 10.86) PIG-A mutant red blood 
cells per million, over patients with benign pancreatic disease (p = 0.013), but not 
quite over healthy donors (p = 0.078), Fig. 4.5. An increase in PIG-A mutant 
frequency was also seen in oesophageal adenocarcinoma patients, who were shown 
to have a three-fold increase in mutant frequency in comparison to healthy and 
gastroesophageal reflux disease patients (Haboubi et al., 2019). This is more than the 
2.075-fold increase viewed in PC patients in comparison to benign patients. This 
increase in erythrocyte PIG-A mutant frequency viewed in this study is due to an 
accumulation of mutation and DNA damage which occurs over several years before 
tumour formation. Computer modelling has predicted the time frame from tumour 
initiation into a founding cell of the tumour to be an average of 11.7 years, although 
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most tumours aren’t diagnosed until subclones with metastatic capabilities have 
already disseminated and formed metastatic deposits, a further 5 - 7 years later 
(Yachida et al., 2010).  This allows a window for diagnosis of 5 - 7 years when PC is 
present, and potentially treatable.  
Questions have been raised about the sources of the PIG-A mutations seen in the 
erythrocytes of the population of PC patients studied. Mature erythrocytes lack 
nuclei since nuclei and other organelles are expelled from the cell during terminal 
erythrocyte maturation within bone marrow (Moras et al., 2017). This suggests 
mutation in PIG-A would have occurred before the shedding of the nuclei before 
maturation. Prior studies have established a Pig-A assay in rodent bone marrow 
erythroid cell populations following treatment with known mutagens 7,12-
dimethyly-benz[a]anthracene and N-ethyl-N-nitrosourea, both of which induced Pig-
A mutant erythrocytes (Revollo et al., 2018; Revollo et al., 2019). The increase in 
both Pig-A mutant immature bone marrow erythroid cells and circulating mature 
erythrocytes suggests the mutation occurs within the bone marrow before erythrocyte 
maturation. If this is the case, some form of tumour-secreted factor may be 
responsible for mutations induced in the bone marrow erythroid precursors.  
A study monitored proteins overexpressed within the secretome of PDAC cell line 
PANC-1 in comparison to control healthy pancreatic cell line HPDE cell line.  Stable 
isotope labelling with amino acids in cell culture in tandem with liquid 
chromatography and DNA microarrays allowed for identification of 68 proteins 
expressed more than 1.5-fold more in the PDAC cell secretome than that of the 
healthy pancreatic epithelium (Grønborg et al., 2006). Several upregulated proteins, 
with a wide variety of roles, had not been associated with PC previously (Grønborg 
et al., 2006).  
In particular, upregulated proteins cathepsin D and TNF-α were of significant 
interest in the Grømborg et al. (2006) study. Aspartatyl protease cathepsin D is 
found upregulated in several cancers, notably breast and colorectal cancers, and in a 
range of neurological diseases (Zaidi et al., 2008).  Secretome analysis of PC cell 
line PANC-1 revealed a 7-fold increase in cathepsin D expression in comparison to 
non-neoplastic pancreatic HDPE cell line (Grønborg et al., 2006). A similar study 
explored the oesophageal squamous cell carcinoma secretome and identified a larger 
137 
 
population of 120 upregulated proteins in malignancy (Kashyap et al., 2010).  
Cathepsin D was also observed to be upregulated in oesophageal squamous cell 
carcinoma, but with a lower 4.88-fold change in comparison to the 7-fold change 
viewed in PC (Grønborg et al., 2006; Kashyap et al., 2010). Cathepsin D’s role in 
malignancy is complicated due to the protein acting as both a mitogen and a protease 
(Mahajan et al., 2020). Mitogenic activity of cathepsin D is viewed in pancreatic and 
gastric cancers, where cancer cell proliferation and dissemination is caused by post-
translational induction of cathepsin D by anterior gradient 2 (Chen et al., 2017). 
Poorer prognosis was associated with higher cathepsin D expression within the 
pancreas in a study of 403 PC patients (Mahajan et al., 2020). This was partially 
attributed to mitogenic activity of cathepsin D but also due to resistance to 
gemcitabine through cathepsin D’s proteolytic activity and its complex regulation by 
acid sphingomyelinase through breakdown of the cathepsin D activator ceramide 
(Mahajan et al., 2020).  
Pro-inflammatory cytokine TNF-α was shown to be overexpressed in PC cell lines 
and levels are further elevated in cells resistant to chemotherapy (Zhao et al., 2016). 
In circulation, TNF-α will encounter numerous cell types, including haematopoetic 
stem cells within the bone marrow. TNF-α plays a key pro-survival role in 
haematopoetic stem cells, yet this is not without risks (Yamashita and Passegué, 
2019). TNF-α has shown to be mutagenic in the  in vitro chromosomal aberration 
and CBMN studies through ROS mediated mechanisms (Yan et al., 2006). 
Endogenous mitogens and mutagens, exemplified here with cathepsin D and TNF-α, 
upregulated in PC may circulate and induce PIG-A mutations within haematopoetic 
stem cells. Haematopoetic stem cell survival, expansion and erythropoiesis may lead 
to the circulation of fully mature PIG-A mutant erythrocytes. This may account for 
some of the PIG-A mutant erythrocytes viewed within our PC patient cohort within 
this study.  
Within the cohort of cancer patients studied, patients with metastatic PC were shown 
to have an elevated number of PIG-A mutant red blood cells in comparison to 
patients with no distant metastases (Fig. 4.8). Despite an increase being seen, this 
was non-significant following Kruskal-Wallis statistical analysis (p = 0.472). This 
may become significant with a bigger patient population with metastatic disease. 
Patient recruitment, following ethical approval, was based within pancreatic surgery 
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clinics at a tertiary referral centre. Care was taken not to approach patients during 
their initial appointments where the diagnosis of PC may have been new. As a result, 
fewer patients with metastatic disease were recruited since following initial 
appointments, those with obvious metastatic disease from imaging were referred to 
local oncology departments for chemo/radiotherapy and they did not undergo 
surgery. All the patients here with metastatic disease were patients who we found to 
have metastatic deposits histologically confirmed during operation (staging or 
resection), which ultimately resulted in an abandoned resection and alternative 
palliative treatment options pursued. In further studies, the potential to recruit 
palliative PC patients from oncology departments before starting therapy would be 
beneficial to capture as many patients as possible to get a bigger population of 
patients with metastatic PC patients to get results which may become significant.  
Cancer is a disease of mutation and accumulating DNA damage. PC is no exception. 
In this study, we have shown an elevated frequency of PIG-A mutant peripheral 
erythrocytes in comparison to healthy donors and donors with benign pancreatic 
disease. Circulating markers of DNA damage are hoped to reflect the state of the 
disease and may show some potential as diagnostic or staging tools. One study 
examined both the nuclear and mitochondrial DNA from lymphocytes from 48 
cancer patients in comparison to 48 controls using quantitative PCR. Damage to the 
genome was detected through reduced amplification, indicative of lesions blocking 
the action of DNA polymerase (Jansen et al., 2015). PDAC patients were shown to 
have significant reduction in mitochondrial DNA damage (p = 0.03) and borderline 
significant reduction in damage in nuclear DNA (p = 0.08) (Jansen et al., 2015). It 
was suggested that the increased oxidative stress in cancer in turn increased the DNA 
repair capacity of the lymphocytes. This reduction of DNA damage contrasts our 
findings of an increased DNA mutation in peripheral red blood cells. Not only does 
cellular DNA mutation show potential in diagnosing PC, cell-free DNA has been 
gaining interest. Analysis of cell-free DNA in 112 patients with pancreatic lesions 
(including 70 PDAC patients) showed hot spot mutations in KRAS, which were only 
present in malignant disease or pre-malignant patients not in healthy controls 
(Xiaoyu Liu et al., 2019). Additionally, cell-free DNA has shown the ability to 
diagnose early stage PC, with cell-free DNA reflecting mutations seen within the 
primary tumour. Interestingly, the Liu et al. (2019) study also showed that cell-free 
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DNA concentrations did not reflect the CA19-9 levels or overall disease staging but 
was correlated with the size of the tumour in those with localised disease. Blood-
based biomarkers have shown potential for use in pancreatic disease, further research 
is needed to identify new markers and to investigate their usefulness.  
Given the limitations of current widely used CA19-9 as a biomarker for PC, 
previously discussed, it cannot be fully relied upon alone for PC diagnosis. When 
used in conjunction with additional biomarkers for other clinical features including 
systemic inflammation, it may perform better than the single biomarkers alone to 
provide further information and provide a more rounded picture of the patient’s 
disease (Brand et al., 2011). One study established a panel of biomarkers for PC 
consisting of the trio of biomarkers CA19-9, ICAM-1 and osteoprotegerin. Within a 
training dataset, PC patients were differentiated from healthy controls and benign 
patients with sensitivity and specificity of 88% and 90% for healthy donors and 76% 
and 90% for benign donors, respectively (Brand et al., 2011). Furthermore, a 
validation set showed great specificity for PC over breast, lung and colon cancer 
with specificities of 100%, 97% and 97%, respectively (Brand et al., 2011). This is 
superior over CA19-9 as a single biomarker, with 81% sensitivity and 90% 
specificity with the cut-off value of 37 kU/L (Thaker et al., 2014). We aim to explore 
a novel biomarker panel in the next chapter to determine whether the combination of 
CA19-9 with the novel biomarker PIG-A, explored within this chapter, shows any 
improvement upon single biomarker use. Additionally, we aim to add in c-reactive 
protein and the neutrophil-to-lymphocyte ratio to the biomarker panel. As markers of 
clinical and sub-clinical inflammation, it may be beneficial due to the strong 
inflammatory links in PC development.  
4.5 Conclusion 
PC diagnosis continues to be a challenge to clinicians due to the late presentation, 
vague symptoms, and aggressive nature of the disease. The erythrocyte PIG-A assay 
has been used extensively in rodent genotoxicity studies and less frequently in 
human population studies. More recently, the assay has been used in two studies 
monitoring cancer cohorts. In this study, we aimed to examine a population of 
patients with pancreatic disease, both benign and malignant, to determine whether 
the assay has any potential in diagnosing PC. In this study, 46 donors: 6 healthy 
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volunteers, 10 patients with benign pancreatic disease and 30 PC patients; donated 
heparinised whole blood which was analysed through the PIG-A mutation assay. 
Healthy donors and patients with benign disease had comparable median mutation 
frequencies of 4.55 (95 % CI 1.48 - 6.51) and 2.64 (95 % CI 2.11 - 4.16) mutated red 
blood cells per million, in keeping with reported values from population studies in 
the literature. PC patients were shown to have a significantly elevated frequency of 
mutated red blood cells (5.81 (95 % CI 6.25 - 10.86)) over patients with benign 
disease (p = 0.013). Staging data on the tumours allowed the examination of any 
correlations with tumour size, nodal involvement, metastasis, overall staging, and 
resection completeness of those who underwent surgery. No significant differences 
were found trends were seen with PC patients with metastatic disease, and those with 
stages III and IV disease had a slight elevation. With larger patient cohorts, these 
results may have become significant. Regardless, the PIG-A assay has shown some 





















Chapter 5: Peripheral 
Blood Mononuclear Cell 
Cytokinesis Block 
Micronucleus Assay and 
Additional Biomarkers 






Chapter 5: Peripheral Blood Mononuclear Cell Cytokinesis Block Micronucleus 
Assay and Additional Biomarkers for Pancreatic Cancer 
5.1 Introduction 
5.1.1 The Cytokinesis Block Micronucleus Assay in Peripheral Blood 
Mononuclear Cells 
The CBMN assay is a well-established technique for assessing chromosomal 
stability in a range of cell lines and primary cell cultures, as discussed previously in 
1.3.1.6 and 3.1.5. The induction of small, membrane bound vesicles containing 
fragmented DNA is studied following exposure to stimuli to determine whether the 
stimuli is genotoxic. As well as being established in numerous cell lines, primary 
human cells have also been explored using this assay. Ex vivo applications of the 
assay include monitoring induction of DNA damage induced through lifestyle and 
dietary factors in lymphocytes and buccal cells from cheek swabs (Bolognesi and 
Fenech, 2013; Sommer et al., 2020). Human reticulocytes are also used in the 
CBMN assay and less commonly urine and nasal swab derived cells have been 
explored with the assay (Sommer et al., 2020). 
The CBMN assay has also been established in human peripheral blood mononuclear 
cells (PBMCs). PBMCs consist of lymphocytes and monocytes and are isolated from 
the buffy layer. Lymphocytes are white blood cells, which circulate through the 
lymphatic system and the blood (Blum and Pabst, 2007), consisting of B-cells, T-
cells and natural killer cells. Only 2% of lymphocytes are present in blood, with the 
remainder present in organs and the lymphatic system (Blum and Pabst, 2007). 
Healthy adults should have lymphocytes within the range of 1.0 to 4.0 x 109 cells/L 
(Gloucester Hospitals NHS Foundation Trust, 2020). Deviations from this can 
signify infection or disease. Lymphocytosis, the elevation of lymphocyte counts, can 
be caused by infection, chronic inflammation of autoimmune disorders and blood or 
lymphatic malignancies (NCH Healthcare System, 2019). In contrast, low 
lymphocyte counts, lymphocytopenia, can be as a result of malnutrition, autoimmune 
disorders, chronic infections like AIDS and also blood and lymphatic cancers (MSD, 
2020). 
Through studying the induction of MN in circulating blood cells, genomic damage 
can be quantified whether the damage comes as a result of exposure to genotoxic 
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compounds, through disease states or simply from increasing age (Kisurina-
Evgenieva et al., 2016).  A healthy population study in a middle aged Korean 
population monitored the MN induction in a study of 150 male donors and 150 
female donors with insignificant medical history (Cho et al., 2017). An increase in 
MN was seen with increasing age across both male and female donors, with female 
donors having an elevated frequency of MN above male donors with 2.69 ± 1.18% in 
comparison to 1.86 ± 0.71% (p < 0.001) (Cho et al., 2017). A Croatian population 
study also determined women to have an elevated frequency of MN in comparison to 
male donors with frequencies of 0.516 ± 0.298% and 0.479 ± 0.344 %, respectively 
(Gajski et al., 2018). Not only did age and gender show an influence on MN 
frequency, Gajski et al. (2018) also determined that the sampling period and 
sampling season influenced the frequency of MN. Male donors were found to have 
highest MN frequency during the summer, whereas female donors had peak MN 
frequency in Spring time (Gajski et al., 2018). Additionally, Gajski et al. (2018) saw 
that nuclear buds (defined as MN-like protrusions from the main nuclei which 
haven’t fully detached) were highest frequency in summer and winter for male and 
female donors, respectively. Radiation exposure was also observed to increase the 
MN frequency in the Croatian population study (Gajski et al., 2018). 
As well as monitoring genotoxicity in healthy populations, the assay has been used 
as a biomonitoring tool following exposure to occupational hazards. Industrial risks 
often involve exposure to potentially harmful chemicals or radiation over extended 
periods. A study of industrial radiographers who study the safety of materials 
through use of X-ray machines or gamma radiation emitting sources were assessed 
with the lymphocyte CBMN assay using 60 exposed workers and 40 non-exposed 
controls (Shakeri et al., 2017). Not only did exposed workers show an elevated 
frequency of MN in comparison to control workers, a dose dependent increase in 
MN was seen with workers exposed to increasing radiation doses (Shakeri et al., 
2017). Further studies have explored the lymphocyte CBMN assay in areas with 
naturally occurring high background radiation including Kerala in southern India, in 
both adult (Karuppasamy et al., 2016) and new-born populations (Das and 
Karuppasamy, 2009); as well as west Sulawesi, Indonesia (Syaifudin et al., 2018). 
Industrial chemical exposure has been explored using the lymphocyte CBMN assay. 
Coke oven workers have also been shown to have an increased MN frequency in 
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comparison to control workers in a population in Northeast China with frequencies 
of 0.74 ± 0.43% and 0.30 ± 0.30%, respectively (Cheng et al., 2009). Exposure to 
styrene, polycyclic aromatic hydrocarbons and common pesticides have also been 
explored (Bolognesi and Holland, 2016; Costa et al., 2016; Sram et al., 2016). 
Accumulation of DNA damage, as quantified in the lymphocyte CBMN assay, can 
lead to the development of disease. This has been explored in several benign and 
malignant diseases. Cardiovascular disease is a prime example of disease explored 
using the assay, given established links between atherosclerotic plaque development 
and genomic instability from oxidative stress (Andreassi et al., 2011). Both coronary 
artery disease and ischaemic heart disease were shown to have elevated frequency of 
micronuclei in lymphocytes in comparison to healthy donors (1.19 ± 0.17 %, 0.59 ± 
0.12 % and 0.36 ± 0.07 %, respectively) (Botto et al., 2001). An additional study of 
patients with dilated cardiomyopathy, confirmed through ultrasonography, were 
shown to have an elevated frequency of micronuclei in comparison to an age and sex 
matched control population (p < 0.001) (Sitaraman et al., 2014). Neurodegenerative 
diseases have also been explored using the lymphocyte CBMN assay, since genome 
instability has been shown to increase the risk of neurodegeneration (Lee et al., 
2015). A study compared the circulating DNA damage in patients with pre-disease 
mild cognitive impairment and fully developed Alzheimer’s disease to establish 
whether genome stability gets progressively worse as disease severity increases (Lee 
et al., 2015). Although no significant overall difference was seen between patients 
with mild impairment and Alzheimer’s disease with MN frequency, a significant 
decrease was seen when mental state was examined, suggesting a link with declining 
cognitive ability (Lee et al., 2015). 
Malignant disease has also been explored, given cancer is a disease resulting from an 
accumulation of DNA damage. A study examined 44 Serbian patients with breast, 
uterine or pharyngeal cancers in comparison to a benign healthy donor cohort. 
Cancer patients were shown to have an elevated frequency of MN with 1.518 ± 
0.505% in comparison to healthy donors with 0.645 ± 0.275% (p < 0.001) 
(Milosevic-Djordjevic et al., 2010). Interestingly, no differences were viewed when 
examining gender, primary tumour site or smoking status of donor (Milosevic-
Djordjevic et al., 2010). Elevated MN frequency has been linked with increased risk 
of developing cancer, due to an increased burden of DNA damage. Studies have 
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explored the elevated MN frequency, showing increased risks of developing bladder, 
thyroid and colorectal malignancies (Bayram et al., 2014; Ionescu et al., 2015; 
Pardini et al., 2017). Furthermore, a large international study, collating results from 
the HUMN studies, established that an elevated frequency of MN was linked with an 
increased risk of cancer development (Bonassi et al., 2007). However, when 
specifically observing pancreatic and hepatobiliary cancers, Bonassi et al (2007) saw 
a reduced risk of cancer development with increasing MN frequency, although this 
was non-significant (p = 0.27). Studies have also monitored the MN response to 
oncological therapies. A study following patients with metastatic colorectal cancer 
through their systemic therapy journeys and recorded the frequency of MN in 
peripheral lymphocytes before, during and after therapy over a six-month period 
(Nikolouzakis et al., 2019). Patients who responded in similar manners to the 
therapy were shown to have a similar pattern in MN frequency across the six-month 
period, often with a dip in the middle and increase at final reading, making a v-
shaped pattern. Patients with shallower ‘V’ trends having better response to therapy 
than non-responders, who had the deepest ‘V’(Nikolouzakis et al., 2019). This 
allows for potential prediction of therapeutic response from the assay as well as 
radiological imaging. Radiotherapy and chemoradiotherapy have also been explored 
in patients with head and neck cancers, with patients treated with chemoradiotherapy 
showed an elevated frequency of MN in binucleated lymphocytes, whereas 
radiotherapy alone did not show an elevation in comparison to healthy controls (Unal 
et al., 2016). However, limitations of this study, including the sampling time post-
therapy which ranges from 60 to 239 months after therapy, may limit the reliability 
of data (Unal et al., 2016). PC has also been examined using the CBMN assay, with 
PC displaying elevated frequencies of peripheral lymphocytes with MN (Chang et 
al., 2004; Chang et al., 2011). 
5.1.2 Other Biomarkers for PC 
A range of biomarkers are currently in use for PC, although their uses are limited. 
Given the diagnostic challenges and poor prognosis, the search for novel PC 
biomarkers continues in the hope to improve the dire outlook for PC patients. A 
panel of biomarkers, using multiple in combination, may improve diagnostic 




CA19-9 is a clinically used serum biomarker for PC, further discussed in 4.1.1.1. 
Elevated CA19-9 levels can be as a result of PC, but also due to a number of benign 
conditions including diabetes mellitus, jaundice and pancreatitis (Howaizi et al., 
2003). 
5.1.2.2 Neutrophil to Lymphocyte Ratio 
From routine full blood counts the neutrophil to lymphocyte ratio (NLR) can be 
calculated by division of number of neutrophils by number of lymphocytes (Gürağaç 
and Demirer, 2016). This provides a measure of sub-clinical inflammation within the 
patient (Gürağaç and Demirer, 2016; Faria et al., 2016; Forget et al., 2017).  A 
healthy population study of 413 non-geriatric donors resulted in a mean NLR of 1.65 
± 1.96 with a range of 0.78 to 3.53 (Forget et al., 2017).  NLR values above this 
signifies increased inflammatory stress in the patient (Farkas, 2019). 
Patients with inflammatory conditions, cancers and systemic infections have been 
shown to have elevated NLR (Gürağaç and Demirer, 2016). Autoimmune 
inflammatory conditions including rheumatoid arthritis and Behçet’s disease were 
shown to have increased NLR, associated with increased disease severity 
(Chandrashekara et al., 2017; Hammad et al., 2018). Additionally, NLR has been 
shown to be a predictor for metabolic syndrome (Liu et al., 2019).  
NLR has been shown to be elevated in a range of malignancies (Gürağaç and 
Demirer, 2016). The immune system plays a complex role in carcinogenesis. 
Neutrophils play an active role in a tumour microenvironment, displaying both pro- 
and anti-tumour properties (Wu et al., 2019). Tumour promoting activities of 
neutrophils include the production of ROS, chemokines, cytokines and enzymes 
which increase the chance of developing cancer (Wu et al., 2019). In PC, neutrophils 
secrete the cytokine TGF-β, which in turn increases collagen production, to 
contribute to the high levels of desmoplasia displayed in pancreatic malignancies 
(Aoyagi et al., 2004). In contrast, lymphocyte infiltration in primary tumours has 
shown some prognostic value in some solid tumours (Hendry et al., 2017). NLR has 
shown potential when studying malignancies of the breast, kidney, colon, ovary and 
the pancreas (Faria et al., 2016). 
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Both neutrophils and lymphocytes have been implicated in previous PC studies. 
Immunohistochemical studies of PC established high neutrophil concentration within 
the tumour microenvironment was linked with poorer disease prognosis in 
comparison to those with high levels of lymphocyte infiltration (Hendry et al., 
2017). Various studies have evaluated the NLR’s use in PC. In a study of 206 PC 
patients, NLR was found to be significantly associated with overall survival of 
patients through both univariate and multivariate analysis (Piciucchi et al., 2017). 
Additionally, within all patients and patients with metastatic PC, Piciucchi et al. 
(2017) determined that patients with NLR below 5 had increased survival in 
comparison to patients with greater NLR values. A meta-analysis determined that 
NLR is a useful prognostic tool within both metastatic and localised PC patients, but 
usefulness can be limited due to both false positives and negatives (Mowbray et al., 
2018). In contrast, a recent study combined the use of NLR with CA19-9 results 
within PC to improve upon NLR as a lone prognostic indicator (Sakamoto et al., 
2018).  
5.1.2.3 CRP 
CRP, like NLR, is another biomarker of clinical inflammation. CRP was first 
discovered in 1930 from serum of patients infected with pneumococci, which reacted 
with ‘fraction C’ containing a carbohydrate antigen of the capsule, hence the name 
C-reactive protein (Tillett and Francis, 1930). CRP is produced and released from 
hepatocytes in the liver in response to inflammatory IL-6 (Agalianos and Dervenis, 
2017). CRP transcription is induced by IL-6, primarily through activation of 
transcription factors STAT3 and C/EBPβ (Voleti and Agrawal, 2005). It is an acute 
phase protein, produced during inflammation or infection where concentrations rise 
and fall rapidly dependent on presence of inflammatory stimulus (Nehring et al., 
2020). It has been shown to increase in concentration as much as 3000-fold in 
response to stimuli (Ansar and Ghosh, 2013). Elevated CRP levels therefore indicate 
systemic inflammation (Inoue et al., 2015). CRP plays roles in activation of the 
complement system through binding to its ligands of both phosphocholine, a 
common component in cell wall antigens of infectious agents such as pneumococci; 
and autoantigens including apoptotic cells, chromatin and histones (Szalai, 2004). 
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A healthy Chinese population study evaluated the CRP concentration in 6060 
healthy volunteers, with the average baseline CRP value to be 1.18 (range 0.6 - 2.47) 
mg/L (Tang et al., 2018). It was established that CRP levels increased with age of 
the donor, particularly above age 45 and CRP levels were found to be greatest in 
male donors (Tang et al., 2018). Elevated CRP values are found in patients with a 
range of conditions. CRP has been well established as a marker for cardiovascular 
disease (Ansar and Ghosh, 2013). Atherosclerotic plaque formation in early 
cardiovascular disease is linked with inflammation and so observing inflammatory 
markers allows for monitoring of disease (Diederichsen et al., 2018). In a large study 
of 1179 participants with no cardiac history, patients who went on to experience 
cardiovascular events (including stroke, myocardial infarction) were proven to have 
elevated CRP in comparison to patients who did not go onto develop cardiovascular 
disease (2.7 and 1.4 mg/L) (Diederichsen et al., 2018).  
Acute pancreatitis is a complex, potentially fatal inflammatory condition, which 
requires careful management and treatment. In response to acute pancreatitis, CRP 
levels raise and peak after 72 - 96 hours (Schütte and Malfertheiner, 2008). Greatly 
elevated CRP is the gold standard for pancreatitis, with values greater than 150 
mg/dL, have been linked with necrotising pancreatitis with a specificity and accuracy 
over 80 and 86%, respectively (Schütte and Malfertheiner, 2008; Staubli et al., 
2015). PC is a malignancy linked with inflammation and prior attacks of pancreatitis 
increase the risk of developing PC. A comprehensive systematic review examined 
the prognostic capabilities of CRP in 485 total PC patients with resectable disease, 
48 % of patients were determined to have high CRP, linked with poorer disease 
prognosis in 4 of the 6 studies (Stevens et al., 2015). However, the conclusions were 
limited with studies analysed having varying definitions of high CRP ranging from 3 
to 10 mg/L (Stevens et al., 2015). A study combined the use of CRP and platelet 
levels to separate PC patients by median survival time (Miyamoto et al., 2017). 
5.1.2.4 Bilirubin 
Bilirubin concentrations are determined from liver function tests, commonly carried 
out in patients with ongoing pancreatic disease. Haemoglobin is broken down within 
the spleen in two stage catalytic degradation producing the haem group and the 
yellow coloured pigment bilirubin (Kalakonda et al., 2018). Under normal 
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physiological conditions, healthy adults should have bilirubin levels below 21 
µmol/L (North Bristol NHS Trust, 2020). Excess bilirubin within the serum causes 
jaundice, signifying disease within the liver, bile ducts or pancreas (Kalakonda et al., 
2018). Obstructive jaundice caused by compression of the bile duct can occur in both 
benign and malignant disease processes, including PC. A study of 1026 patients with 
obstructive jaundice, 546 patients (53.22%) presented with malignant disease 
consisting of PDAC, hilar or distal cholangiocarcinoma, ampulla and ductal 
adenocarcinoma (Garcea et al., 2011). Garcea et al. (2011) were able to distinguish 
between benign and malignant obstructive jaundice with optimal sensitivity and 
specificity of 71.9% and 86.9%, respectively, with bilirubin levels above 100 
µmol/L. Not only can bilirubin levels reflect malignant obstructive jaundice; it has 
also been used as a predictor for disease outcome. A study of 113 patients with 
pancreatic head tumours identified pre-operative bilirubin above 4.6 mg/dL to be a 
useful marker to predict recurrence of tumour post-surgery (Yang et al., 2016).  
5.1.2.5 Novel Biomarkers 
Due to the limitations in the current blood-based system with CA19-9, many teams 
are currently searching for novel biomarkers for PC, which may offer a more suitable 
alternative. For example, PAM4 is showing promise. PAM4 (clivatuzumab) is a 
murine monoclonal antibody, which has demonstrated a high specificity for mucin 
MUC5AC, which is expressed in early pancreatic neoplasia (David V Gold et al., 
2013; Liu et al., 2015). The Gold et al. (2013) study demonstrated the diagnostic 
capabilities of PAM4 and found it able to identify two thirds of stage I PDAC due to 
elevated levels of the MUC5AC. As a result, this shows promise for earlier diagnosis 
of PC. A phase I clinical trial using PAM4 also showed that it is not only limited to 
diagnosis and can also be used as a therapeutic intervention. Ocean et al. (2012) gave 
38 untreated patients ytrium-90-labelled humanised PAM4 in combination with a 
low-dose of chemotherapeutic gemcitabine. 16% of patients showed partial 
responses to the treatment and 42% were shown to have disease stabilisation as 
determined by computer tomography. Although promising, 28 of the 38 patients 
developed grade 3/4 myelosuppression following the first cycle of treatment (Ocean 
et al., 2012). 
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Additionally, intercellular adhesion molecule-1 (ICAM-1) is showing potential for 
diagnosis. ICAM-1 plays a role in cell-cell adhesion in normal conditions, under 
inflammatory stress and also in malignancy (Tempia-Caliera et al., 2002). 
Comparison of healthy and malignant pancreatic tissue showed a 5.4-fold increase in 
ICAM-1 expression and so is being explored for diagnostic potential (Tempia-
Caliera et al., 2002). A recent study by Mohamed et al. (2016) analysed whether 
serum ICAM-1 values would have a better chance than CA19-9 of differentiating 
between benign pancreatic conditions such as pancreatitis from malignant PC. It was 
determined that ICAM-1 had a greater specificity and sensitivity than CA-19-9 with 
differentiating between benign and malignant conditions yet performed equally 
poorly when staging PC (Mohamed et al., 2016).  
Several blood-based biomarkers are being explored with the aim of earlier diagnosis 
of PC.  A blood-based system is beneficial in several manners. To start, a blood-
based system is comparatively cheaper and more accessible than scanning techniques 
discussed above. This would allow for blood samples to be taken on a more local 
basis, such as their local GP surgery or outpatient referral unit should pancreatic 
disease be a potential cause of the patient’s visit. Additionally, the results from the 
blood-test would either confirm or deny the need of visualisation of the pancreas and 
so reduces unnecessary appointments in already busy radiology departments. A high 
level of biomarkers would also allow for fast-tracking of patients to scans and 
screenings sooner to catch the disease in an earlier, more treatable stage.  
Blood-tests are also a lot less invasive than the endoscopic techniques used for visual 
confirmation of the tumour. Given the painful nature of late disease, additional 
unnecessary pain and discomfort is not ideal for the patient. EUS and ERCP, 
although highly accurate do risk considerable side effects including iatrogenic 
pancreatitis, perforation and bleeding which are not to be taken lightly (Majumder et 
al., 2012). Additionally, blood-based systems allow for repeated measurements to be 
taken over a period of time and can be used as a screening system, given none is 
currently in place for PC, such as those present for oesophageal cancer (Lakatos et 
al., 2016). Patients deemed at risk of developing PC, such as those with a family 
history of PC, those with diabetes, chronic pancreatitis, and genetic predisposition 
for developing cancer would be ideal targets of continual screening with a blood-
based system. The monitoring would allow identification of early changes and so 
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would allow the disease to be caught at a stage where surgical resection could be 
possible.  
5.1.3 Aims 
In this chapter, we aim to explore the human PBMC CBMN assay in patients with 
benign and malignant pancreatic disease. As elevated frequencies of binucleated 
PBMCs with MN have been seen in other malignancies, we aim to determine 
whether the assay has potential in PC for both diagnosis and staging. Additionally, 
we will be exploring additional clinical parameters CA19-9, CRP and NLR both 
alone and in combination with the PBMC CBMN and erythrocyte PIG-A assay 
results we have seen in chapter 4. Given the complexity of PC diagnosis and 
drawbacks of individual biomarkers, a combination of biomarkers may offer a more 
suitable approach for PC diagnosis and staging to improve patient outcome.  
5.2 Methods 
5.2.1 Ethics and Permissions 
As seen in chapter 4.2.1. 
5.2.2 The PBMC CBMN Assay 
5.2.2.1 PBMC Isolation 
10 mL of donated heparinised whole blood was inverted 5 times gently. 4.5 mL of 
heparinised whole blood was gently layered on top of an equal volume of 
Histopaque®-1077 (Sigma) in a 15 mL centrifuge tube. This was carried out twice. 
The layered blood and Histopaque were centrifuged at 104 g for 30 minutes with the 
lowest break and acceleration settings available. Following centrifugation, the 
plasma was removed and stored for future analysis, and the white buffy layer was 
removed through gentle swirling action with Pasteur pipette (Fig. 5.1). Buffy layer 
was washed three times in 10 mL pre-warmed PBS before the cell pellet was 
resuspended in 10 mL complete PBMC media (RPMI 1640 (Gibco) supplemented 
with 10% FBS, 1% glutamine and 1% penicillin-streptomycin). Buffy layer cells 
were suspended in media and returned to incubator for 24 hour incubation. 
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5.2.2.2 PBMC Micronucleus Assay 
Following 24 hour incubation, the PBMCs were centrifuged (21 g, 5 minutes) and 
resuspended in plain RPMI 1640 (Gibco) supplemented with 1% penicillin-
streptomycin. Ten microlitres of PHA were added to induce cell division in the 
lymphocytes and cells were returned to the incubator for 48 hours. After incubation, 
30 µL (0.6 µg/mL) cytochalasin B was added, cells returned to incubator for further 
48 hour incubation. Cells were harvested after final incubation and washed three 
times in PBS (Gibco). 
5.2.2.3 Slide Preparation 
Freshly washed, harvested cells were resuspended in 1 mL PBS, with care taken to 
resuspend the cell pellet by gentle flicking to prevent cell damage and lysis. 100 µL 
cell suspension was adhered to microscope slides using a Cytospin centrifuge at 30 g 





Figure 5.1: Blood separation following centrifugation with Histopaque®-1077 into 
(top to bottom): plasma, buffy layer, histopaque, red blood cells. 
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determine whether the cell density suitable before remaining slides. If suitable, the 
remaining slides were centrifuged. If not, the cell density was adjusted through 
addition or removal of PBS from cell suspension and remainder of slides prepared. 
Slides were airdried and fixed in 90 % ice-cold methanol for 10 minutes. Slides were 
airdried again before staining in 20 % Giemsa (Gurr® VWR International Limited) 
for eight minutes. Slides were washed and airdried. Slides were dipped in xylene for 
10 seconds within a fume hood and the coverslip applied to cytodot using DPX 
mounting medium and air dried before scoring. 
5.2.2.4 Slide Scoring 
Prepared and stained slides were manually scored under a light microscope at 100 x 
objective and oil. Care was taken to assess all cells on the slide. One thousand 
binucleated lymphocytes were examined per slide, with those with micronuclei as 
defined in Table 1.1 (Fenech, 2007) were quantified. Five slides were prepared per 
donor with three scored. 
5.2.3 Human Erythrocyte PIG-A Assay 
As described in 4.2.2. 
5.3 Results 
5.3.1 PBMC CBMN Assay  
The human PBMC CBMN assay was performed on PBMCs isolated from peripheral 
blood from consenting donors with benign and malignant pancreatic disease and 
healthy donors (Fig. 5.2). Healthy CBMN data was kindly provided from another 
study within this laboratory. Healthy donors and benign patients had similar 
frequencies of PBMCs with MN with 0.397 ± 0.214% and 0.427 ± 0.243% in 
healthy and benign donors, respectively. As a result, healthy and benign donors were 
were combined. Healthy donors and patients with benign pancreatic disease, such 
cysts and pancreatitis, have a lower frequency of PBMC with micronuclei in 
comparison to PC patients with mean frequencies of 0.438 ± 0.235% and 1.619 ± 
1.001%, respectively. A parametric t-test showed this increase seen in cancer 
patients is significant (p<0.000). 
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Given the increase between benign and malignant donors, PC patient PBMC CBMN 
results were explored further to explore the relationship. TNM tumour staging 
allowed further comparison, further described in Tables 7.1 and 7.2 in Appendix 
7.4. T-stage (Fig. 5.3) represents the size of the tumour. As tumour size increases, 
the frequency of binucleated PBMC also increases up to T3b disease. A one-way 
ANOVA determined this increase to be non-significant (p=0.742). No post-hoc 





Figure 5.2: Frequency of micronuclei within binucleated PBMCs from patients with 
benign and healthy (n=12) and malignant (n=18) pancreatic disease. Bars represent 









































Lymph node involvement, described by N-stage, was also associated with an 
increase in micronuclei in peripheral PMBCs of PC patients (Fig. 5.4). A one-way 
ANOVA determined the increase to be non-significant (p=0.590). 
 
Figure 5.3: Frequency of micronucleated binucleate PBMCs of PC patients as 
tumour size, represented by T-staging increases (n=4 T1, n=6 T2, n=2 T3, n=1 
T3b). Bars represent the mean and the error bars represent the standard deviation. 
Figure 5.4: Frequency of binucleated PBMCs with micronuclei in PC patients  as 
nodal involvement of disease, signified by N-stage, increases (n=5 N0, n=5 N1, n=2 

















































































Unlike with tumour size and lymph node involvement, the presence of metastatic 
disease does not result in an induction of micronuclei in human PBMCs in PC 
patients (Fig. 5.5). The decrease was determined non-significant through a t-test 
(p=0.581).  
TNM staging was used to determine overall staging of disease in PC patients, seen in 
Fig. 5.6. The frequency of PBMCs with micronuclei increased from stage IA to stage 
IIB, with a decrease to stage IV. No significant increases were observed through a 
one-way ANOVA (p=0.257). Stage IA (0.794±0.559%) and stage IIB 
(2.147±01.388%) disease had the largest difference, but this increase was non-
significant (p=0.597). 
 
Figure 5.5: Frequency of binucleated PBMCs with micronuclei from PC patients 
with either non-metastatic disease (M0) or distant metastatic disease (M1) (n=15 







































Since both the human erythrocyte PIG-A assay and the human PBMC CBMN assay 
assess DNA damage in two different forms in two alternative blood cell populations, 
their results were compared (Fig. 5.7). Overall, a slight negative correlation was 
viewed in donors suggesting that there was little evidence of correlation between 









Figure 5.6: Frequency of binucleated PBMCs with micronuclei from peripheral 
blood of PC patients as overall stage of disease increases (n=2 IA, n=4 IB, n=4 IIB, 










































5.3.2 Lone Biomarker Studies 
Here, we show the differences between benign and malignant pancreatic patients and 
PC of increasing stages for CA19-9, NLR and CRP independently. 
5.3.2.1 CA19-9 
CA19-9, the currently in use biomarker for PC, levels were examined within donors 
with benign and malignant disease. Corresponding CA19-9 values were only 
available for 27 donors. Elevated CA19-9 serum concentrations were viewed in 
some donors with malignant disease, but this was shown to be non-significant 
through a Mann Whitney U test (p=0.530).  It is noteworthy that of the 22 donors 
with PC, 27.273% of donors (6) were shown to have insignificant CA19-9 levels 
ranging from 2 to 33 kU/L. All benign donors in the study were shown to have 
CA19-9 levels below the cut-off of 37 kU/L. There is a 237.93-fold increase between 
serum CA19-9 concentrations in malignant pancreatic donors in comparison to those 
with benign disease.  
Figure 5.7: Correlation between the human erythrocyte PIG-A assay and human 
peripheral PBMC CBMN assay in patients with pancreatic disease (n=20). 

























Figure 5.8: Mean serum CA19-9 concentrations in patients with benign and 
malignant pancreatic disease (n=5 benign, n=22 malignant). Bars represent the 
mean and error bars show the standard deviation. 
Further examination of PC patients’ CA19-9 levels determined an increase from 
stage IA disease to later stages, although this difference was determined to be non-
significant using a Kruskal-Wallis test (p=0.454). Furthermore, given we only have 





































Figure 5.9: Mean concentrations of serum CA19-9 in PC patients with increasing 




The NLR, calculated from full blood counts, is a measure of sub-clinical 
inflammation. NLR values were established for 28 donors with both benign and 
malignant pancreatic disease. An elevated NLR was seen in PC patients, with a 1.61- 
fold increase seen over patients with benign disease, although this was non-
significant through a Mann Whitney U test (p=0.104). 
Further examination of PC patients with respect to overall staging of disease showed 
an unclear pattern. Statistically significant differences were identified between the 
groups (p=0.000) but this is likely due to the one donor with staged IA and their high 



































Figure 5.10: Mean NLR values in patients with benign and malignant pancreatic 




Figure 5.11: Mean NLR in PC patients with increasing tumour staging (n=1 IA, n=4 
IB, n=3 IIB, n=5 III, n=6 IV). 
5.3.2.3 CRP 
CRP concentrations signify clinical inflammation. Overall, PC patients were shown 
to have elevated CRP levels, with a 2.727-fold increase seen over patients with 
benign pancreatic disease, but given the large standard deviation in the malignant 
donor group, this was determined non-significant (p=0.605). CRP values below 5 are 
normal, 45.455% (10) of the PC donors were shown to have CRP levels elevated 
above this. 
 
Figure 5.12: Mean CRP values in patients with benign and malignant pancreatic 






















































Further examination of PC patients showed an unclear pattern with CRP values as 
stage of PC increases. Without stage IB disease, a steady stepwise increase in CRP 
concentration is seen as disease becomes more advanced. However, IB disease was 
shown to have a highly elevated mean CRP of 47.25 ± 84.5 mg/L, due to one of the 
four donors having a greatly elevated CRP of 174. No results were statistically 
significant. 
5.3.3 Combination of Biomarkers 
Combining the human erythrocyte PIG-A mutant frequency with the PBMC CBMN 
results and other clinical parameters from patients, we aimed to further separate 
patients and determine whether this had any potential for the diagnosis of pancreatic 
disease. Different parameters were combined through simple multiplication to 
provide an overall arbitrary factorial score, with each biomarker having equal 
weighting.  
5.3.3.1 PIG-A and CA19-9 
Multiplication of PIG-A mutant frequencies and CA19-9 values resulted in further 
separation of benign and malignant donors. Benign donors had a mean score of 
83.067 ± 54.013 in comparison to malignant donors with scores of 12707.143 ± 
29877 (Fig. 5.14). The increase was shown to be close to significance through a 



















Figure 5.13: Mean CRP concentrations in PC patients with increasing disease stage 
(n=1 IA, n=4 IB, n=3 IIB, n=4 III, n=6 IV). 
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The resulting score was also explored for overall disease staging (Fig. 5.15). Early 
stage disease (IA) was shown to have a lower score in comparison to later stages, 
which were much more comparable. This may result from only one donor analysed 
with stage IA disease, but also may signify an early stage disease marker but more 
work would need to be done to determine this. No statistical differences between the 













Figure 5.14: Score from combining PIG-A and CA19-9 blood test results 




5.3.3.2 PIG-A and Neutrophil-to-Lymphocyte Ratio 
The NLR and PIG-A results were combined through multiplication. Differences 
between benign and malignant donors were seen in Fig. 5.16. There is a five-fold 
increase between the score of benign and malignant donors, which came close to 














Figure 5.15: Score from combination of PIG-A and CA19-9 across PC 
patients with increasing stage of disease (n=1 IA, n=3 IB, n=3 IIB, n=5 
III, n=6 IV). 
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TNM staging of PC patients was used to establish whether there is a link between 
score and stage of disease, Fig. 5.17. Stage IA disease was shown to have a higher 
score than higher stage disease, but this could be explained by one donor with stage 
IA disease. This high value seen in the one donor with IA disease resulted in a 
significant difference between groups determined through a one-way ANOVA 
(p=0.001). 
 
Figure 5.17: Score calculated with PIG-A and NLR values as PC stage increases 


































Figure 5.16: Score from NLR and PIG-A results in donors with benign 
and malignant disease (n=6 benign, n=22). 
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5.3.3.3 PIG-A and C-Reactive Protein 
PIG-A mutant frequency and biomarker for clinical inflammation, CRP, were 
combined through multiplication to produce a score. A 4.775-fold increase in score 
was seen between benign and malignant donors (Fig. 5.18). The increase in score 
seen in malignant donors was established as a significant increase by the Mann 
Whitney U test (p=0.033). 
 
Figure 5.18: Score generated with CRP and PIG-A values in patients with benign 
and malignant pancreatic disease (n=6 benign, n=22 malignant).(* shows p<0.05). 
TNM staging of donors with PC allowed further comparison of score generated with 
CRP values and PIG-A mutant frequencies. Stage IB and stage IV disease was 
shown to have scores four-times that of stage IA disease, Fig. 5. 19. But overall 
pattern was unclear, and no statistically significant differences were viewed between 

















5.3.3.4 PIG-A and PBMC CBMN 
Combining the PIG-A mutant frequency with frequency of PMBC with micronuclei 
through multiplication provided a score which was explored. Donors with malignant 
disease had 6.751-times greater score than donors with benign pancreatic disease 
(Fig. 5.20) although this increase was deemed non-significant through a t-test 
(p=0.137). 
 
Figure 5.20: Score generated with PIG-A and PBMC CBMN assay in patients with 































Figure 5.19: Score generated with CRP and PIG-A values as disease 




TNM staging provided overall staging of disease. An elevation in score is seen as 
disease becomes more advanced, with a peak seen in stage III disease (Fig. 5.21). No 
statistically significant differences were seen in the score as staging of disease 
increases (p=0.696). 
 
Figure 5.21: Score calculated from PIG-A and PBMC CBMN results as disease 
stage increases in PC patients (n=2 IA, n=4 IB, n=4 IIB, n=3 III, n=3 IV). 
5.3.3.5 PIG-A, CA19-9, NLR, CRP and PBMC CBMN 
A combination of all biomarkers assessed may be more likely to further separate 
patients. Data for all parameters was not available for all patients and so only results 
for a maximum of 13 patients could be analysed. Of the thirteen, no patients had 
benign disease and so patients with malignant disease were only able to be analysed. 
TNM staging was explored to determine whether there was a discernible difference 
between scores generated with the staging of disease. Firstly, size or T-stage of 
disease was examined (Fig. 5.22). Although patients with T1 disease showed a lower 
score, 669.917 in comparison to 468483 and 173856, this was deemed non-
significant through a one-way ANOVA (p=0.631) and no further post-hoc tests 




















Figure 5.22: Comparison of score by T-stage of disease from PC patients (n=2 T1, 
n=5 T2, n=1 T3). Bars show the mean and error bars show the standard deviation. 
Nodal involvement in patients with PC was explored (Fig. 5.23). Fewer patients had 
available N-staging, accompanied with other clinical parameters. There was an 
unclear pattern overall with an increase between N0 and N1, followed by N2 disease 
showing a lower score than both N0 and N1 disease. A one-way ANOVA 
determined no statistically significant differences between the groups (p=0.495), 


























Patients with metastatic disease (Fig. 5.24) showed an increase in score over patients 
with localised PC, 698,523 in comparison to 298,902. This was determined to be 
non-significant through a T-test (p=0.140). 
 
Figure 5.23: Biomarker score with increasing nodal involvement of disease in PC 
patients (n=4 N0, n=2 N1, n=2 N2). 
Figure 5.24: Biomarker score in patients with localised PC (M0) and 



































Finally, overall staging of PC was compared with the biomarker score calculated 
through multiplying biomarker values together (Fig. 5.25). Stage IA disease had a 
lower score of 683.521 in comparison to more advanced disease which was 
determined to be non-significant through a one-way ANOVA (p=0.645). This may 
be because of small sample size, which resulted in only donor with complete 
parameter data having stage IA disease.   
5.3.4 PIG-A: High or Low 
Here, PIG-A mutant erythrocyte frequency of all donors was analysed. Fig. 5.26 
shows the frequency distribution of the PIG-A mutant frequency of all donors. 
Figure 5.25: Biomarker score in PC patients with increasing stage of PC (n=13). 

















































Figure 5.26: Frequency distribution of PIG-A mutation frequencies from 


















The median of all PIG-A mutant erythrocyte frequencies from all donors was 
determined to be 4.860 x 10-6. Any PIG-A mutant frequencies below this value were 
defined as low PIG-A values and any equal to or above the median were defined as 
high PIG-A values. Proportions of donors with high or low PIG-A values within 
each donor group is seen in Fig. 5.27. Within groups of donors, healthy and benign 
donors had only 33.33% and 10% of donors with high PIG-A values. In comparison, 
68.97% of PC patients displayed high PIG-A values.  
TNM staging data was also explored for patients with malignant disease. Tumour 
size, classified by T-stage, is explored in Fig. 5.28. In the highest stages, T3b and 
T4, all donors have high PIG-A values in contrast to the smaller sized tumours, 























Figure 5.27: Percentage of donors with PIG-A mutant frequencies below 
and above 4.8 x10-6, defined as low and high PIG-A values, within 




Figure 5.28: Percentage of donors with high and low PIG-A values across 
increasing T-stage in donors with PC (n=2 T1, n=9 T2, n=2 T3, n=3 3b, n=1 T4). 
A similar pattern was viewed when exploring nodal involvement (Fig. 5.29). More 
advanced disease, N2, had 100% of donors with high PIG-A values with lower 

























Additionally, M-staging (Fig. 5.30) also showed an increased percentage of donors 
with high PIG-A values with metastatic disease in comparison to non-metastatic 























Figure 5.29: Percentage of donors with high and low PIG-A values with 




The pattern seen in overall staging of PC is less clear (Fig. 5.31). This may be 




























Figure 5.30: Percentage of donors with high or low PIG-A values with 




5.3.5 Questionnaire Data 
Questionnaire responses were minimal, with only 8 donors fully completing and 
returning questionnaires. Within this small cohort, dietary quality score (DQS) was 
evaluated in benign and malignant donors. Donors with malignant disease were 
shown to have a mildly elevated DQS, signifying a diet which is nutritionally better, 
but this increase was non-significant (p=0.172). Furthermore, no link was observed 
between DQS, dietary fat content and alcohol consumption with PIG-A alone. 
Interestingly, a slight decrease in average PIG-A mutant frequency was seen in past-
smokers in comparison to non-smokers (p=0.176). An interesting finding showed an 
increased PIG-A mutant frequency as self-reported health declined; however, this 
was also determined non-significant (p=0.180). Further questionnaire responses are 
explored further in depth within Appendix 7.5. 
5.3.6 Survival 
Given the abysmal survival rates for PC, the survival of patients was explored. Of 
the PC patients we have survival data for, 20% (5) of PC patients have unfortunately 























Figure 5.31: Percentage of donors with high and low PIG-A values as 
stage of PC increases (n=2 IA, n=4 IB, n=6 IIB, n=6 III, n=7 IV). 
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Staging of PC has an influence over survival. Early stage disease shows greater 
survival (100%) in comparison to stage IIB disease (83.33%) and IV disease 





















Figure 5.32: Percentage of live donors with PC at increasing stages of disease (n=2 
IA, n=4 IB, n=6 IIB, n=6 III, n=7 IV). 
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We aimed to explore whether there were differences in PIG-A mutant frequency in 
patients who survived in comparison to patients who did not. Patients who survived 
were shown to have a lower PIG-A mutant frequency in comparison to patients who 
did not survive with mean PIG-A mutant frequencies of 9.143 ± 5.852 and 11.132 ± 
6.702 x 10-6, respectively. This difference was determined to be non-significant 
through a Mann Whitney U test (p=0.684). 
 
Figure 5.33: Mean PIG-A mutant frequencies in PC patients who did and did not 
survive (n=20 live, n=5 dead). 
Furthermore, we aimed to see whether the results from the human PBMC CBMN 
assay correlated with survival. A decrease in micronuclei frequency was observed 
within PBMCs of PC patients who died, although this was deemed non-significant 


























Figure 5.34: Induction of micronuclei using the human PBMC CBMN assay in PC 
patients who did and did not survive (n=12 live, n=3 dead). 
5.4 Discussion 
In this chapter, the PBMC CBMN assay was harnessed to assess genome stability 
within donors with benign and malignant pancreatic disease, which is also loosely 
correlated with cancer staging. Further clinical parameters have also been examined, 
and through combining of multiple biomarkers, we aimed to improve the use of them 
in comparison to lone biomarkers.  
5.4.1 PBMC CBMN 
Within this study, we have shown a significantly elevated frequency of micronuclei 
within PBMCs of donors with malignant pancreatic disease in comparison to benign 
donors. This correlated with the data in Chapter 4 showing increased PIG-A mutant 
erythrocytes in PC. Previous studies have also explored the PBMC CBMN assay 
within PC patient populations, with results supporting the results seen in our study. 
An elevated MN frequency was seen in a population of PC patients in comparison to 
controls with 1.39 ± 0.43% and 1.11 ± 0.43% respectively (Chang et al., 2004). 
Lymphocytes from PC patients in the Chang et al. (2004) study were also shown to 
induce greater MN in response to H2O2, indicative of BRCA1 mutations. A larger 
case-control study monitored the MN frequency in peripheral lymphocytes from 346 








































controls also showed an increased frequency of 15.3 ± 0.3 in PC patients in 
comparison to 10.7 ± 0.3 (Chang et al., 2011). 
Exploring PC patients further, it is seen that the percentage of PMBC with 
micronuclei differs depending on TNM staging of disease. Tumour size, nodal 
involvement and overall staging tend to increase the DNA damage viewed in 
PMBCs, although this has not been significant in this study (p= 0.742, 0.590 and 
0.581, respectively). In contrast, as disease becomes metastatic, there appears to be 
less chromosomal damage than in patients with localised disease. In the large 
published PC study, no significant association was discovered between the stage of 
disease and the frequency of MN (Chang et al., 2011). This is supporting our results, 
where no significance was determined. Although a larger population may have made 
the increases seen in tumour size, nodal involvement, and overall staging statistically 
significant. Previous studies across other malignancies show contrasting results. A 
study of breast cancer within an Iranian population showed highest micronuclei 
frequency within donors with metastatic disease, and lymph node involvement didn’t 
show an increase in micronuclei (Salimi and Eskandari, 2018). A study of bladder 
cancer showed a higher frequency of MN in donors with disease not invading the 
muscular lining of the bladder in contrast to those with more advanced disease, 
whose disease was infiltrating the muscular wall of the bladder, although differences 
were non-significant (Pardini et al., 2017).  
Correlation between the PBMC CBMN assay and PIG-A results in donors with 
pancreatic disease was slightly negative. This is likely since the PIG-A assay 
measuring the frequency of specific point mutations within PIG-A rather than 
monitoring overall genome stability, seen in the CBMN assay and so results from 
both may not reflect each other. For example, a murine study explored diet-induced 
obesity using both the blood cell CBMN assay and Pig-A assay. Mice fed on a diet 
of 60% fat were shown to have 3-4 fold increased frequency of Pig-A mutant cells 
but no change was shown in MN frequency, suggesting diet induced obesity is 
mutagenic (Wickliffe et al., 2016). Individual patients may be exposed to unique 
combinations of lifestyle factors and environmental factors, which will in turn affect 
DNA in different manners. For example, tobacco smoking is mutagenic so a donor 
who had smoked all their life may show higher PIG-A mutations and less in the way 
of micronuclei in PBMCs in contrast to a donor who has lived a healthy life but is 
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geriatric and DNA stability may have decreased, leading to cancer formation who 
may have higher percentage of MN in PMBCs but insignificant mutagenicity 
measured through PIG-A.  
The ex vivo CBMN assay has been well established and used for a long time. Once 
one is used to the assay, it was a simple and convenient assay with easily determined 
endpoints. Drawbacks of the assay included the difficulty of PBMC separation. 
PBMC isolation, achieved through density gradient separation using histopaque, 
required gentle layering of whole blood onto histopaque. Several samples were 
ruined through incorrect layering of the blood on top of the histopaque, breaking the 
surface and mixing the two layers. This resulted in incomplete separation of the 
layers, seen in Fig. 5.1, resulting in red stained plasma coupled with no observable 
buffy layer. As a result, PBMC CBMN results were not available for all donors in 
this study. Additionally, the protocol followed for the assay required optimisation, 
with initial attempts having too few binucleated PBMCs for feasible scoring, 
requiring a doubling of the time exposed to Cytochalasin-B from 24 to 48h. Slide 
preparation was also a challenge initially due to the fragility of primary PBMCs. 
Suspension of cell pellets had to be achieved through gentle flicking of the tube 
otherwise microscope slides would be prepared, stained, and observed under a light 
microscope to find that PBMCs would be lysed. Additionally, in comparison to 
established cell lines, slide quality was considerably poorer in the primary PBMCs, 
with additional time required for scoring slides in comparison to established cell 
lines. With advances in semi-automated scoring systems such as the Metafer system 
used within Chapter 3 and the novel flow cytometry based scoring of the PBMC 
CBMN assay (Rodrigues et al., 2018), slide preparation and scoring issues may no 
longer be relevant in the future.  
5.4.2 Combining Biomarkers 
Given the current challenges associated with diagnosis of PC, combining multiple 
biomarkers to form a battery of tests is likely to outperform individual biomarkers 
alone. Here, we combined biomarkers through simple multiplication of individual 
values to give a score. Multiplication of values to provide a score gives all 
biomarkers explored within the study equal weighting. 
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Table 5.1: Average scores generated through combining different biomarkers in 
donors with benign and malignant pancreatic disease. 
Combination of 
Biomarkers 
Benign Malignant Fold Change 
PIG-A Alone 4.028±3.101 8.557±6.060 2.124 
PIG-A and CA19-9 83.067±54.013 12707.143±29877 152.97 
PIG-A and NLR 6.966±3.100 29.592±38.764 4.248 
PIG-A and CRP 24.851±14.419 118.18±161.46 4.755 
PIG-A and CBMN 2.167±2.070 14.633±11.057 6.751 
All the above N/A 391122±540552 N/A 
Combination of CA19-9 with PIG-A resulted in the largest fold-change between 
benign and malignant donors of 159.97, which is 72.016 times greater than the fold 
change when using just PIG-A alone. Differentiation between benign and malignant 
pancreatic disease is a common diagnostic problem. Challenges arise between 
differentiation of benign and malignant disease both from imaging studies and blood 
test results, often with malignancy only confirmed through histopathological 
examination of surgical specimens. Issues have been raised previously with CA19-9 
alone, given its elevation in benign conditions (Howaizi et al., 2003) and cases of 
insignificant levels in malignant disease (Muratore et al., 2016). In this study, CA19-
9 levels alone give a 67.33-fold increase between benign and malignant disease, 
where combination with PIG-A increases the difference to 159.97-fold. This 
suggests use in combination with PIG-A may result in better differentiation between 




Table 5.2: Average scores generated by combining biomarkers in donors with PC 
with increasing stage disease, and associated fold-changes in score from earliest 




IA IB IIB III IV 
Fold 
change 
(IA – IV) 
PIG-A Alone 11.004 8.073 7.954 8.228 12.447 1.131 
PIG-A and 
CA19-9 
24.018 6209.3 43612 12533 10163 423.155 
PIG-A and 
NLR 
171.606 27.842 13.249 22.266 34.572 0.201 
PIG-A and 
CRP 
60.044 186.83 50.234 82.343 198.54 3.307 
PIG-A and 
CBMN 
8.337 11.168 19.060 20.342 17.791 2.134 
All of the 
above 
683.52 315751 773170 88033 128954 188.661 
 
Table 5.2 explores scores of combined biomarkers for PC patients. Combining 
CA19-9 and PIG-A again provides the largest fold-change between the earliest stage 
disease and most advanced disease.  A combination of the two gives greater 
separation than even the combination of all biomarkers together. Previous studies 
have combined novel biomarkers with current biomarker CA19-9 to improve CA19-
9 performance within PC (Kaur et al., 2017; Murali Manohar et al., 2017; Jahan et 
al., 2019). Additionally, combination of CA19-9 with current biomarker CA-125 in 
ovarian cancer has been used to differentiate between serous and epithelial type 
cancers (Zhang et al., 2018). Continual use of the CA19-9 blood test may continue to 
be beneficial in patients while in combination with other novel biomarkers yet care 
184 
 
should still be taken given that 5-10% of the population remain Lewis antigen 
negative (Ballehaninna and Chamberlain, 2011).  
Other than PIG-A alone, the poorest performing biomarker panel appeared to be 
PIG-A in combination with NLR. Previous studies had shown the usefulness of NLR 
when in used in combination with current PC biomarker, CA19-9, as a prognostic 
marker in 66 patients with recurring PC (Sakamoto et al., 2018). However, NLR as a 
biomarker has been shown to be non-specific, having been explored in a range of 
disease processes including systemic infection (Gürağaç and Demirer, 2016), 
metabolic syndrome (Chuan Chuan Liu et al., 2019), various autoimmune disorders 
(Chandrashekara et al., 2017; Hammad et al., 2018) and a range of malignancies 
(Gürağaç and Demirer, 2016). General inflammatory markers including CRP and 
NLR, although have prognostic capabilities within PC, may not be the most suitable 
tools for diagnostic and staging.  
5.4.3 High or Low PIG-A 
Through a simple binary high-low system, with a cut-off point established using the 
median value of all PIG-A values from all donors, we have explored the usefulness 
of PIG-A as a biomarker for pancreatic disease. It was established that more donors 
with malignant disease had PIG-A values which fell into the high category than in 
comparison to healthy and benign donors. This is an important hurdle for biomarkers 
to pass, however tweaking of the cut-off point may differentiate benign and 
malignant donors further to minimise the risk of both false-positives and false-
negatives, both which can be detrimental to the patient’s journey.  
5.4.4 Questionnaire  
Questionnaire data collected from patients provided insight into lifestyle and dietary 
choices from patients with both benign and malignant pancreatic disease. Dietary 
quality, quantitated using the DQS outlined in Table 2.5, was shown to be non-
significantly elevated in patients with PC (p=0.172). This tends to contrast literature 
sources, which have previously linked PC development with poor dietary choices. 
As much as 30-50% of PC cases have been linked to nutritional intake, with grilled 
meats and fried foods increasing PC risk (Midha et al., 2016). Furthermore, in our 
questionnaire data, we have seen a decreased frequency of circulating PIG-A mutant 
erythrocytes in past smokers and frequent consumers of alcoholic beverages in 
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comparison to controls. This is unexpected given both smoking and alcohol 
consumption give rise to known mutagens including B[a]P and acetaldehyde, 
renowned for their DNA adduct formation as seen in the in vitro data in Chapter 3. 
There are limitations with our questionnaire data given the poor patient response, 
resulting in only eight fully, correctly completed questionnaires being received. 
Questionnaires were provided to donors to complete in their own time and return 
using a stamped, addressed envelope. It is understandable given the amount of 
information and leaflets provided to the patients from both the clinical and research 
staff that it may be forgotten and be the least important document provided. In 
hindsight, perhaps the patients should have completed the questionnaires within 
surgical clinics, however these were often tight for time with the high volume of 
patients to see in a limited time frame. The resulting data, although interesting, 
cannot be fully relied upon because of the small population. This may account for 
some of the deviations from trends seen within the literature. 
5.4.5 Survival 
Our survival data shows an increased survival in comparison to reported values 
within the literature and discussed in 1.2.6. Median overall survival of PC patients 
has been estimated between 20 and 24 months (Bittoni et al., 2014). Currently, 
within the UK, 25.4% of patients survive 1 year post-diagnosis (Cancer Research 
UK, 2020b). This is close to our 20% patient survival but given the time frame of 
patient recruitment between October 2017 and September 2019, we would expect the 
survival to be lower. However, with longer patient follow-up this may reveal closer 
results to reported values. Additionally, recruitment within surgical clinics may be 
skewing our data, since patients undergoing surgery have better overall survival both 
in the short and long-term (Huang et al., 2018). 
5.5 Conclusion 
Here, we explored the peripheral PBMC CBMN assay for its use diagnosing and 
staging PC. Exploring the PBMCs CBMN in a population of PC patients, we 
discovered an elevated frequency of MN in PBMCs of PC patients in comparison to 
patients with benign pancreatic disease (p<0.000), supporting elevations also viewed 
within the literature. Within PC donors, increases in MN frequency were also viewed 
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as TNM staging and overall staging of disease increased, although this was non-
significant.  
Combinations of biomarkers were also explored, to determine whether a whole panel 
of clinical parameters in combination with our PBMC MN and PIG-A results would 
be useful in a diagnostic or staging setting. Of all assessed, combination of CA19-9 
and PIG-A appeared to show the most promise, with the greatest fold changes when 
differentiating between benign and malignant pancreatic disease and when 
examining staging of PC.  
Furthermore, overall survival data and questionnaire data was analysed. Survival 
data requires longer follow-up to determine whether values are in line with literature. 
Poor questionnaire involvement with patients limits the usefulness of data collected 






























Chapter 6: General Discussion 
6.1 General Discussion 
Despite PC being one of the rarer malignancies, only accounting for 3% of all cancer 
cases in the UK (Cancer Research UK, 2020c), it remains the fourth leading cause of 
cancer related mortality in the UK (Cancer Research UK, 2014b). With median 
overall survival between 20 and 24 months, PC has one of the worst prognoses of all 
solid malignancies (Bittoni et al., 2014). PC is expected to become the second 
leading cause of cancer related mortality by 2030 (Bittoni et al., 2014). The bleak 
prognosis arises from a combination of vague, late presenting symptoms, late 
diagnosis, limited treatment options and an aggressive disease state often believed to 
be systemic at diagnosis. PC diagnosis remains a challenge, with blood-based 
biomarker CA19-9 not being fully relied upon and difficulties differentiating 
between benign and malignant disease from imaging studies alone. Often, a 
definitive diagnosis is only achieved following histopathological examination of 
biopsies or surgical specimens. Advances in PC diagnosis are needed urgently to 
improve patient outcomes, increase survival, and save lives.  
Blood-based biomarkers are a cheap, non-invasive, and accessible methods of 
determining information about a patient’s health from a small blood sample. Current 
blood-based biomarkers for PC are discussed in 5.1 including CA19-9, CRP, 
bilirubin, and the neutrophil to lymphocyte ratio. Novel biomarkers are continually 
being investigated for their promise in PC diagnosis, with ICAM-1 and MUCA5 
showing great potential (Tempia-Caliera et al., 2002; David V. Gold et al., 2013). 
6.2 Presented Work 
Here, we have examined the use of two blood-based assays for their potential use in 
PC diagnosis. Both assays quantify DNA mutation within separate blood cell 
populations. Given that cancer is a disease initiated within the DNA, an increased 
mutational load may be indicative of malignant disease and even the staging of the 
malignancy.  
6.2.1 Human Erythrocyte PIG-A Assay 
The human erythrocyte PIG-A assay was used to examine a novel population of 
patients with benign and malignant pancreatic disease alongside healthy donors. 
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Healthy donors were found to have a median mutant frequency of 4.55 x 10-6 (95% 
CI 1.48-6.51), comparable to reported healthy donor mutant frequencies from 
population studies including means of 2.9 x 10-6 and 5.25 x 10-6 and median value of 
2.8 x 10-6 (Dertinger et al., 2015; Cao et al., 2016; Haboubi et al., 2019). Patients 
with benign pancreatic disease showed a comparable mutant frequency in 
comparison to healthy donors, with a median of 2.64 x 10-6 (95% CI 2.11-4.16).  
PC patients were found to have an elevated mutant frequency over benign pancreatic 
donors with a median of 5.81 (95% CI 6.25-10.86) (p=0.013) but not over healthy 
donors (p=0.078). A previous study within our research group has shown an elevated 
PIG-A mutant frequency in oesophageal adenocarcinoma patients, with a 3-fold 
increase shown between oesophageal adenocarcinoma patients in comparison to 
healthy donors and gastroesophageal reflux disease patients (Haboubi et al., 2019). 
This is greater than our 2.075-fold increase seen in our study between benign and 
malignant pancreatic donors, but this does not diminish the potential shown here 
within PC. Other DNA based assays have also shown an increased circulating DNA 
mutation in PC donors, including within the lymphocyte CBMN assay (Chang et al., 
2004). 
Furthermore, our results showed a slight increase in PIG-A mutant frequency in 
patients with metastatic disease, although this was determined non-significant. 
Further study and a larger population of donors with metastatic disease may examine 
whether this increase becomes significant and if so, whether this could be exploited 
for use as a staging tool. Given the invasive nature of a lot of diagnostic techniques 
for PC, stratification of patients could be carried out based upon PIG-A mutant 
frequency and reduce unnecessary invasive procedures and fast-track patients with 
greatly elevated PIG-A for quicker access to the right procedures and clinicians.  
6.2.2 Human PBMC Cytokinesis Block Micronucleus Assay 
The human PBMC CBMN assay was used to explore a cohort of patients with both 
benign and malignant pancreatic disease. An elevated frequency of PBMCs with 
micronuclei was viewed in PC patients (p<0.000). This elevation within the 
malignant pancreatic cohort has also been viewed within a PC population in a 
previous study of PC patients (Chang et al., 2004). In a later experiment, the group 
further classified BRCA1 mutant patients through a challenge assay and exposure to 
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H2O2 (Chang et al., 2004). A further, larger population study carried out by the same 
group also established an elevated MN frequency within PC patients, although it was 
unclear whether this cohort was treatment naïve (Chang et al., 2011). Previous 
studies have also explored the PBMN CBMN assay in other malignancies. A study 
of colorectal cancer patients throughout therapeutic interventions took pre-treatment 
measures and compared their results to control, non-cancer patients. The treatment 
naïve colorectal cancer patients were shown to have a 3.45-fold increased frequency 
of MN over healthy controls (Nikolouzakis et al., 2019). This is a similar to the 
3.696-fold increase viewed here in PC patients over benign and healthy donors. This 
fold-increase is also larger than those seen in previous PC studies of 1.577 and 1.252 
(Chang et al., 2004; Chang et al., 2011).  Furthermore, a study of papillary thyroid 
cancer showed a 2.67-fold increase over an age and gender matched control 
population (Gerić et al., 2015). Furthermore, a study of a range of cancers including 
breast, uterine and pharyngeal cancers identified a 2.35-fold increase in MN 
frequency in cancer patients in comparison to benign donors. This places our MN 
induction differences within the same fold-change as seen within the literature, but 
greater than previous PC specific studies.  
The large PC population study determined no changes in MN frequency as staging of 
PC increases (Chang et al., 2011). In contrast, our study has seen slight elevation in 
MN frequency as tumour size and nodal involvement increases and a decrease in 
MN frequency as disease becomes metastatic, although these results remain non-
significant. A larger population within our study may have led to significant results, 
with greater statistical power behind the results. 
6.2.3 Biomarker Panel 
Currently, the only biomarker clinically in use for PC is CA19-9. However, its use is 
limited since it’s a modified Lewis antigen (Tempero et al., 1987). As a result, 5-
10% of the population has a Lewis negative phenotype and so CA19-9 test results 
may not be clinically relevant (Ballehaninna and Chamberlain, 2011). For example, 
in our study 27.27% of donors with a clinically confirmed PC diagnosis were shown 
to have insignificant CA19-9 levels below the 37 kU/L cut-off value (Thaker et al., 
2014). The CA19-9 levels within PC patients ranged from as low as 2 kU/L to 33 
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kU/L (mean 9.333±11.793). As a result, CA19-9 alone would not be a reliable 
blood-based biomarker for PC. 
Given the multifactorial complexity of PC, a panel of biomarkers with a wide range 
of sources is likely to provide a better option for diagnosing PC from a blood-based 
perspective. A biomarker panel of a tumour marker in combination with biomarkers 
for other features like systemic inflammation can perform better than a tumour 
marker alone and provide further clinical information (Brand et al., 2011). Building 
upon this, we aimed to study a panel of biomarkers including the PC tumour marker 
CA19-9, two DNA mutation assays: the novel PIG-A assay and PBMC CBMN 
assay, and two inflammatory markers: CRP for clinical and NLR for subclinical 
inflammation, given the strong links with inflammation in pancreatic carcinogenesis. 
In this pilot study, we simply multiplied the values from each of the five lone 
biomarkers to provide an arbitrary factorial score. Multiplication gave each 
biomarker equal weighting and was simple enough for our pilot study with a 
relatively small population. Other larger studies have combined biomarkers through 
more complicated methods, including regression analysis, receiving operating 
characteristic curves and the area under the curve (Balasenthil et al., 2011; Fahrmann 
et al., 2019). These techniques could be used on future, larger studies using our 
biomarker panel in the future, if this panel shows promise.  
We studied a biomarker panel of all the previously mentioned markers, alongside 
smaller panels of a duo of PIG-A and each marker individually. Since no donors 
with all five biomarkers recorded had benign disease, a fold change between benign 
and malignant donors could not be established for the full panel. However, when 
overall staging of PC there was a 188.661-fold increase in biomarker score from 
stage IA disease to stage IV, but this difference was determined non-significant 
through a one-way ANOVA (p=0.645). The largest increases were viewed in the 
combination of PIG-A and CA19-9 of 152.97 and 423.155-fold increases when 
disease and disease stage were compared, respectively. The increase between benign 
and malignant donors almost reached significance (p=0.053) whereas the increase 
viewed in overall disease staging was non-significant (p=0.428).  
Combination of CA19-9 and PIG-A appeared to the most suitable combination of 
biomarkers assessed in this study for both PC diagnosis and staging. Although care 
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should be taken due to the Lewis antigen negative population (Ballehaninna and 
Chamberlain, 2011). Combination of CA19-9, which is not expressed in 5-10% of 
the population (Ballehaninna and Chamberlain, 2011), with the ubiquitously 
expressed PIG-A gene may improve upon the use of CA19-9 alone. For example, 
our combination of PIG-A and CA19-9 has increased the fold-change viewed in 
overall staging than that of just CA19-9 alone. Furthermore, previous studies have 
also combined novel biomarkers with CA19-9 to improve the performance of CA19-
9 in PC patients (Kaur et al., 2017; Murali Manohar et al., 2017; Jahan et al., 2019). 
6.2.4 In Vitro Model of Pancreatic Cancer 
In an in vitro model of PC, we aimed to determine the sources of some of the 
mutations viewed in the in vivo studies and to further explore the role that dietary 
and lifestyle choices play in pancreatic carcinogenesis. PC development can be 
heavily influenced by lifestyle factors, with as many as 37% PC cases thought to be 
avoidable by making healthier life choices (Cancer Research UK, 2014b). We 
modelled smoking, a high fat diet and alcohol abuse using associated chemicals 
B[a]P, DCA and acetaldehyde in both the PDAC cell line PANC-1 and the L5178Y 
cell line, widely used in genotoxicity assessments. 
Smoking has been shown to be linked with 29% of all PC cases (Cancer Research 
UK, 2014b) and is implicated in reducing median survival time in PDAC by almost 
half (Zhang et al., 2016). Here, smoking modelled by B[a]P was only explored 
within the metabolically competent PANC-1 cell line. An induction of MN in the 
CBMN assay was seen at both 20 and 50µM. B[a]P has a known carcinogenic 
mechanism, undergoing sequential oxidation, hydration and further oxidation to 
form ultimate mutagenic product BPDE, which forms adducts namely at N2 guanine 
position (Alexandrov et al., 2010; Shah et al., 2016). B[a]P is only one of over 4,000 
chemicals in the complex mixture of compounds present in cigarette smoke which 
could play a role in pancreatic carcinogenesis (Barone et al., 2016). Due to this 
complex composition of cigarette smoke and clear induction of DNA mutation, 
viewed by the CBMN assay in PANC-1, we expected to view an elevated PIG-A 
mutant frequency in erythrocytes of smokers. Questionnaire data from study 
participants showed a small snapshot of lifestyle and dietary choices from eight 
donors. Within this, we had two groups of never smokers and past smokers, with no 
193 
 
current smokers. Interestingly, our past smokers showed a slight reduction in PIG-A 
mutant frequency in comparison to the non-smoking group, but this was non-
significant. This does not reflect the in vitro work, but this could come as a result of 
a small population of donors who completed the questionnaire not being truly 
representative, an alternative measure of mutation in the PIG-A assay and CBMN 
assay and additionally may show past smokers having a higher activity of DNA 
repair mechanisms following on from years of smoking.  
Obesity is an increasing concern globally. Several malignancies have been linked 
with obesity, including PC. Specifically, 12% of PC cases have been attributed to 
obesity (Cancer Research UK, 2014b). High-fat diets are likely to cause obesity. 
Dietary fats are digested with the aid of bile with bile acids emulsifying fats into 
micelles which can then be absorbed (Boyer, 2013; Pavlović et al., 2018; Chen and 
Cassaro, 2019). Increased serum concentrations of bile acid DCA has been observed 
in obese donors (Xie et al., 2015). Following DCA treatment, induction of MN was 
viewed in the PANC-1 cell line at 50 and 300µM (significantly) and at 150µM in the 
L5178Y cell line (non-significant). Previous studies have also shown induction of 
DNA damage by DCA in an oesophageal adenocarcinoma cell line, diminished by 
vitamin C treatment highlighting the ROS-based genotoxic mechanism (G. J.S. 
Jenkins et al., 2007). Furthermore, an induction of Pig-A mutants were viewed in the 
in vitro Pig-A assay in L5178Y, but this was non-significant. Questionnaire data also 
showed an increased PIG-A mutant frequency in donors who had poorer DQS values 
with regards to dietary fats, but this was also non-significant. Induction of PIG-A 
mutants viewed both in vivo and in vitro, although non-significant may signify the 
mutagenic potential of obesity. A larger donor population would further explore this. 
Additionally, studying further bile acids involved in obesity and inflammatory 
markers associated with obesity-driven inflammation may provide further insight.  
Consumption of alcoholic beverages is ingrained in western society, but 
overindulgence and abuse of alcohol can lead to a range of long-term health 
problems. Alcohol abuse has increased the risk of PC development by 20% (Cancer 
Research UK, 2014b). Alcohol is one of the most common inducers of pancreatitis, 
with up to a third of acute pancreatitis cases in the US coming as a result of it 
(Chowdhury and Gupta, 2006). Ethanol is metabolised within the body to toxic 
intermediate acetaldehyde, which was used to model alcohol abuse in vitro.  Of the 
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three chemicals tested, acetaldehyde was the most potent, inducing higher 
proportions of DNA damage at lower doses than either DCA or B[a]P. Significant 
induction of MN were viewed in both the PANC-1 and L5178Y cell lines at both 2.5 
and 1µM, respectively. Following on from this, Pig-A mutations were induced in a 
dose dependent manner following acetaldehyde exposure, with significance at 1µM. 
Similar to B[a]P, acetaldehyde forms DNA adducts, primarily at the N2 guanine 
position (Mizumoto et al., 2017b). Both questionnaire and human in vivo PIG-A data 
did not reflect in vitro work. In fact, we saw a negative correlation between 
erythrocyte mutant PIG-A frequency and alcohol units consumed per week. Equally 
important to consider is the small population of completed questionnaires and this 
data was skewed by one donor with high alcohol consumption. A larger population 
would allow further exploration of this and to determine whether mutations seen in 
vitro may reflect some of those seen in the in vivo PIG-A mutation assay. 
6.3 Future Work 
Although promising results have been seen in this thesis, this is still only a 
preliminary pilot study. With only 30 patients diagnosed with PC as donors to the 
study, it is sufficient for preliminary results within our pilot study. Future work on a 
larger scale would be beneficial to give further statistical power behind the results 
collected. A particularly interesting patient cohort, which would be good to recruit to 
future studies would be PC patients from oncology departments before initiating 
chemo or radiotherapy. These patients would have disease too advanced for surgery 
and are a patient group we may have missed since ethical approval granted 
permission from recruitment within surgical departments. Having more patients with 
higher staged disease would be good to examine, allowing better analysis of the PIG-
A results with regards to staging of disease. For example, only one donor in this 
study had T4 disease and so very little information could have been elucidated from 
this.  
An interesting further study would be a fully blinded study, where diagnoses can be 
predicted using the cut-off value determined in chapter 5.3.3, 4.860 x 10-6, with 
mutation frequencies above this value would be predicted to be cancer. In our study, 
68.97% of all PC patients were defined to have a high PIG-A in comparison to just 
10% of benign pancreatic donors. While taking into consideration the small 
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population studied in this pilot study, a greater patient population in a future study 
may result in fewer than 10% of benign donors with high PIG-A, and a greater 
proportion of PC patients with high PIG-A. Further work could then be carried out 
once official diagnoses are revealed by modifying the cut-off value to improve its 
diagnostic value by improving accuracy, sensitivity, and specificity.  
Questions have been raised about the specificity of PIG-A as a biomarker for 
pancreatic malignancy due to the elevation viewed within oesophageal 
adenocarcinoma. Currently these are the two malignancies explored within our 
research group, given both diseases have dismal prognoses. Although a wider range 
of malignancies were explored by Horibata et al. (2016) during therapeutic 
interventions, no pre-treatment bloods were taken, so we cannot determine whether 
there are elevated PIG-A mutant frequencies in other malignancies. Further studies 
to establish the PIG-A mutant frequencies across a variety of malignancies would be 
beneficial. If elevated PIG-A mutant frequencies are common across all cancers, the 
human erythrocyte PIG-A assay could be incorporated into a battery of tests used in 
suspected cancer cases to help differentiate between benign and malignant disease. 
Suspected blood-borne malignancies would be especially interesting to examine, 
since bone marrow is the source of blood cell precursors. Furthermore, exploration 
of other malignancies would determine whether PIG-A mutant elevation is non-
specific or purely limited to gastrointestinal malignancies and will ultimately guide 
the future use of the assay.  
The human PBMC CBMN assay is well established and has been used extensively. 
Beneficial future work which would improve upon the current PBMC CBMN assay 
would include automation of the scoring of the assay. Semi-automated Metafer 
scoring of the CBMN assay carried out in the PANC-1 and the L5178Y cell lines 
within chapter 3. Primary human PBMCs were too small to be identified using the 
current classifiers. Producing and testing a new classifier on the Metafer system, 
which could identify primary human PBMCs would be better in the future. Although 
manual scoring remains the gold standard for the CBMN assay, the semi-automated 
Metafer system has its advantages over the manual system. Semi-automated scoring 
allows for quicker examination of cells, with an entire slide being able to be scored 
within 30 minutes, in comparison to a minimum of an hour for manual CBMN 
scoring. Additionally, the Metafer system requires the scoring of 2,000 binucleated 
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cells per slide, in comparison to 1,000 cells in manual scoring. This provides a 
greater statistical power for results collected through this manner. Semi-automated 
scoring would also bypass a lot of the problems associated with slide preparation 
discussed within 5.4.1. 
6.4 Conclusion 
Challenges in diagnosing PC result in the majority of patients diagnosed with 
advanced PC, too late for curative intervention. This helps to maintain the dismal 
prognosis faced by PC patients. Improvements in PC diagnosis are needed urgently 
to help improve the bleak outlook. 
Here, we have assessed the use of two blood-based biomarkers and explored their 
use within a biomarker panel for PC diagnosis. The human erythrocyte PIG-A assay 
monitors the mutation status of the X-linked PIG-A gene through flow cytometric 
detection of GPI anchored proteins on the erythrocyte surface. We have viewed an 
increased frequency of PIG-A mutant erythrocytes within donors with PC in 
comparison to both benign pancreatic and healthy donors. Furthermore, when PC 
staging was examined, an elevated PIG-A frequency was observed in patients with 
metastatic disease in comparison to localised disease. The assay has potential for use 
in diagnosis and staging of PC. It may also show potential for patient stratification 
for more invasive investigative procedures for PC diagnosis such as EUS or ERCP. 
An elevated frequency of MN in PBMCs was also observed within PC patients, but 
did not show much potential with staging disease. A range of biomarker panels were 
assessed, with a combination of CA19-9 and PIG-A showing most potential for 
diagnosing and staging PC, improving upon use of the single biomarkers alone.  
A further in vitro study was also used to identify lifestyle and dietary choices which 
























Chapter 7: Appendices 
7.1 Study Documentation 
The following documents were prepared and applied for REC committee approval 
via IRAS. Approval granted by Cornwall and Plymouth REC and ABMU R&D. 
7.1.1 Patient Information Sheet 
                                                                                              
                                                                                                                                                                                                                                                           
                           
 
Patient Information Sheet– 25th January 2017, Version 4.0 
 





Blood cell mutation analysis in pancreatic disease  
     
Chief Investigator: Miss Lucy Nichols, Co-investigator: Professor 
Gareth Jenkins, Clinical lead: Professor Bilal Al-Sarireh. 
                     
You are being invited to take part in a research study which makes part of a 
PhD. Before you decide it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and 
members of hospital staff. Ask us if there is anything that is not clear or if you 
would like more information. Please take time to decide whether or not you 
wish to take part in the study. 
If you do decide to take part, please let us know beforehand if you have been 
involved in any other study during the last year. If you decide not to take part 
or to withdraw at any other time without explanation, your future care will not 
be affected by your decision. Thank you for reading this. 
Dept. of Surgery 
Morriston Hospital 







What is the purpose of the study? 
 
You are undergoing investigations for pancreatic disease. We would like to 
develop blood-based tests so that in the future we can detect pancreatic 
disease more simply. In order to do so we require donated blood samples 
from patients with a range of pancreatic diseases. We will compare the 
results of our test in patients with different types of disease. We then can see 
if our newly developed test can (in the future) detect early forms of 
pancreatic disease. 
 
We plan to investigate this by: 
 
a) Asking you to fill out a questionnaire about your lifestyle. 
b) Taking a blood test from the intravenous line which will be inserted as 
a matter of routine. This will be approximately 10mls (2 teaspoons). 
c) We may later analyse tissue taken during biopsy and/or surgery for 
routine purposes. You will not have to provide extra tissue samples, 
we will use “left-over” tissue. We will obtain this from the pathology 
dept. 
d) We may carry out genetic analysis on the blood sample donated. 
e) Samples will be disposed of at the end of the study. 
 
Why have I been chosen? 
You are being investigated for the presence of pancreatic disease. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, 
you are still free to withdraw at any time and without giving a reason. This will 
not affect the standard of care you receive in the future. 
 
What do I have to do? 
You will be approached and informed about the study while attending the 
Department for your follow-up clinic appointment, OR while attending your 
follow-up outpatient appointment in the main outpatients department. The 
researcher will: 
• Ask you about your health in general, and any previous operations 
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• Explain the purpose of this study in further details and answer your 
questions 
Taking part in this study will not affect the standard treatment that you 
receive. 
You can opt out of the study at any stage. 
 
What will happen to me if I take part? 
If you decide to take part in this study you will be asked to sign the necessary 
consent form, then you will have: 
1) A questionnaire which will take no longer than 10 minutes to 
complete, which will ask you about your diet, lifestyle and 
medications. It will also ask you to give your weight and height 
measurements. 
2) A blood test will also be offered to you, which you can accept or 
refuse. We will take this blood using a standard blood test.  
3) We may (in some cases) obtain some “left-over” biopsy tissue to 
study some cellular details to compare to the blood data. You will not 
have to provide any additional biopsies for this. 
 
 
What are the possible disadvantages and risks of taking 
part? 
There are no known risks associated with taking part. The blood test will be 
taken by trained staff, although some minimal discomfort may be 
experienced, as per all blood tests. 
 
What are the possible benefits of taking part? 
There will not be immediate benefits from taking part in this study. The study 
will help develop a novel blood test that may be beneficial to patients in the 
future. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research 
will be kept strictly confidential. Your name and address will be removed from 
the information when it is shown to other medical staff outside the study. 
 
Who is organising the research? 
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This study is being organised by the staff of the surgery department of ABM 
University Health Board and Swansea University. 
 
Who has reviewed the study? 
The Research Ethics Committee of Cornwall and Plymouth has reviewed this 
study. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action.  Regardless of 
this, if you wish to complain, or have any concerns about any aspect, or 
about the way you have been treated during the course of this study then 
you should immediately inform Professor Bilal Al-Sarireh (Dept Surgery, 
Morriston hospital, 01792 487418).  The normal National Health Service 
complaint complaints mechanisms are also available to you.  If you are still 
not satisfied with the response, you may contact the Mr Raymond Cibrowski, 
Registrar & Chief Operating Officer (Email: 
researchgovernance@swansea.ac.uk or misconduct@swansea.ac.uk).    
 
Contact for Further Information 
If you want more information, before or after you return your form, you can 
phone (9am-5pm Mon-Fri) 
Professor Gareth Jenkins on  
Miss Lucy Nichols on  
Professor Bilal Al-Sarireh  
The Cornwall and Plymouth Research Ethics Committee has reviewed and 










7.1.2 Informed Consent Form 
        
  
                                                                                                                                          
                  
  
Participant Consent Form Version 1, 14th November 2016 
Title of research “Blood cell mutation analysis in pancreatic disease” 
CI: Prof Gareth Jenkins 
 
The participant should complete the whole of this sheet himself/herself.  
(Please initial each statement if it applies to you) 
 
I have read the Information Sheet for Patients dated November 2016    
           
I have received enough information about the study, have been given 
the opportunity to ask questions and discuss the project and have received 
satisfactory answers to all my questions.       
       
I understand that relevant sections of my medical notes may be accessed by  
members of the research team, the  
Health Board or from regulatory authorities for the purposes of monitoring or auditing  
    
 
The study, including the risks and benefits, has been explained to me by 
a member of the clinical research team 
 
 
I consent to having a blood sample taken for analysis by the research team 
 
I agree to completing the questionnaire associated with this study 
 
 








I understand that researchers may access “left-over” biopsy material for further analysis 
 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 





(NAME IN BLOCK CAPITALS)...................................................................................…  
 
Investigator’s signature....................................................… Date: .............................. 
 
(NAME IN BLOCK CAPITALS).................................................................................….  
  




The REC requested separate questionnaires for male and female participants to avoid 
confusion around final questions about male or female specific health concerns. 
7.1.3.1 Questionnaire – Male 





We are interested in the type of foods you eat and how frequently you eat them. 
 
Questions about your diet 
 
1. Do you eat meat?      Yes ☐   No ☐   
 
If Yes, how many times a week do you eat meat? 




If No, how old were you when you last ate meat?  
_____years old 
 
2. Do you eat any fish?    Yes ☐   No ☐   
 
If Yes, how many times a month do you eat the following? 
(put ‘0’ if less than once a month) 
 
Fatty fish   ____times a month        Other fish ____times a month 
(including sardines,                                       (including Cod, tuna, haddock) 
salmon, mackerel, herring)  
 
If No, how old were you when you last ate fish?  
_____years old 
 
3. Do you eat any dairy products?  Yes ☐   No ☐   
(including milk, cheese, butter, yoghurt) 
 
If No, how old were you when you last ate dairy products? _____years old 
 
4. Do you eat any eggs?    Yes ☐  No ☐   
(including eggs in cakes and other baked foods) 
 
If Yes, how many eggs do you eat each week?  
_____eggs each week 
Put “0” if eaten less than once a week 
 
If No, how old were you when you last ate eggs? 
_____years old 
 
5. What type of milk do you use most often? 
 
Full cream                 ☐ Soya milk fortified with calcium          ☐ 
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Semi-skimmed       ☐ Soya milk not fortified with calcium   ☐ 
Skimmed/fat free           ☐ Other                                                     ☐ 
None                      ☐ 
 
How much milk do you drink each day, including milk with tea, coffee, cereals, etc. 
Less than a quarter of a pint (<150ml)         ☐ Three quarters of a pint      ☐   
                                                                                 (450ml)  
Quarter of a pint (150ml)                           ☐ One pint (600ml)                 ☐ 
Half a pint (300ml)                                     ☐ More than one pint                ☐   
                                                                 (>600ml)  
 
6. What type of spread do you use most often on bread, crispbreads, vegetables, etc.? 
 
Butter                                                 ☐ Hard margarine                   ☐ 
                                                                                 (in wrapper not tub) 
Dairy spread e.g. Clover                                          ☐   Soya margarine or               ☐   
                                                                 other milk free margarine  
Low or reduced fat spread                 ☐ Cholesterol lowering            ☐     
                                                                 spread e.g.benecol/Flora pro active 
Olive based spread  e.g. Olivio                 ☐ Other margarine                ☐                    




How thickly do you spread it? 
Thick ☐      Medium ☐    Thin ☐ 
 
Do you add it to potatoes?   Yes ☐   No ☐ 
Do you add it to other vegetables?  Yes ☐   No ☐ 
 
 
7. What type of fat do you use most often for cooking? 
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Butter                                                                                          ☐ Lard                                   ☐ 
Soft margarine                                                                             ☐ Olive oil                                 ☐ 
Hard margarine                                                                                  ☐ Other vegetable oil            ☐ 
Solid vegetable fat e.g. White flora                                                 ☐ None                                 ☐ 
 
 
8. Do you eat organic food? 
Never             ☐ 
Sometimes     ☐ 
Usually             ☐ 
Always               ☐ 
 
 
9. How much bread, crispbread, etc. do you normally eat each day?      
          (Put ‘0’ if none)          (Put ‘0’ if none)  
White bread  ____  Crispbread   ____  
                  (slices per day)     (biscuits per day) 
Brown bread  ____  Sweet biscuits ____ 
                       (slices per day)   (biscuits per day) 
Wholemeal bread ____ 
                  (slices per day) 
 
 
10. What type of beakfast cereal do you eat most often? 
 
Bran cereal            ☐ Muesli, oat clusters, etc                         ☐ 
e.g. Branflakes  
Wholemeal cereal     ☐ Other                                                           ☐ 
e.g. Weetabix  e.g. cornflakes, Rice krispies  
Porridge,                    ☐  None                                                       ☐ 
hot oat cereal 
 
How many bowls of cereal do you eat each week? 
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_____bowls a week 
Put ‘0’ if none    
 
 
11. How much of the following do you drink each day? 
Put ‘0’ if none 
 
Tea          ____ cups daily Pure fruit juice              ____ glasses daily 
Herb tea    ____ cups daily fruit drinks, squash             ____ glasses daily 
Coffee     ____ cups daily “Diet” fizzy soft drinks ____ glasses/cans   
             daily 
Water        ____ glasses daily Fizzy soft drinks                ____ glasses/cans  
     daily 
  
12. How many teaspoons of sugar, in total, do you add to your tea, coffee, cereal, fruit, etc. each 
day 
____teaspoons each day 
Put ‘0’ if none 
 
13. At present, about how many alcoholic drinks do you have each week? 
Put ‘0’ if none 
Beer, lager or cider  ____pints each week Sherry or fortified wine    ____glasses each    
                                                                                                                   week 
Red wine      ____glasses each week Spirits – whisky, gin,   
                                                                        brandy ____glasses each   
                                                                                                                   week 
White wine                   ____glasses each week 
 
13. How often do you eat the following? 
 
Please cross one box for each item 
 

















Fresh fruit       
Dried fruit 
(raw) 




      
Pasta, e.g. 
spaghetti 
      
Rice       
Pizza       
Chips       
Other 
potatoes 
      
Peas       
Baked 
beans 
      
Lentils, 
dried beans 
      
Tomatoes       
Carrots       
Green 
vegetables 




      
Salad/raw 
vegetables 
      































      
Cheese       
Cottage 
cheese 
      
Soya 
cheese 
      
Yoghurt, 
dairy 








      
Cream, ice 
cream 









      
Chocolate, 
any type 


















      
Jam, 
marmalade 











We are interested in the type of activities you undertake. 
 
Questions about your lifestyle 
 




If you have stopped smoking cigarettes, how old were you when you gave up?  ____years old 
 
If you smoke now, how many cigarettes, do you usually smoke each day?       ____cigarettes a day 
 
 
2. Do you smoke cigars?    Yes ☐ No ☐ 
3. Do you smoke a pipe?    Yes ☐ No ☐ 
 
4. Do you have a paid job at present? 
Yes, full-time        ☐  Yes, part-time ☐  No  ☐ 
 
If Yes, we would like to know the type and amount of physical activity involved in your work.  
Please put a cross in the appropriate box. 
 
Sedentary occupation  ☐ 
You spend most of your time sitting (such as in an office) 
 
Standing occupation  ☐ 
You spend most of your time standing or walking, but your work does not require intense physical effort (e.g. shop assistant, 
hairdresser, guard) 
 
Manual work   ☐ 
This involves some physical effort including handling of heavy objects and use of tools (e.g. plumber, electrician, carpenter) 
 
Heavy manual work  ☐ 




5. In a typical week during the past year, how many hours did you spend per week on the 
following activities? Put ‘0’ if none 
    
In Summer In Winter 
Walking, including to 
work, shopping and        ____hours per week     ____hours per week 
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leisure time  
 
Cycling, including  
cycling to work,             ____hours per week     ____hours per week 
and during leisure time  
 
Gardening            ____hours per week     ____hours per week 
 




In Summer In Winter 
 
Physical exercise such ____hours per week     ____hours per week 
as keep-fit/aerobics,    
swimming, jogging, tennis, etc. 
 
Housework, such as  ____hours per week     ____hours per week 
cleaning, washing,  
cooking and childcare 
 
 
6. In a typical week during the past 12 months, did you practice any of these activities 
vigorously enough to cause sweating or a faster heartbeat? 
Yes ☐  No ☐ 
 
If Yes, for how many hours per week in total did you practice such vigorus activity? _____hours per 
week 
 
7. What is your weight? 
Stones_____pounds____ OR ____.__ Kg 
 
8. Please indicate your marital status 
Single       ☐  Separated  ☐ 
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Married or living as married ☐  Divorced   ☐ 






We are interested in your past medical history and your current state of health. 
 
Questions about your health 
 
1. In the past six years, have you had any broken/fractured bones? 
Yes ☐  No ☐ 
 
If Yes, please give details:  ______(bone)   ______(year) 
       ______(bone)   ______(year) 
        ______(bone)   ______(year) 
 
 
2. In the last six years, has your doctor told you that you that you had any of the following? 
 
 
 Yes Year first 
diagnosed 
No 
Cancer    
Type of cancer: 
 
Polyps in large intestine    
Enlarged prostate (men only)    
High blood pressure    
High blood cholesterol    
Angina    
Stroke    
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Heart Attack    
Cardiac arrhythmias/ palpatations/ 
irregular heartbeat 
   
Blood clot in leg    
Blood clot in lung or elsewhere    
Diabetes    
Thyroid disease    
Cataract in eye    
Stomach ulcer    
Duodenal ulcer    
Gallstones    
Have you had your gallbladder 
removed? 
   
Crohn’s disease    
Ulcerative colitis    
Asthma    
Bronchitis/emphysema    
Rheumatoid Arthritis    
 Yes Year first 
diagnosed 
No 
Osteoarthritis    
Depression requiring treatment    
Other significant Illnesses or operations,  





3. Do you regularly take any vitamins, minerals or other supplements? 
   Yes ☐  No ☐ 
 
If Yes, do you take: (you can cross more than one box) 
 
Multivitamins (with minerals)         ☐ Vitamin A ☐ 
Multivitamins (without minerals)  ☐ Vitamin B    ☐ 
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Fish oil (including cod liver oil)      ☐ Vitamin C         ☐ 
Evening primrose oil                          ☐ Vitamin D         ☐ 
Garlic                                                  ☐ Vitamin E     ☐ 
Iron                                                        ☐ Other               ☐ ________ 
Zinc                                                            ☐    (name and brand) 
Calcium                                                    ☐ 
 
 
4. Have you taken any medications for most of the last 4 weeks? 
 Yes ☐ No ☐ 
 







5. About how many bowel movements do you have each week? 
____a week 
 
How often do you take laxatives? (Put ‘0’ if never) 
____times a month 
 
 
6. How would you describe your health now? 
Excellent ☐     Good ☐    Fair ☐  Poor ☐ 
 
 
QUESTION FOR MEN ONLY 
 
7. Have you had a vasectomy?  Yes ☐ No ☐ 








Thank you for taking the time to complete this questionnaire. 
 
Please return to Miss Lucy Nichols 








7.1.3.2 Questionnaire – Female 
 




We are interested in the type of foods you eat and how frequently you eat them. 
 
Questions about your diet 
 
1. Do you eat meat?      Yes ☐   No ☐   
 
If Yes, how many times a week do you eat meat? 
 _____times a week 
 
If No, how old were you when you last ate meat?  
_____years old 
 




If Yes, how many times a month do you eat the following? 
(put ‘0’ if less than once a month) 
 
Fatty fish   ____times a month        Other fish ____times a month 
(including sardines,                                       (including Cod, tuna, haddock) 
salmon, mackerel, herring)  
 
If No, how old were you when you last ate fish?  
_____years old 
 
3. Do you eat any dairy products?  Yes ☐   No ☐   
(including milk, cheese, butter, yoghurt) 
 
If No, how old were you when you last ate dairy products? _____years old 
 
4. Do you eat any eggs?    Yes ☐  No ☐   
(including eggs in cakes and other baked foods) 
 
If Yes, how many eggs do you eat each week?  
_____eggs each week 
Put “0” if eaten less than once a week 
 
If No, how old were you when you last ate eggs? 
_____years old 
 
5. What type of milk do you use most often? 
 
Full cream                 ☐ Soya milk fortified with calcium          ☐ 
Semi-skimmed       ☐ Soya milk not fortified with calcium   ☐ 
Skimmed/fat free           ☐ Other                                                     ☐ 
None                      ☐ 
 
How much milk do you drink each day, including milk with tea, coffee, cereals, etc. 
Less than a quarter of a pint (<150ml)         ☐ Three quarters of a pint      ☐   
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                                                                                 (450ml)  
Quarter of a pint (150ml)                           ☐ One pint (600ml)                 ☐ 
Half a pint (300ml)                                     ☐ More than one pint                ☐   
                                                                 (>600ml)  
 
6. What type of spread do you use most often on bread, crispbreads, vegetables, etc.? 
 
Butter                                                 ☐ Hard margarine                   ☐ 
                                                                                 (in wrapper not tub) 
Dairy spread e.g. Clover                                          ☐   Soya margarine or               ☐   
                                                                 other milk free margarine  
Low or reduced fat spread                 ☐ Cholesterol lowering            ☐     
                                                                 spread e.g.benecol/Flora pro active 
Olive based spread  e.g. Olivio                 ☐ Other margarine                ☐                    




How thickly do you spread it? 
Thick ☐      Medium ☐    Thin ☐ 
 
Do you add it to potatoes?   Yes ☐   No ☐ 
Do you add it to other vegetables?  Yes ☐   No ☐ 
 
 
7. What type of fat do you use most often for cooking? 
Butter                                                                                          ☐ Lard                                   ☐ 
Soft margarine                                                                             ☐ Olive oil                                 ☐ 
Hard margarine                                                                                  ☐ Other vegetable oil            ☐ 





8. Do you eat organic food? 
Never             ☐ 
Sometimes     ☐ 
Usually             ☐ 
Always               ☐ 
 
 
9. How much bread, crispbread, etc. do you normally eat each day?      
          (Put ‘0’ if none)          (Put ‘0’ if none)  
White bread  ____  Crispbread   ____  
                  (slices per day)     (biscuits per day) 
Brown bread  ____  Sweet biscuits ____ 
                       (slices per day)   (biscuits per day) 
Wholemeal bread ____ 
                  (slices per day) 
 
 
10. What type of beakfast cereal do you eat most often? 
 
Bran cereal            ☐ Muesli, oat clusters, etc                         ☐ 
e.g. Branflakes  
Wholemeal cereal     ☐ Other                                                           ☐ 
e.g. Weetabix  e.g. cornflakes, Rice krispies  
Porridge,                    ☐  None                                                       ☐ 
hot oat cereal 
 
How many bowls of cereal do you eat each week? 
_____bowls a week 
Put ‘0’ if none    
 
 
11. How much of the following do you drink each day? 




Tea          ____ cups daily Pure fruit juice              ____ glasses daily 
Herb tea    ____ cups daily fruit drinks, squash             ____ glasses daily 
Coffee     ____ cups daily “Diet” fizzy soft drinks ____ glasses/cans   
             daily 
Water        ____ glasses daily Fizzy soft drinks                ____ glasses/cans  
     daily 
  
12. How many teaspoons of sugar, in total, do you add to your tea, coffee, cereal, fruit, etc. each 
day 
____teaspoons each day 
Put ‘0’ if none 
 
13. At present, about how many alcoholic drinks do you have each week? 
Put ‘0’ if none 
Beer, lager or cider  ____pints each week Sherry or fortified wine    ____glasses each    
                                                                                                                   week 
Red wine      ____glasses each week Spirits – whisky, gin,   
                                                                        brandy ____glasses each   
                                                                                                                   week 
White wine                   ____glasses each week 
 
13. How often do you eat the following? 
 
Please cross one box for each item 
 















Fresh fruit       
Dried fruit 
(raw) 




      
Pasta, e.g. 
spaghetti 
      
Rice       
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Pizza       
Chips       
Other 
potatoes 
      
Peas       
Baked 
beans 
      
Lentils, 
dried beans 
      
Tomatoes       
Carrots       
Green 
vegetables 




      
Salad/raw 
vegetables 
      































      
Cheese       
Cottage 
cheese 
      
Soya 
cheese 









      
Cream, ice 
cream 











      
Chocolate, 
any type 


















      
Jam, 
marmalade 











We are interested in the type of activities you undertake. 
 
Questions about your lifestyle 
 
1. Have you ever smoked cigarettes    Yes ☐   No  ☐ 
 
If you have stopped smoking cigarettes, how old were you when you gave up?  ____years old 
 
If you smoke now, how many cigarettes, do you usually smoke each day?       ____cigarettes a day 
 
 
2. Do you smoke cigars?    Yes ☐ No ☐ 
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3. Do you smoke a pipe?    Yes ☐ No ☐ 
 
4. Do you have a paid job at present? 
Yes, full-time        ☐  Yes, part-time ☐  No  ☐ 
 
If Yes, we would like to know the type and amount of physical activity involved in your work.  
Please put a cross in the appropriate box. 
 
Sedentary occupation  ☐ 
You spend most of your time sitting (such as in an office) 
 
Standing occupation  ☐ 
You spend most of your time standing or walking, but your work does not require intense physical effort (e.g. shop assistant, 
hairdresser, guard) 
 
Manual work   ☐ 
This involves some physical effort including handling of heavy objects and use of tools (e.g. plumber, electrician, carpenter) 
 
Heavy manual work  ☐ 




5. In a typical week during the past year, how many hours did you spend per week on the 
following activities? Put ‘0’ if none 
    
In Summer In Winter 
Walking, including to 
work, shopping and        ____hours per week     ____hours per week 
leisure time  
 
Cycling, including  
cycling to work,             ____hours per week     ____hours per week 




Gardening            ____hours per week     ____hours per week 
 




In Summer In Winter 
 
Physical exercise such ____hours per week     ____hours per week 
as keep-fit/aerobics,    
swimming, jogging, tennis, etc. 
 
Housework, such as  ____hours per week     ____hours per week 
cleaning, washing,  
cooking and childcare 
 
 
6. In a typical week during the past 12 months, did you practice any of these activities 
vigorously enough to cause sweating or a faster heartbeat? 
Yes ☐  No ☐ 
 
If Yes, for how many hours per week in total did you practice such vigorus activity? _____hours per 
week 
 
7. What is your weight? 
Stones_____pounds____ OR ____.__ Kg 
 
8. Please indicate your marital status 
Single       ☐  Separated  ☐ 
Married or living as married ☐  Divorced   ☐ 








We are interested in your past medical history and your current state of health. 
 
Questions about your health 
 
1. In the past six years, have you had any broken/fractured bones? 
Yes ☐  No ☐ 
 
If Yes, please give details:  ______(bone)   ______(year) 
       ______(bone)   ______(year) 
        ______(bone)   ______(year) 
 
 
2. In the last six years, has your doctor told you that you that you had any of the following? 
 
 
 Yes Year first 
diagnosed 
No 
Cancer    
Type of cancer: 
 
Polyps in large intestine    
Enlarged prostate (men only)    
High blood pressure    
High blood cholesterol    
Angina    
Stroke    
Heart Attack    
Cardiac arrhythmias/ palpatations/ 
irregular heartbeat 
   
Blood clot in leg    
Blood clot in lung or elsewhere    
Diabetes    
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Thyroid disease    
Cataract in eye    
Stomach ulcer    
Duodenal ulcer    
Gallstones    
Have you had your gallbladder 
removed? 
   
Crohn’s disease    
Ulcerative colitis    
Asthma    
Bronchitis/emphysema    
Rheumatoid Arthritis    
 Yes Year first 
diagnosed 
No 
Osteoarthritis    
Depression requiring treatment    
Other significant Illnesses or operations,  





3. Do you regularly take any vitamins, minerals or other supplements? 
   Yes ☐  No ☐ 
 
If Yes, do you take: (you can cross more than one box) 
 
Multivitamins (with minerals)         ☐ Vitamin A ☐ 
Multivitamins (without minerals)  ☐ Vitamin B    ☐ 
Fish oil (including cod liver oil)      ☐ Vitamin C         ☐ 
Evening primrose oil                          ☐ Vitamin D         ☐ 
Garlic                                                  ☐ Vitamin E     ☐ 
Iron                                                        ☐ Other               ☐ ________ 
Zinc                                                            ☐    (name and brand) 
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Calcium                                                    ☐ 
 
 
4. Have you taken any medications for most of the last 4 weeks? 
 Yes ☐ No ☐ 
 







5. About how many bowel movements do you have each week? 
____a week 
 
How often do you take laxatives? (Put ‘0’ if never) 
____times a month 
 
 
6. How would you describe your health now? 




QUESTIONS FOR WOMEN ONLY 
 
8. Have you had your menopause (stopped having periods)? 
Yes ☐      No ☐     Not sure ☐  
   (because taking HRT, irregular periods, etc) 
 
If Yes, how old were you when you stopped having periods? 
_____years old 
 
9. How many periods have you had in the last 12 months? 
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_____periods (Put ‘0’ if no periods) 
 
10. Have you ever taken the contraceptive pill? 
Yes ☐ No ☐ 
If Yes, for how long altogether have you used the pill? _____years 
                (Put ‘0’ if less than one year) 
 
Are you currently taking the contraceptive pill?        Yes ☐  No ☐ 
If No, at what age did you stop? _____years old 
 
11. Have you ever taken Hormone Replacement Therapy (HRT)?    
              Yes ☐   No ☐ 
 
If Yes, for how long altogether have you used HRT?     ____years 
               (Put ‘0’ if less than one year) 
 
Are you currently taking HRT?                Yes ☐   No ☐ 
If No, at what age did you stop?                                ____years old 
 
12. During the last six years, have you had any children? 
             Yes ☐   No ☐ 
 
If Yes, please enter the years of birth and sex below: 
1. ________(YEAR)  Boy ☐ Girl ☐ 
2. ________(YEAR)  Boy ☐ Girl ☐ 
3. ________(YEAR)  Boy ☐ Girl ☐ 
 
 
13. Have you ever had a hysterectomy (womb removed)? 
Yes ☐ No ☐ 
If Yes, at what age _____years old 
 
 
14. Have you ever had an operation to remove one or both ovaries?     Yes ☐ No 




If Yes, were one or both ovaries removed? 
One ☐   Both ☐   Don’t know ☐ 
 
At what age? ____years old 
 
15. Have you ever had breast screening by mammography (x-ray)?                                   Yes ☐ 
No ☐ 
If Yes, how many times in the last ten years? ____times 
When did you last have a breast screen?         ____YEAR 
 
16. Have you ever had a cervical smear test? 
Yes ☐ No ☐ 
If Yes, how many times in the last ten years?   ____times 




Thank you for taking the time to complete this questionnaire. 
 
Please return to Miss Lucy Nichols 














7.2 PANC-1 Expanded Dose Range Viability  
Outside of the dose ranges of DCA tested in the PANC-1 cell line in chapter 3.3.1, 
other doses were assessed but not used further. 
DCA doses beyond 300µM were shown to be too cytotoxic to PANC-1 cells through 
severe reduction of RPD. RPD was reduced beyond the point of usefulness within 
genotoxicity assessment, Fig. 7.1. 
 
Figure 7.1: Cytotoxicity in PANC-1 determined by RPD in increasing 
concentrations of DCA. Bars represent means and error bars show the standard 
deviation. 
7.3 L5178Y Mononucleate MN Assay 
7.3.1 DCA 
Initial cytotoxicity experiments determined a suitable dose range of DCA in the 
L5178Y cell line, which was more sensitive in comparison to the PANC-1 cell line. 
From the vehicle control, there was an increase to an RPD of 116.00 ±27.50% at 
20µM and then a decrease at 150µM of 71.67±26.52%. No statistical significance 
was determined via the Mann Whitney U assay, although at top dose showed a p-
value of 0.088. Above this dose, results were inconsistent and below 50±5% RPD 



















The mononucleate MN assay in the L5178Y cell line showed no statistically 
significant increase in micronuclei at both concentrations of DCA used, Fig 7.3. The 
results from the vehicle control and 20µM DCA are comparable with 0.23±0.11% 
and 0.22±0.02% cells with micronuclei, respectively. 150µM DCA induced 
0.26±0.10% micronucleated cells, which is not significantly higher than the control 






Figure 7.2: Cytotoxicity induced by increasing DCA concentrations in L5178Y cell 
line determined by RPD calculations. Bars represent the mean (n=3) and the error 





















Figure 7.3: Induction of micronuclei in the L5178Y cell line following 4h exposure 
to increasing DCA concentrations for 4h in the mononucleate MN assay. Bars 
represent the mean (n=3) and the error bars show the standard deviation. Red 
dashed line represents the RPD. 
7.3.2 Acetaldehyde 
Initial dose-range finding experiments determined a suitable dose range of 
acetaldehyde in the L5178Y cell line since these cells were more sensitive than the 
PANC-1 cell line. Cytotoxicity was determined through RPD calculations, Fig 7.4. 
A dose-dependent decrease in RPD was observed which was significant at 1µM 














































Figure 7.4: Cytotoxicity induced by 4h exposure to increasing concentrations of 
acetaldehyde in the L5178Y cell line. There is a dose-dependent decrease in RPD as 
acetaldehyde dose increases. Bars represent the mean (n=3) and error bars show 
the standard deviation. (* show p<0.05) 
The induction of micronuclei was studied in the mononucleate micronucleus assay 
following acetaldehyde exposure, Fig. 7.5. Similarly to DCA, micronuclei induction 
by the vehicle control and the lowest dose, 0.25µM, was comparable with 
0.17±0.03% and 0.16±0.11%, respectively. Significant induction of micronuclei was 

































































Figure 7.5: Induction of micronuclei in L5178Y cell line following 4h exposure to 
acetaldehyde in the mononucleate micronucleus assay. A significant induction was 
seen at 1µM actealdehyde. Bars represent the mean and the error bars represent the 
standard deviation. Red dashed line represents the RPD (* shows p<0.05, ** shows 
p<0.01). 
7.4 TNM Staging Definitions 
The most up to date staging for pancreatic tumours is the AJCC 8th edition, further 
described below. This provides information about the size, lymph node involvement 
and metastasis of the disease to provide a better all-around image of disease. 
Table 7.1: definitions of TNM staging for pancreatic tumours according to the 







Stage  Definition 
T1 Maximum tumour diameter ≤2cm 
T2 Maximum tumour diameter >2, ≤4cm 
T3 Maximum tumour diameter >4cm 
T4 Tumour involves coeliac axis, common hepatic artery, or superior 
mesenteric artery 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N2 Metastasis in ≥4 lymph nodes 
M0 No distant metastasis 
M1 Distant metastasis 
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Table 7.2: Definitions of staging dependent on pancreatic tumour TNM staging from 
the AJCC/UICC 8th edition (Cong et al., 2018). 
Stage T N M 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1-T3 N1  M0 
III T4 (or any T) Any N (N2) M0 
IV Any T Any N M1 
 
 
7.5 Questionnaire Data 
Questionnaire responses for donors in the study was poor. Only 8 donors returned 
completed questionnaires with correctly filled out questions. Of 8 donors, 7 donors 
had PC and 1 had benign pancreatic disease. Dietary Quality Score values were 
calculated from examining the dietary portion of the questionnaire, discussed in 2.3.2 
and Table 2.5. DQS values were similar, with a range of 8-10. Patients with PC were 
shown to have a marginally elevated DQS values in comparison to benign donors 
with mean scores of 9.143±0.69 and 8, respectively. This was determined non-
significant through a t-test (p=0.172). A lower DQS signifies a poorer diet, so this 
suggests a better diet within this small population of PC patients. Only one donor has 
benign disease, so may not be truly representative.  
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We examined whether there was a link between PIG-A mutant frequencies and DQS 
in donors with both benign and malignant disease. Only 5 of the 8 donors with 
completed questionnaires had full PIG-A results. No overall link was seen between 
the two.  
Figure 7.7: Correlation between PIG-A mutant frequencies and DQS in donors with 













Figure 7.6: Mean DQS scores in malignant and benign pancreatic donors (n=8). 
















Further in-depth analysis explored dietary fats and whether that had any impact on 
the PIG-A mutant frequency. When examining fats used on bread, a greater PIG-A 
mutant frequency was seen with a lower score, with no significance (p=0.176). 
However, with cooking fats and overall fats the changes are not as obvious.  
Figure 7.8: Mean PIG-A in donors with increasing DQS values for fat used in bread 
and cooking, and overall fat use (n=5) 
Smoking status of the donors was assessed. 50 % of our donors with completed 
questionnaires were past smokers with remaining 50% have never smoked. We 
further examined whether the smoking status of the donor influenced PIG-A mutant 
frequency. Patients who had never smoked (n=3) were shown to have an elevated 
PIG-A mutant frequency over the previous smokers (n=2) although this was non-



























Bread Fat Cooking Fat Overall Fat
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Alcohol consumption was also examined. The lone benign donor did not consume 
any alcohol. In contrast, across the 7 malignant donors there was an average weekly 
alcohol consumption of 7.514±12.961 units, ranging from 0 to 33.3 units. A 
comparison of the PIG-A mutant frequency and the units of alcohol consumed per 
week, Fig. 7.10, did not show much of a correlation and was skewed from one donor 
who consumed 33.3 units per week. 
 
Figure 7.10: Relationship between alcohol consumption in units per week and PIG-
A mutant frequency (n=5). 



































































Further information collected from the questionnaire allowed further insight into 
other health conditions experienced by the patients within our study. Diabetes 
mellitus was the most common comorbidity, with 62.5% (5) of our patients 
recording it as an ongoing health concern. Previously, diabetes mellitus has been 
described as both a symptom of early PC and a cause of PC. High cholesterol was 
the next most common condition experienced, besides pancreatic pathologies, being 
experienced by 37.5% (3) patients. Interestingly, the third most common other 
condition was cataracts, seen in 25% (2) of our patients. Self-reported health was a 
question found in the questionnaire. Interestingly, those with worse self-reported 
health tended to have an elevated PIG-A mutant frequency, although this was 
deemed non-significant through a one-way ANOVA (p=0.180). 
Figure 7.11: Mean PIG-A mutant frequencies in decreasing self-reported health 
(n=5). 
 
7.6 Conference Attendance 
Poster – April 2017 – Swansea University Medical School Postgraduate 
Research Conference  
Although survival rates for cancers have improved, survival for pancreatic cancer 
patients has failed to improve within the last four decades. Most cases are diagnosed 
at an advanced stage where patients are not eligible for surgical intervention. As a 
result, there is a push towards non-invasive techniques for earlier diagnosis of 
























The Pig-A assay has been used extensively in rodent models to monitor genotoxic 
responses to stimuli and more recently has been applied to human population studies. 
Particularly, cancer patients have been shown to have a higher mutation frequency 
than healthy individuals.  X-linked Pig-A is ubiquitously expressed and encodes the 
catalytic domain of N-acetyl glucosamine transferase responsible for the first step of 
GPI anchor biosynthesis. The mutation status of peripheral erythrocytes was 
determined using a trio of antibodies against GPI anchored proteins and flow 
cytometry. In parallel with the micronucleus assay, a more complete view of in vivo 
mutations is given.  Initial consenting patients donated 10ml of peripheral blood 
from which a Pig-A mutation frequency was measured to determine whether the 
assay has potential in differentiating between benign and malignant pancreatic 
conditions. 
The micronucleus assay was also used to assess chromosomal damage in an in vitro 
model of pancreatic cancer induced by poor diet and lifestyle. Approximately 37% 
of cases of pancreatic cancer can be avoided through better dietary and lifestyle 
choices. Benzo-[a]-pyrene, a common contaminant of cigarette smoke, was shown to 
induce micronuclei formation in the panc-1 cell line following 24-hour exposure.  
Flash Presentation – May 2018 – Swansea University Medical School 
Postgraduate Research Conference 
Can the Novel PIG-A Assay Diagnose Pancreatic Cancer? 
Fewer than 5% of pancreatic cancer patients survive 5 years post-diagnosis since the 
majority of patients are diagnosed with advanced disease. Advances in earlier 
diagnosis of pancreatic cancer would improve survival rates of pancreatic cancer 
patients. 
A novel blood test determines the mutation status of the X-linked PIG-A gene 
through flow cytometric detection of GPI anchored proteins on the surface of red 
blood cells. Previous studies have shown higher levels of PIG-A mutant erythrocytes 
in cancer patients and so the test is being explored within a pancreatic cancer cohort 
to determine its potential in diagnosis. 10µL whole blood stained with a triplicate of 
antibodies against erythrocyte specific CD-235a and GPI-anchored CD-55 and CD-
59.  A GPI deficient population was identified and quantified as PIG-A mutants. To 
date, 13 patient samples resulted in mean mutant frequencies of 8.47±6.70 X10-6 in 
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malignant pancreatic patients and 2.15±0.32 X10-6 in benign patients. Additionally, 
primary lymphocytes were harvested from whole blood using histopaque, cultured 
for 48h in presence of phytohemagglutinin and with cytokinesis block cytochalasin 
B for an additional 48h. Giemsa stained slides were scored for the frequency of 
micronuclei in 1000 binucleated lymphocytes. This provided a measure of 
chromosomal stability and a secondary measure of in vivo DNA damage.  
An in vitro approach was also used to assess DNA damage induced by known risk 
factors because 39% of pancreatic cancer cases are linked to avoidable causes. 
Micronuclei induction was studied in the pancreatic ductal adenocarcinoma cell line 
PANC-1 in response to a trio of chemicals, benzo-[a]-pyrene, bile acid deoxycholic 
acid and acetaldehyde, to mimic smoking, poor diet and excess alcohol consumption. 
An increase in DNA damage was seen following exposure to the three chemicals 
independently. Additional endpoints will be assessed and this will also be correlated 
with in vivo PIG-A data collected from patients.  
Poster – September 2018 – UKEMS Annual Meeting, Magdalen College, 
Oxford 
PIG-A Assay: Potential Pancreatic Cancer Diagnostic Tool? 
Pancreatic cancer remains one of the greatest challenges of modern medicine. It is an 
aggressive disease with consistently low survival rates, with little improvement over 
the past four decades. Eighty percent of patients are diagnosed with metastatic 
disease, limiting treatment to palliative chemo and radiotherapy. Earlier diagnosis 
would allow more patients to have potentially curative surgery. 
 The human erythrocyte PIG-A assay has been investigated to determine its use as a 
new diagnostic tool for pancreatic cancer. X-linked PIG-A gene encodes a catalytic 
subunit involved in GPI anchor biosynthesis. A single mutation is enough to result in 
GPI deficient cells. Mutation in the PIG-A gene is identified through flow cytometric 
detection of GPI anchored CD-55 and CD-59 on the surface of erythrocytes. Patients 
were recruited from surgical clinics at a tertiary referral centre for pancreatic cancer, 
at Morriston Hospital, Swansea. To date, 24 patients have been recruited. PIG-A 
mutation frequencies in a healthy, benign pancreatic and malignant pancreatic cohort 
are 3.71±2.03 (n=3), 3.04±1.40 (n=4) and 8.12±6.60 (n=13), respectively. Pancreatic 
cancer patients show a higher mean PIG-A mutant frequency and a wider range of 
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mutant frequencies, potentially linked to stage of disease. The lymphocyte 
micronucleus assay was used to provide a secondary measure of DNA damage. An 
in vitro model of pancreatic cancer was also explored to determine sources of the 
DNA mutations reflected in the in vivo tests. Specifically, alcohol consumption, 
smoking and obesity were modelled using acetaldehyde (0-2.5µM), B[a]P (0-50µM) 
and deoxycholic acid (0-500µM) exposure in the PANC-1 cell line.  Significant 
micronuclei induction was seen using B[a]P above 20µM and acetaldehyde at 2.5µM 
but the pattern was less clear with deoxycholic acid. 
A larger patient cohort is needed to fully elucidate whether the PIG-A assay will be 
beneficial as either a diagnostic or staging tool alongside imaging studies.  
Oral Presentation – April 2019 - UKEMS/BTS Joint Meeting – Robinson 
College, Cambridge 
In vitro and in vivo study of the PIG-A assay in pancreatic cancer. 
Pancreatic cancer is a complex disease. Approximately 40% of cases are attributed to 
avoidable lifestyle and dietary causes. It is difficult to diagnose due to a late onset of 
non-specific symptoms. The PIG-A assay has been used extensively in rodent 
toxicology studies and more recently in humans and in vitro. Through flow 
cytometric detection of fluorescently labelled GPI-anchored proteins, the mutation 
status of the x-linked PIG-A gene is determined. 
The human erythrocyte PIG-A assay has been applied to samples from donors with 
benign and malignant pancreatic conditions, with the lymphocyte micronucleus 
assay used as a secondary measure of DNA damage. Reported PIG-A mutation 
frequencies for healthy volunteers are comparable to values found for healthy 
patients and benign pancreatic patients (4.59±2.11 and 3.37±1.21 respectively). 
Cancer patients have an increased level of mutated erythrocytes (8.33±6.16). As the 
TNM stage of the tumour increased there was an increase in the number of mutated 
erythrocytes, but this was significant as disease became metastatic. An increase in 
micronucleated lymphocytes was seen in cancer patients (1.80%) in comparison to 
benign patients (1.29%). 
The In vitro Pig-A assay and micronucleus assay have been used to monitor 
mutations induced by pancreatic carcinogens deoxycholic acid, benzo-[a]-pyrene and 
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acetaldehyde to model a high fat diet, smoking and alcohol abuse respectively. 
Mutations seen in the in vitro assay may reflect some mutations seen in vivo. This 
increase in mutations quantified through both the PIG-A and micronucleus assay 
may be useful as a diagnostic or staging tool for patients with pancreatic disease. 
Poster – May 2019 – Pancreatic Symposium, Cancer Research UK Cambridge 
Institute, Cambridge 
PIG-A Assay:  potential novel diagnostic tool for pancreatic cancer 
As much as 80% of all pancreatic cancer patients are diagnosed with locally 
advanced or metastatic disease, limiting treatment options and causing a poor 
prognosis. Blood-based biomarkers are a cheap, easy and accessible method of 
diagnosis and monitoring disease progression. Currently used CA19-9 although 
helpful cannot be fully relied upon so the search for more blood-based biomarkers 
for pancreatic cancer is of high importance.  
The human erythrocyte PIG-A assay is being explored to determine whether it has 
any potential in diagnosing pancreatic cancer. The simple blood-based assay 
monitors the mutation status of the x-linked PIG-A gene through detecting GPI 
anchored proteins on the erythrocyte surface by flow cytometry. PIG-A mutant 
erythrocytes lack GPI anchors, in turn lacking the GPI anchored proteins and so are 
non-fluorescent during analysis. The mutant erythrocytes are quantified per million 
red blood cells analysed. Healthy donors in population studies have approximately 5 
mutant erythrocytes per million analysed. Studies within our research group have 
shown elevated level of mutation in peripheral erythrocytes of gastrointestinal cancer 
patients and so this is being investigated in pancreatic cancer, where improvements 
in diagnosis are mostly needed. 
To date, 45 consenting donors have provided 10ml heparinised blood and a lifestyle 
questionnaire. Blood was analysed in parallel with the human erythrocyte PIG-A 
assay and the lymphocyte cytokinesis block micronucleus assay to provided two 
measures of DNA damage in two separate blood cell populations.  Stated PIG-A 
mutation frequencies in population studies are comparable to the PIG-A mutation 
frequencies found in healthy and benign pancreatic patients (4.59±2.11 and 
3.37±1.21 respectively). Elevated mutated erythrocytes are found in cancer patients 
(8.67±6.33). Comparison of TNM tumour staging showed a significant increase in 
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mutated erythrocytes in metastatic disease. An increase in micronucleated 
lymphocytes were also seen in cancer patients in comparison to benign patients with 
frequencies of 1.80% and 1.29%, respectively. No significance was found when 
comparing TNM staging with results from the lymphocyte cytokinesis block 
micronucleus assay.  
In this pilot study, an increase has been viewed in the frequency of mutated 
erythrocytes in cancer patients in comparison to patients with benign disease. There 
was also an increase in mutated erythrocytes in patients with metastatic pancreatic 
cancer. The PIG-A assay has shown potential for use either as a diagnostic tool or a 
staging tool for those with pancreatic disease, although greater patient numbers are 
required to fully explore this.  
Oral Presentation – May 2019 – Swansea University Medical School 
Postgraduate Research Conference 
An investigation of the PIG-A assay in pancreatic cancer 
Within the last 4 decades, cancer survival rates have improved in most malignancies. 
Pancreatic cancer, however, has bucked the trend with a consistently low five-year 
survival rate of 7%. It’s an aggressive disease with 40% of cases caused by lifestyle 
and dietary causes. With vague, non-specific symptoms, 80% of patients are 
diagnosed with advanced disease. Improvement in diagnosis would allow for earlier 
intervention and may improve patient outcome.  
The PIG-A assay is being explored for its use in pancreatic disease. The assay 
monitors the mutation status of the x-linked PIG-A gene through flow cytometric 
detection of GPI-anchored proteins on the surface of cells. It has been used 
extensively in rodent genotoxicology studies but more recently in human blood cell 
populations and in vitro studies. 
The human erythrocyte PIG-A assay has been carried out on heparinised blood 
samples from consenting donors with benign and malignant pancreatic disease. To 
date, 44 patients have donated samples. PIG-A mutation frequencies in healthy and 
benign donors (4.59±2.11 and 3.37±1.21 respectively) are comparable to reported 
mutation frequencies in population studies. An elevated level of mutations are seen 
in cancer patients (8.33±6.16). Clinical parameters have been correlated with the 
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mutation frequency, with metastatic disease having a significant increase in mutated 
erythrocytes in comparison to localised disease. The lymphocyte micronucleus assay 
was used as a secondary measure of DNA damage in an alternative cell population. 
An increase in micronucleated lymphocytes was seen in cancer patients.  
An in vitro model of pancreatic cancer using PANC-1 cell line modelled exposure to 
known risk factors for pancreatic carcinogenesis including a high fat diet 
(deoxycholic acid), smoking (benzo-[a]-pyrene) and alcohol abuse (acetaldehyde). 
Induction of DNA damage was studied using the micronucleus assay and the in vitro 
Pig-A. Mutations seen in the in vitro study may reflect some of those seen in vivo. 
Poster – November 2019 – ACEMS/JEMS Joint Meeting – Tokyo 
A novel blood based biomarker for pancreatic cancer 
Diagnosing pancreatic malignancies remains a challenge due to late presentation and 
vague symptoms. Approximately 80% of patients present too late for potentially 
curative surgery. Earlier diagnosis would increase likelihood of patients being 
eligible for potentially curative resection that may improve patient outcomes. 
The PIG-A assay is being explored for its use in pancreatic disease. The mutation 
status of X-linked PIG-A is determined via flow cytometric detection of GPI 
anchored proteins on the surface of erythrocytes. Mutation in PIG-A has previously 
been shown to result in GPI anchor deficient cells that are quantified. To date, 51 
consenting patients with pancreatic disease including 23 benign patients and 28 
treatment naïve cancer patients have donated blood samples. Whole blood was 
stained with antibodies against erythrocyte specific CD-235a and GPI anchored CD-
55 and CD-59 before flow cytometry analysis. Cancer patients have shown an 
elevated frequency of mutated erythrocytes (8.67±6.33) in comparison to benign and 
healthy donors (4.59±2.11 and 3.37±1.21).As tumour staging becomes more 
advanced, the PIG-A mutant frequency increases which is significant when disease is 
metastatic. Chromosomal stability was monitored in the lymphocytes from the 
donors using the micronucleus assay. An increase in micronucleated lymphocytes 
was seen in cancer patients and there is a positive correlation when compared to 
PIG-A mutation frequency.  
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An increase of DNA damage assessed by two methods is seen in pancreatic cancer 
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